

## chain nodes :

9 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33  
34 35 36 37 39 40 41 42 43 51 52 53 59 60

## ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15 61 62 63

## chain bonds :

9-10 9-59 16-17 17-37 18-19 19-20 20-21 20-22 21-39 23-24 24-25  
25-26 25-27 26-40 28-29 30-35 30-36 31-34 32-33 33-43 34-41  
34-42 51-52 51-53 52-60

## ring bonds :

1-2 1-6 2-3 3-4 3-61 4-5 4-63 5-6 10-15 10-11 11-12 12-13  
13-14 14-15 61-62 62-63

## exact/norm bonds :

9-59 10-15 10-11 11-12 12-13 13-14 14-15 16-17 17-37 18-19  
19-20 20-21 20-22 21-39 23-24 24-25 25-26 25-27 26-40 28-29  
30-35 30-36 32-33 33-43 34-41 34-42 51-52 51-53 52-60

## exact bonds :

3-61 4-63 9-10 31-34 61-62 62-63

## normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

## isolated ring systems :

containing 1 :

G1:OH,CN,NH<sub>2</sub>,H,O,C

G2:O,S,N,[\*1],[\*3],[\*4],[\*5],[\*6],[\*7],[\*8],[\*9]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:CLASS 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS  
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS  
26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS  
33:CLASS 34:CLASS 35:Atom 36:Atom 37:Atom 39:Atom 40:Atom 41:Atom  
42:Atom 43:Atom 51:CLASS 52:CLASS 53:CLASS 59:CLASS 60:Atom  
61:Atom 62:Atom 63:Atom

09/807,599

=> d his

(FILE 'HOME' ENTERED AT 15:21:40 ON 10 OCT 2002)

FILE 'REGISTRY' ENTERED AT 15:21:46 ON 10 OCT 2002

L1 STRUCTURE UPLOADED  
L2 QUE L1  
L3 1 S L2

FILE 'STNGUIDE' ENTERED AT 15:22:40 ON 10 OCT 2002

FILE 'REGISTRY' ENTERED AT 15:25:33 ON 10 OCT 2002

FILE 'STNGUIDE' ENTERED AT 15:25:33 ON 10 OCT 2002

FILE 'REGISTRY' ENTERED AT 15:26:07 ON 10 OCT 2002

L4 24386 S C6-C6N/EA  
L5 STRUCTURE UPLOADED  
L6 QUE L5  
L7 35 S L6  
L8 50 S L6 SUB=L4 SAM  
L9 1450 S L6 SUB=L4 FUL

FILE 'CAPLUS' ENTERED AT 15:28:04 ON 10 OCT 2002

L10 119 S L9

FILE 'REGISTRY' ENTERED AT 15:28:53 ON 10 OCT 2002

L11 STRUCTURE UPLOADED  
L12 QUE L11  
L13 1047 S L12 SUB=L9 FUL

FILE 'CAPLUS' ENTERED AT 15:30:23 ON 10 OCT 2002


L14 58 S L13  
L15 41 S L14 AND PATENT/DT  
L16 17 S L14 NOT L15  
L17 1 S L16 AND 2002/SO  
L18 2 S L16 AND 2001/SO  
L19 6 S L16 AND 2000/SO  
L20 49 S L14 NOT (L17 OR L18 OR L19)

=> d bib abs hitstr 1-49

09/807,599

L20 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2002 ACS  
AN 2002:31420 CAPLUS  
DN 136:85815  
TI Preparation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives as GPR14 antagonists  
IN Tarui, Naoki; Santo, Takashi; Watanabe, Hiroyuki; Aso, Kazuyoshi; Ishihara, Yuji  
PA Takeda Chemical Industries, Ltd., Japan  
SO PCT Int. Appl., 217 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002530	A1	20020110	WO 2001-JP5784	20010704
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001071018	A5	20020114	AU 2001-71018	20010704
	JP 2002097142	A2	20020402	JP 2001-203519	20010704
PRAI	JP 2000-206865	A	20000704		
	JP 2000-2000206865A		20000704		
	WO 2001-JP5784	W	20010704		
OS	MARPAT 136:85815				
GI					



AB A G-protein-coupled receptor (GPR14) antagonist comprises compds. represented by the formula (I) or a salt thereof (wherein Ar represents optionally substituted aryl; X represents a spacer consisting of 1-4 atoms in the straight chain moiety; n is an integer of 1 to 10; R represents hydrogen or an optionally substituted hydrocarbon group, provided that R may be bonded to the substituent of Ar to form a ring; and Y represents optionally substituted amino or N-contg. heterocyclyl). These compds. are antagonists of orphan receptor GPR14 protein (urotensin II receptor) and are useful as inhibitors of vasoconstriction for the prevention or treatment of hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction, or heart failure. Thus, a mixt. of 4-bromo-1-[3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1-butanone, 1-phenylpiperazine, K<sub>2</sub>CO<sub>3</sub>, and DMF was stirred at 80.degree. for 2 h, followed by treatment of the product with a mixt. of 1 M aq. KOH and methanol and then with 1 N HCl/EtOAc to give 4-(4-phenyl-1-piperazinyl)-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-butanone trihydrochloride (II). N-(2-{4-[bis(4-



fluorophenyl)methyl]piperazin-1-yl)ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carboxamide trihydrochloride in vitro showed IC<sub>50</sub> of 1.7 nM for inhibiting the binding of [<sup>125</sup>I]urotensin to human GPR14. A capsule and a tablet formulation contg. II were prepd.

IT 387874-87-5P 387875-14-1P 387875-16-3P  
387875-18-5P 387875-55-0P 387875-57-2P  
387875-59-4P 387875-66-3P 387875-68-5P  
387875-72-1P 387875-74-3P 387875-76-5P  
387875-78-7P 387875-80-1P 387875-82-3P  
387875-84-5P 387875-86-7P 387876-31-5P  
387876-34-8P 387876-36-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tetrahydrobenzazepine derivs. as GPR14 antagonists and vasoconstriction inhibitors for treatment and prevention of hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction, or heart failure)


RN 387874-87-5 CAPLUS

CN 1-Butanone, 4-[4-(4-pyridinylmethyl)-1-piperazinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387874-86-4


CMF C24 H32 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 387875-14-1 CAPLUS


CN 1-Butanone, 4-[4-(phenylmethyl)-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-13-0

09/807,599


CMF C26 H34 N2 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 387875-16-3 CAPLUS

CN 1-Butanone, 4-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-15-2


CMF C26 H33 F N2 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



09/807,599


RN 387875-18-5 CAPLUS

CN 1-Butanone, 4-[4-(diphenylmethoxy)-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-17-4


CMF C32 H38 N2 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 387875-55-0 CAPLUS

CN 1-Butanone, 4-[4-[(2-fluorophenyl)methyl]-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-54-9

CMF C26 H33 F N2 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2

09/807,599




RN 387875-57-2 CAPLUS

CN 1-Butanone, 1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-[4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-56-1


CMF C27 H33 F3 N2 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 387875-59-4 CAPLUS


CN 1-Butanone, 4-[4-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-58-3

CMF C29 H40 N2 O3 S


09/807,599



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 387875-66-3 CAPLUS

CN 1-Butanone, 4-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-65-2


CMF C27 H34 N2 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




09/807,599

RN 387875-68-5 CAPLUS  
CN 1-Butanone, 4-[4-(phenylthio)-1-piperidiny]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 387875-67-4  
CMF C25 H32 N2 O S



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 387875-72-1 CAPLUS  
CN 1-Butanone, 4-[4-[(2,4-difluorophenyl)methyl]-1-piperidiny]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 387875-71-0  
CMF C26 H32 F2 N2 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

09/807,599




RN 387875-74-3 CAPLUS

CN 1-Butanone, 1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-[4-[[4-(1H-tetrazol-1-yl)phenyl]methyl]-1-piperidiny]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-73-2


CMF C27 H34 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 387875-76-5 CAPLUS


CN 1-Butanone, 4-[4-[(4-methoxyphenyl)methyl]-1-piperidiny]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-75-4

CMF C27 H36 N2 O2


09/807,599



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 387875-78-7 CAPLUS

CN Benzenesulfonamide, 4-[[1-[4-oxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butyl]-4-piperidinyl]methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-77-6


CMF C26 H35 N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 387875-80-1 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-4-[[1-[4-oxo-4-(2,3,4,5-tetrahydro-1H-3-




09/807,599

benzazepin-7-yl)butyl]-4-piperidiny]methyl]-, bis(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1

CRN 387875-79-8


CMF C28 H39 N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 387875-82-3 CAPLUS

CN Benzoic acid, 4-[[1-[4-oxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butyl]-4-piperidiny]methyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-81-2

CMF C28 H36 N2 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2

09/807,599




RN 387875-84-5 CAPLUS

CN 1-Butanone, 4-[4-[[ (4-fluorophenyl)thio]methyl]-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-83-4


CMF C26 H33 F N2 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 387875-86-7 CAPLUS


CN 1-Butanone, 4-[4-[(3-fluorophenyl)methyl]-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 387875-85-6

CMF C26 H33 F N2 O


09/807,599



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 387876-31-5 CAPLUS

CN 1-Butanone, 4-[4-(phenylmethyl)-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 387876-34-8 CAPLUS


CN 1-Butanone, 4-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 387876-36-0 CAPLUS

CN 1-Butanone, 4-[4-(diphenylmethoxy)-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)- (9CI) (CA INDEX NAME)

09/807,599



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/807,599

~~L20~~ ANSWER 2 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 2001:851111 CAPLUS

DN 136:5926

TI Preparation of benzoaromatic derivatives as melanin concentrating hormone antagonists

IN Ishihara, Yuji; Terauchi, Jun; Suzuki, Nobuhiro; Takekawa, Shiro; Aso, Kazuyoshi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 285 pp.



CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087834	A1	20011122	WO 2001-JP4015	20010515
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	JP 2001332407	A2	20011130	JP 2000-148674	20000519
PRAI	JP 2000-148674	A	20000516		
	JP 2001-116219	A	20010413		
OS	MARPAT 136:5926				
GI					



AB Title compds. [I; R = H, halo, cyclic; X = bond, spacer contg. a chain with one to six atoms; Y = spacer with one to six atoms; A = benzene; B = 5-9 membered nitrogen contg. nonarom. heterocycle; R1 = H, hydrocarbon,

heterocycle; R2 = H, hydrocarbon, heterocycle; R1R2 = nitrogen contg. heterocycle; YR2 = nitrogenous heterocycle], melanin-concg. hormone antagonist, which contains a compd. represented by the formula or a salt thereof are prepd. useful as prevention or remedy for adiposity, diabetes, or high blood pressure. Thus, the title compd. II was prepd. and biol. tested.

IT 374810-62-5P 374810-64-7P 374810-68-1P  
374810-84-1P 374810-88-5P 374811-04-8P  
374811-06-0P 374811-12-8P 374811-34-4P  
374811-44-6P 374811-82-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzoarom. derivs. as melanin concg. hormone antagonists)


RN 374810-62-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[1,4-dioxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 374810-61-4


CMF C20 H27 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 374810-64-7 CAPLUS


CN 4-Piperidineethanol, 1-[1,4-dioxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 374810-63-6

CMF C21 H30 N2 O3


09/807,599



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 374810-68-1 CAPLUS

CN Piperidine, 1-[1,4-dioxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butyl]-4-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 374810-67-0


CMF C26 H32 N2 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 374810-84-1 CAPLUS


CN 4-Piperidinol, 1-[1,4-dioxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

09/807,599

CM 1

CRN 374810-83-0


CMF C19 H26 N2 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 374810-88-5 CAPLUS

CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[1,4-dioxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 374810-87-4

CMF C25 H29 Cl N2 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2




09/807,599



RN 374811-04-8 CAPLUS  
CN 1H-3-Benzazepine-7-butanamide, 2,3,4,5-tetrahydro-.gamma.-oxo-N-[1-(phenylmethyl)-4-piperidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 374811-03-7  
CMF C26 H33 N3 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 374811-06-0 CAPLUS  
CN 1H-3-Benzazepine-7-butanamide, 2,3,4,5-tetrahydro-.gamma.-oxo-N-(2,2,6,6-tetramethyl-4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 374811-05-9  
CMF C23 H35 N3 O2


09/807,599



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 374811-12-8 CAPLUS

CN 1H-3-Benzazepine-7-butanamide, 2,3,4,5-tetrahydro-.gamma.-oxo-N-[2-(4-pyridinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 374811-11-7


CMF C21 H25 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 374811-34-4 CAPLUS

CN 1H-3-Benzazepine-7-butanamide, 2,3,4,5-tetrahydro-.gamma.-oxo-N-(4-


09/807,599

pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 374811-33-3


CMF C20 H23 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 374811-44-6 CAPLUS

CN 1H-3-Benzazepine-7-butanamide, N-ethyl-2,3,4,5-tetrahydro-.gamma.-oxo-N-(4-pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 374811-43-5

CMF C22 H27 N3 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2

09/807,599




RN 374811-82-2 CAPLUS

CN 1H-3-Benzazepine-7-butanamide, 2,3,4,5-tetrahydro-N-methyl-N-(1-methyl-4-piperidiny)-.gamma.-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 374811-81-1


CMF C21 H31 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 531 THERE ARE 531 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L20~~ ANSWER 3 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 2001:676587 CAPLUS

DN 135:236445

TI 4,4'-Diaminodiphenyl sulfone and acetylcholinesterase inhibitor combinations for prevention and treatment of dementia

IN Bain, Allen I.; Zolotoy, Alexander

PA Immune Network Ltd., Can.

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066096	A2	20010913	WO 2001-CA271	20010305
	WO 2001066096	A3	20011129		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-187310P P 20000306

AB 4,4'-Diaminodiphenylsulfone (I) is a bactericide and anti-inflammatory agent. It is known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycetic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposi's sarcoma, pneumocystis carinii (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. It is also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer disease and related neurodegenerative disorders. Donepezil-HCl (donepezil) is an acetylcholinesterase inhibitor that is currently used for the symptomatic treatment of Alzheimer disease in patients in need of such therapy. It has now been found that combinations of I and cholinesterase inhibitors unexpectedly show synergistic effects in the prevention and/or treatment of dementia. The present invention relates to novel compns. and methods of preventing and/or treating dementia using combinations of I and a cholinesterase inhibitor (preferably donepezil). The method involves the administration to such individuals a drug compn. of I and a cholinesterase inhibitor. The invention also relates to a method of preventing and/or treating dementia including senile dementia, that involves the use of this combination of drugs. A combination of I and donepezil improved the learning deficit in aged rats and has a greater effect than the use of either drug alone.

IT 142852-51-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(4,4'-diaminodiphenyl sulfone and acetylcholinesterase inhibitor combinations for prevention and treatment of dementia)


RN 142852-51-5 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

09/807,599


CRN 142852-50-4  
CMF C25 H32 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



L20 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2002 ACS  
 AN 2001:603494 CAPLUS  
 DN 135:190842  
 TI Melanin-concentrating hormone antagonists  
 IN Ishihara, Yuji; Suzuki, Nobuhiro; Takekawa, Shiro  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 88 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001226269	A2	20010821	JP 2000-46827	20000218
OS	MARPAT 135:190842				

AB Provided are melanin-concg. hormone antagonists for preventing and treating obesity, diabetes, diabetic complications, atherosclerosis, or rheumatoid arthritis; and for use as appetite inhibitor. The melanin-concg. hormone antagonists are novel piperidine derivs. The MCH antagonists comprise formula I [i.e. Ar-X1-X4-C5H9N-X2-C6H4-X3-R2], where Ar is a substituted group-contg. arom. ring, X1 is a substituted group-contg. divalent main chain of 1-5 atoms, X2, X3 and X4 are linking arms, and R2 is a basic substituting group, and its salts.

IT 215045-14-0P 215045-20-8P 265100-57-0P  
 265100-58-1P 265101-15-3P 265101-17-5P  
 265101-18-6P 265101-19-7P 265101-21-1P  
 265101-22-2P 265101-25-5P 265101-27-7P  
 265101-29-9P 265101-30-2P 265101-32-4P  
 265101-33-5P 265101-34-6P 265101-35-7P  
 265101-37-9P 265101-80-2P 265101-81-3P  
 265101-83-5P 265101-86-8P 265101-88-0P  
 265101-90-4P 265101-93-7P 265101-95-9P  
 265101-97-1P 265102-00-9P 265102-03-2P  
 265102-10-1P 265102-13-4P 265102-16-7P  
 265102-21-4P 265102-23-6P 265102-24-7P  
 265102-26-9P 265102-27-0P 265102-28-1P  
 265102-29-2P 265102-38-3P 265102-39-4P  
 265102-41-8P 265102-44-1P 265102-46-3P  
 265102-48-5P 265102-53-2P 265102-55-4P  
 265102-56-5P 265102-57-6P 265102-58-7P  
 265102-59-8P 265102-60-1P 265102-64-5P  
 265102-65-6P 265102-66-7P 265102-67-8P  
 265102-68-9P 265102-69-0P 265102-70-3P  
 265102-71-4P 265102-72-5P 265102-73-6P  
 265102-74-7P 265102-75-8P 355395-73-2P  
 355395-74-3P 355395-93-6P 355395-95-8P  
 355395-96-9P 355395-98-1P 355396-00-8P  
 355396-02-0P 355396-04-2P 355396-13-3P  
 355396-15-5P 355396-17-7P 355396-19-9P  
 355396-21-3P 355396-23-5P 355396-28-0P  
 355396-41-7P 355396-48-4P 355396-80-4P  
 355396-84-8P 355396-91-7P 355396-94-0P  
 355396-96-2P 355396-98-4P 355396-99-5P  
 355397-01-2P 355397-03-4P 355397-05-6P  
 355397-07-8P 355397-09-0P


RL: ANT (Analyte); SPN (Synthetic preparation); THU (Therapeutic use);  
 ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

09/807,599

(melanin-concg. hormone antagonists preventing and treating obesity, diabetes, diabetic complications, atherosclerosis, or rheumatoid arthritis; and for use as appetite inhibitor)


RN 215045-14-0 CAPLUS

CN Benzenecarboximidamide, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 215045-20-8 CAPLUS


CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 265100-57-0 CAPLUS

CN Benzonitrile, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 265100-58-1 CAPLUS

CN Benzenecarboximidamide, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 1-B

—NHMe

RN 265101-15-3 CAPLUS


CN Benzonitrile, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265101-17-5 CAPLUS

CN Benzenecarboximidic acid, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



—OEt


RN 265101-18-6 CAPLUS

CN Benzenecarboximidamide, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-  
(9CI) (CA INDEX NAME)

—NH<sub>2</sub>


RN 265101-19-7 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]- (9CI)  
(CA INDEX NAME)




RN 265101-21-1 CAPLUS

CN Benzenemethanamine, N,N-diethyl-4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 265101-22-2 CAPLUS  
 CN Benzonitrile, 3-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI)  
 (CA INDEX NAME)




● 2 HCl

RN 265101-25-5 CAPLUS  
 CN 1H-2-Benzazepine, 8-[2-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 265101-27-7 CAPLUS  
 CN Piperidine, 1-(4-cyanobenzoyl)-4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265101-29-9 CAPLUS


CN Benzonitrile, 4-[[4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-7-yl]oxy]methyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265101-30-2 CAPLUS

CN 1H-2-Benzazepine, 7-[[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 265101-32-4 CAPLUS


CN Benzonitrile, 4-[[4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]methyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265101-33-5 CAPLUS

CN 1H-2-Benzazepine, 8-[[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265101-34-6 CAPLUS

CN Benzonitrile, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265101-35-7 CAPLUS


CN 1H-2-Benzazepine, 8-[2-[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



09/807,599

RN 265101-37-9 CAPLUS


CN Benzenamine, N,N-dimethyl-4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 265101-80-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265101-81-3 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-7-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 265101-83-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 265101-86-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265101-88-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-(4-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 265101-90-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265101-93-7 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-8-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 265101-95-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265101-97-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[3-(4-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 265102-00-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-03-2 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)






RN 265102-10-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-13-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-16-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-21-4 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-

09/807,599


piperidinyl)ethyl]thio]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265102-23-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-24-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-26-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]sulfinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265102-27-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-28-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-29-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-38-3 CAPLUS


CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-(4-piperidinylethoxy)]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265102-39-4 CAPLUS


CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-7-[2-(4-piperidinylethoxy)]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265102-41-8 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-7-[2-(4-piperidinylethoxy)]-2-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



09/807,599


RN 265102-44-1 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)




RN 265102-46-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-48-5 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)




RN 265102-53-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[3-[[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]thio]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-55-4 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-56-5 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-57-6 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-58-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-59-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-(4-piperidinyl)propyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265102-60-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[[3-(4-piperidinyl)propyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265102-64-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(trifluoroacetyl)-1H-2-benzazepin-8-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-65-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-66-7 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-67-8 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-(4-piperidinyl)ethyl]thio]- (9CI) (CA INDEX NAME)






RN 265102-68-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(trifluoroacetyl)-1H-2-benzazepin-8-yl]sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-69-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-70-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-71-4 CAPLUS  
 CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-(4-piperidinyl)ethyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 265102-72-5 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(trifluoroacetyl)-1H-2-benzazepin-8-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-73-6 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-74-7 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-75-8 CAPLUS  
 CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-(4-piperidinyl)ethyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 355395-73-2 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



09/807,599


RN 355395-74-3 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[3-(4-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 355395-93-6 CAPLUS

CN 1H-2-Benzazepine, 2-benzoyl-2,3,4,5-tetrahydro-8-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 355395-95-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-7-yl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 355395-96-9 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-7-(4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 355395-98-1 CAPLUS  
CN Benzonitrile, 4-[[4-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-7-yl]oxy]-1-piperidiny]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 355396-00-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 355396-02-0 CAPLUS  
CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-(4-piperidinyloxy)- (9CI) (CA INDEX NAME)



RN 355396-04-2 CAPLUS


CN Benzonitrile, 4-[[4-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 355396-13-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 355396-15-5 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-8-[2-(4-piperidinyl)ethoxy]-2-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 355396-17-7 CAPLUS


09/807,599

CN Benzonitrile, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 355396-19-9 CAPLUS

CN Benzonitrile, 3-chloro-4-[[4-[2-[[2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 355396-21-3 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[3-(4-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 355396-23-5 CAPLUS


CN Benzonitrile, 4-[[4-[3-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 355396-28-0 CAPLUS


09/807,599

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 355396-41-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 355396-48-4 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 355396-80-4 CAPLUS


CN 1H-2-Benzazepine, 8-[3-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]propoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 1-B



RN 355396-84-8 CAPLUS  
 CN Piperidine, 1-[4-(4,5-dihydro-1H-imidazol-2-yl)benzoyl]-4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-(9CI) (CA INDEX NAME)




RN 355396-91-7 CAPLUS  
 CN 1H-2-Benzazepine, 7-[[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]oxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 355396-94-0 CAPLUS  
 CN 1H-2-Benzazepine, 8-[[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]oxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)


09/807,599



RN 355396-96-2 CAPLUS

CN Benzenecarboximidamide, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 3 HCl

PAGE 1-B

—NH<sub>2</sub>

RN 355396-98-4 CAPLUS


CN 1H-2-Benzazepine, 8-[2-[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 355396-99-5 CAPLUS

09/807,599


CN 1H-2-Benzazepine, 8-[2-[1-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 355397-01-2 CAPLUS

CN Benzenecarboximidamide, 3-chloro-4-[[4-[2-[[2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

—NH<sub>2</sub>

RN 355397-03-4 CAPLUS


CN 1H-2-Benzazepine, 8-[2-[1-[[2-chloro-4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 355397-05-6 CAPLUS


CN 1H-2-Benzazepine, 8-[2-[1-[[2-chloro-4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[[2-(trifluoromethyl)phenyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 355397-07-8 CAPLUS

CN 1H-2-Benzazepine, 8-[3-[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]propoxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 355397-09-0 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

09/807,599

120 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 2001:463221 CAPLUS

DN 135:61247

TI Preparation of sulfonylaminomethylpiperidinylethylamines for antiobesity, antidiabetics, and antihypertensives

IN Sato, Yoshinari; Itani, Hiromichi; Ito, Tatsunobu; Sakata, Yoshihiko; Hatakeyama, Yoshifumi; Ohashi, Hiroko

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 64 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001172257	A2	20010626	JP 2000-302567	20001002
PRAI	JP 1999-284407	A	19991005		
OS	MARPAT 135:61247				


AB The compds. R1R2(NR6)pR5AR3(SO2)sR4 [R1 = (un)substituted (un)satd. C ring, heterocyclyl; R2 = bond, (un)substituted lower alkylene; R3 = piperidinediyl, (CH2)n, CHR7, NH, CO; R7 = indolylmethyl; n = 1-4; R4 = (un)substituted aryl, aralkyl, heterocyclyl; R5 = bond, lower alkylene, (CH2)mCO; m = 0-1; R6 = H, OH; A = N-contg. satd. heterocyclylene; p = 0-1; s = 0-1] are prepd. N-[[4-[(naphthalen-1-yl)sulfonylaminomethyl]piperidin-1-yl]carbonylmethyl]-2-indolinecarboxamide (263.0 mg) was reacted with borane-Me2S complex in THF under reflux for 2 h and treated with HCl under reflux for 1 h to give 104.8 mg N-(indolin-2-yl)methyl-N-[4-[(naphthalen-1-yl)sulfonylaminomethyl]piperidin-1-yl]ethylamine hydrochloride showing good inhibitory activity against neuropeptide Y receptor in vitro.

IT 345956-12-9P 345956-30-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of sulfonylaminomethylpiperidinylethylamines for antiobesity, antidiabetics, and antihypertensives)

RN 345956-12-9 CAPLUS

CN 1-Naphthalenesulfonamide, N-[2-[4-[(1,3,4,5-tetrahydro-7-methoxy-2H-2-benzazepin-2-yl)methyl]-1-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 345956-30-1 CAPLUS

CN 1-Naphthalenesulfonamide, N-[[4-[2-[[2-(1,3,4,5-tetrahydro-7-methoxy-2H-2-

09/807,599

benzazepin-2-yl)ethyl]amino]ethyl]-1-piperidinyl]methyl]-,  
trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 3 HCl

PAGE 1-B

—OMe

09/807,599

L20 ANSWER 6 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 2001:98457 CAPLUS

DN 134:147611

TI Preparation of tetrahydrobenzo[d]azepines as metabotropic glutamate receptor 1 antagonists

IN Adam, Geo; Binggeli, Alfred; Maerki, Hans-Peter; Mutel, Vincent; Wilhelm, Maurice; Wostl, Wolfgang

PA F. Hoffmann-La Roche A.-G., Switz.

SO Eur. Pat. Appl., 85 pp.



CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1074549	A2	20010207	EP 2000-116091	20000727
	EP 1074549	A3	20020731		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6218385	B1	20010417	US 2000-630702	20000801
	NO 2000003966	A	20010207	NO 2000-3966	20000804
	CN 1283623	A	20010214	CN 2000-122523	20000804
	JP 2001089472	A2	20010403	JP 2000-236848	20000804
	JP 3260350	B2	20020225		
	BR 2000003375	A	20010313	BR 2000-3375	20000807
PRAI	EP 1999-115557	A	19990806		
OS	MARPAT 134:147611				
GI					





AB The title compds. (I) [wherein R1 = H, alkyl, O, halo, OR, cycloalkoxy, (un)substituted cycloalkylalkoxy, cyanoalkoxy, (fluoro)alkoxy, aminoalkoxy, alkenyloxy, phenylalkoxy, heterocyclalkoxy, sulfonyloxyalkoxy, SR, carboxyalkylthio, NR2, hydroxyalkylamino, or heterocyclalkylamino; n = 1-6; R = independently H, alkyl, or alkenyl; R2 = NO2 or CN; R3 = H, alkyl, O, S, SR, alkylsulfonyl, cycloalkyl, CONR2, NR2, alkyl, OR, or (un)substituted piperazino, carbamoylalkyl, alkoxyalkyl, fluoroalkyl, trifluoroacetoxyalkyl, carboxyalkyl, phenylthioalkyl, heterocyclalkoxy, acylamino, alkylamino, phenoxyalkylamino, heterocyclalkylamino, fluoroalkoxy, etc.; R4 = H, alkyl, alkenyl, NO2, OR, NR2, or (un)substituted fluoroalkoxy, fluoroalkyl, phenylalkyl, alkoxyalkanol, aminoalkyl, carboxyalkyl, alkylsulfonyloxyalkyl, fluoroalkenyl, heterocyclalkyl, heterocyclalkylamino, alkoxy-carbonylamino, alkoxy-carbonylhydrazino, aminofluoroalkenylamino; or R4 and R1 or R3 and R4 form an addnl. ring; R5 and R6 = independently H, alkyl, alkoxy, NH2, HO2, SO2NH2, or halo; or R5 and R6 = OCH2O; R7 and R8 = independently H, alkyl, alkoxy, NH2, NO2, or halo; R9 and R10 = independently H or alkyl; R11 and R12 = independently H, alkyl, OH, alkoxy, alkoxy-carbonyloxy, or alkanoyloxy; R13 and R14 = independently H, T, or alkyl; R15 and R16 = independently H, T, alkyl, OH, alkoxy, alkoxy-carbonyloxy, or alkanoyloxy; or R15 and R16 = O; X = N or C; Y = N, NH, or CH] were prepd. For example, addn. of Et 2-cyano-3,3-bis(methylthio)acrylate to 2,3,4,5-tetrahydro-1H-benzo[d]azepine.bul.HCl using TEA and K2CO3 in EtOH gave 2-cyano-3-methylsulfanyl-3-(1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)acrylic acid Et ester (64%). The benzazepinylacrylate ester was treated with NH2C(NH)NH2.bul.HNO3 and 1,8-diazabicyclo[5.4.0]undec-7-ene in DMF to give II (R = H). Ethylation of II (R = H) with EtI in DMF in the presence of K2CO3 afforded the preferred metabotropic glutamate receptor 1 (mGluR1) antagonist II (R = Et), which gave an IC50 values of 0.009 .mu.M and 0.003 .mu.M, resp. in functional and binding assays for the characterization of mGluR1 antagonist properties. I are useful in the prevention or control of acute and/or chronic neurol. disorders and as radiolabeled mGluR1 receptor antagonists in binding assays (no data).

IT 324554-90-7P 324556-97-0P 324557-55-3P


324557-58-6P 324557-98-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tetrahydrobenzo[d]azepine mGluR1 antagonists by addn. of chloroheterocycles or halobenzenes to tetrahydrobenzo[d]azepines or by cycloaddn. of guanidines to 3-methylthio-3-(tetrahydrobenzo[d]azepin-3-yl)acrylates)

RN 324554-90-7 CAPLUS

CN 1H-3-Benzazepine, 3-(4-butyl-5-methyl-3-nitro-2-pyridinyl)-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 324556-97-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[2-methyl-5-nitro-6-[3-(4-


09/807,599

pyridinyl)propoxy]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 324557-55-3 CAPLUS

CN 1-Propanol, 3-[[6,7,8,9-tetrahydro-3-nitro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-5H-cyclohepta[b]pyridin-4-yl]amino]- (9CI) (CA INDEX NAME)




RN 324557-58-6 CAPLUS

CN 5H-Cyclohepta[b]pyridin-4-ol, 6,7,8,9-tetrahydro-3-nitro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 324557-98-4 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[6,7,8,9-tetrahydro-4-[(4-methoxyphenyl)methoxy]-3-nitro-5H-cyclohepta[b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



09/807,599

L20 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 2000:277975 CAPLUS

DN 132:308254

TI Preparation of heterocyclic compounds as thermogenesis accelerators

IN Ishihara, Yuji; Fujisawa, Yukio; Furuyama, Naoki; Ishichi, Yuji; Sasaki, Mitsuru

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 260 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000023437	A1	20000427	WO 1999-JP5705	19991015
	W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9961236	A1	20000508	AU 1999-61236	19991015
	JP 2000186088	A2	20000704	JP 1999-293493	19991015
	JP 2000186091	A2	20000704	JP 1999-293649	19991015
	EP 1122252	A1	20010808	EP 1999-947923	19991015
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	JP 1998-295213	A	19981016		
	JP 1998-295488	A	19981016		
	WO 1999-JP5705	W	19991015		
OS	MARPAT 132:308254				
GI					



AB The title compds. I [T1 = (CH2)<sub>k</sub>; T2 = (CH2)<sub>m</sub>; T3 = (CHR)<sub>n</sub>; A is a benzene ring which may be further substituted; L is O, S or the like; n is an integer of 0 to 6; R is hydrogen, optionally substituted hydrocarbyl, or the like; R1 is optionally substituted hydrocarbyl, etc.; R2 is hydrogen, acyl or the like; X is O, S, etc.; and k and m are each independently a no. of 0 to 5 and satisfy the relationship: 1 < k + m < 5] are prepd. I are useful in the treatment of obesity. The concn. of cAMP in fat cells in the presence of 7-[2-[1-(phenylmethyl)-4-piperidinyl]ethoxy]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine dihydrochloride (10<sup>-6</sup> M) was 46.7 pmol/mL, vs. 2.7 pmol/mL in control fat cells. (Thermogenesis is increased when the concn. of cAMP in fat cells is increased). Formulations are given.


IT 265099-50-1P 265099-51-2P 265099-52-3P  
265099-53-4P 265099-54-5P 265099-55-6P  
265099-56-7P 265099-57-8P 265099-58-9P  
265099-59-0P 265099-60-3P 265099-61-4P  
265099-64-7P 265099-65-8P 265099-66-9P  
265099-67-0P 265099-68-1P 265099-69-2P  
265099-70-5P 265099-77-2P 265099-78-3P  
265099-79-4P 265099-80-7P 265099-81-8P  
265099-82-9P 265099-83-0P 265099-84-1P  
265099-87-4P 265099-88-5P 265099-89-6P  
265099-90-9P 265099-91-0P 265099-92-1P  
265099-93-2P 265099-94-3P 265099-95-4P  
265099-96-5P 265099-97-6P 265099-98-7P  
265099-99-8P 265100-00-3P 265100-01-4P  
265100-02-5P 265100-03-6P 265100-04-7P  
265100-05-8P 265100-06-9P 265100-07-0P  
265100-08-1P 265100-09-2P 265100-10-5P  
265100-11-6P 265100-12-7P 265100-13-8P  
265100-16-1P 265100-19-4P 265100-22-9P  
265100-24-1P 265100-26-3P 265100-28-5P  
265100-29-6P 265100-30-9P 265100-31-0P  
265100-33-2P 265100-35-4P 265100-37-6P  
265100-39-8P 265100-40-1P 265100-41-2P  
265100-42-3P 265100-43-4P 265100-44-5P  
265100-45-6P 265100-46-7P 265100-47-8P  
265100-48-9P 265100-49-0P 265100-50-3P  
265100-51-4P 265100-52-5P 265100-53-6P  
265100-54-7P 265100-55-8P 265100-56-9P  
265100-57-0P 265100-58-1P 265100-59-2P  
265100-60-5P 265100-61-6P 265100-62-7P  
265100-63-8P 265100-64-9P 265100-65-0P  
265100-66-1P 265100-67-2P 265100-68-3P  
265100-69-4P 265100-70-7P 265100-71-8P  
265100-72-9P 265100-73-0P 265100-74-1P  
265100-75-2P 265100-77-4P 265100-79-6P  
265100-81-0P 265100-82-1P 265100-84-3P  
265100-86-5P 265100-87-6P 265100-88-7P  
265100-89-8P 265100-90-1P 265100-91-2P  
265100-92-3P 265100-93-4P 265100-94-5P  
265100-95-6P 265100-96-7P 265100-97-8P  
265100-98-9P 265100-99-0P 265101-00-6P  
265101-01-7P 265101-02-8P 265101-03-9P  
265101-04-0P 265101-05-1P 265101-06-2P  
265101-07-3P 265101-08-4P 265101-09-5P  
265101-10-8P 265101-11-9P 265101-12-0P  
265101-13-1P 265101-14-2P 265101-15-3P  
265101-16-4P 265101-17-5P 265101-18-6P  
265101-19-7P 265101-20-0P 265101-21-1P  
265101-22-2P 265101-23-3P 265101-24-4P  
265101-25-5P 265101-26-6P 265101-27-7P  
265101-28-8P 265101-29-9P 265101-30-2P  
265101-31-3P 265101-32-4P 265101-33-5P  
265101-34-6P 265101-35-7P 265101-36-8P  
265101-37-9P 265101-38-0P 265101-39-1P  
265101-40-4P 265101-41-5P 265101-42-6P  
265101-43-7P 265101-44-8P 265101-45-9P  
265101-46-0P 265101-47-1P 265101-48-2P  
265101-49-3P 265101-50-6P 265101-51-7P

265101-52-8P 265101-53-9P 265101-54-0P  
 265101-55-1P 265101-56-2P 265101-57-3P  
 265101-58-4P 265101-59-5P 265101-60-8P  
 265101-61-9P 265101-62-0P 265101-63-1P  
 265101-64-2P 265101-65-3P 265101-66-4P  
 265101-67-5P 265101-68-6P 265101-69-7P  
 265101-70-0P 265101-71-1P 265101-72-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of heterocyclic compds. as thermogenesis accelerators)


RN 265099-50-1 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-7-[2-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 265099-51-2 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-7-[2-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265099-52-3 CAPLUS


CN 1H-3-Benzazepine, 7-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 265099-53-4 CAPLUS

09/807,599


CN 1H-3-Benzazepine, 7-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-, dihydrochloride (9CI) (CA  
INDEX NAME)



● 2 HCl


RN 265099-54-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 265099-55-6 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 265099-56-7 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Page 65




RN 265099-57-8 CAPLUS  
 CN 1H-2-Benzazepine, 8-[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-, dihydrochloride (9CI) (CA  
 INDEX NAME)




● 2 HCl

RN 265099-58-9 CAPLUS  
 CN 1H-3-Benzazepine, 7-[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propoxy]-  
 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 265099-59-0 CAPLUS  
 CN 1H-3-Benzazepine, 7-[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propoxy]-  
 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-, dihydrochloride (9CI) (CA  
 INDEX NAME)






● 2 HCl


RN 265099-60-3 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[2-[1-(phenylmethyl)-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 265099-61-4 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[2-[1-(phenylmethyl)-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265099-64-7 CAPLUS

CN 1H-2-Benzazepine-8-methanol, 2,3,4,5-tetrahydro-2-(phenylmethyl)-.alpha.-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 265099-65-8 CAPLUS  
 CN 1H-2-Benzazepine-8-methanol, 2,3,4,5-tetrahydro-2-(phenylmethyl)-.alpha.-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 265099-66-9 CAPLUS  
 CN 1H-3-Benzazepine-7-methanol, .alpha.-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265099-67-0 CAPLUS  
 CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-3-(phenylmethyl)-.alpha.-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 265099-68-1 CAPLUS  
 CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-3-(phenylmethyl)-.alpha.-

09/807,599


[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265099-69-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)



RN 265099-70-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265099-77-2 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-.alpha.-[2-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe

RN 265099-78-3 CAPLUS  
 CN 1H-3-Benzazepine-7-methanol, 3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-  
 .alpha.-[2-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]ethyl]-,  
 dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

— OMe

RN 265099-79-4 CAPLUS  
 CN 1H-3-Benzazepine-7-methanol, .alpha.-[2-[1-[(4-chlorophenyl)methyl]-4-  
 piperidinyl]ethyl]-3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl

RN 265099-80-7 CAPLUS  
 CN 1H-3-Benzazepine-7-methanol, .alpha.-[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]-3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl


PAGE 1-B

—Cl

RN 265099-81-8 CAPLUS  
 CN 1H-2-Benzazepine-8-methanol, .alpha.-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265099-82-9 CAPLUS  
 CN 1H-2-Benzazepine-8-methanol, .alpha.-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]-2,3,4,5-tetrahydro-2-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265099-83-0 CAPLUS  
 CN 1H-3-Benzazepine, 7-[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265099-84-1 CAPLUS  
 CN 1H-3-Benzazepine, 7-[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265099-87-4 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-8-[2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 265099-88-5 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-8-[2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 265099-89-6 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 265099-90-9 CAPLUS  
 CN 1H-2-Benzazepine, 8-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-, dihydrochloride (9CI) (CA  
 INDEX NAME)



● 2 HCl


RN 265099-91-0 CAPLUS  
 CN 1H-2-Benzazepine, 8-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-, dihydrochloride (9CI) (CA  
 INDEX NAME)



● 2 HCl


RN 265099-92-1 CAPLUS  
 CN 1H-2-Benzazepine, 8-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)






RN 265099-93-2 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-8-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 265099-94-3 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-8-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265099-95-4 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-8-[2-[1-[(4-methylphenyl)methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265099-96-5 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-8-[2-[1-[(4-methylphenyl)methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 265099-97-6 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-8-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 265099-98-7 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-8-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)


09/807,599



● 2 HCl

RN 265099-99-8 CAPLUS  
CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-8-[2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI)  
(CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

Me

RN 265100-00-3 CAPLUS  
CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-8-[2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 265100-01-4 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-8-[2-[1-[(4-methylphenyl)methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 265100-02-5 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-8-[2-[1-[(4-methylphenyl)methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

Me

RN 265100-03-6 CAPLUS


CN 1H-2-Benzazepine, 8-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-, dihydrochloride (9CI) (CA  
INDEX NAME)



● 2 HCl

RN 265100-04-7 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 265100-05-8 CAPLUS

09/807,599

CN 1H-2-Benzazepine, 8-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Cl

RN 265100-06-9 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-, dihydrochloride (9CI) (CA  
INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

— Cl

RN 265100-07-0 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-  
2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-, dihydrochloride (9CI) (CA  
INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

— Cl

RN 265100-08-1 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Cl


RN 265100-09-2 CAPLUS

CN 1H-2-Benzazepine-8-methanol, 2,3,4,5-tetrahydro-2-(2-phenylethyl)-.alpha.-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 265100-10-5 CAPLUS


CN 1H-2-Benzazepine-8-methanol, 2,3,4,5-tetrahydro-2-(2-phenylethyl)-.alpha.-  
[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA  
INDEX NAME)



● 2 HCl


RN 265100-11-6 CAPLUS

CN 1H-3-Benzazepine-7-methanol, .alpha.-[2-(1-ethyl-4-piperidinyl)ethyl]-  
2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265100-12-7 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-3-(phenylmethyl)-.alpha.-  
[2-(1-propyl-4-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 265100-13-8 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-.alpha.-[2-[1-(1-  
methylethyl)-4-piperidinyl]ethyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)






09/807,599


RN 265100-16-1 CAPLUS

CN 1H-3-Benzazepine-7-methanol, .alpha.-[2-(1-butyl-4-piperidiny)ethyl]-  
2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 265100-19-4 CAPLUS


CN 1H-3-Benzazepine-7-methanol, .alpha.-[2-(1-butyl-4-piperidiny)ethyl]-  
2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX  
NAME)



● 2 HCl

RN 265100-22-9 CAPLUS


CN Piperidine, 1-acetyl-4-[3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-  
benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 265100-24-1 CAPLUS

CN Piperidine, 1-acetyl-4-[3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-  
benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 265100-26-3 CAPLUS

CN 1-Piperidineacetic acid, 4-[3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 265100-28-5 CAPLUS


CN 1-Piperidineacetic acid, 4-[3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265100-29-6 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]thio]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-30-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)




RN 265100-31-0 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 265100-33-2 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 265100-35-4 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-37-6 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265100-39-8 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265100-40-1 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265100-41-2 CAPLUS  
 CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265100-42-3 CAPLUS  
 CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265100-43-4 CAPLUS  
 CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 265100-44-5 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-45-6 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfonyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 265100-46-7 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 265100-47-8 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-(phenylmethyl)-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265100-48-9 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-(phenylmethyl)-N-[[1-(phenylmethyl)-4-piperidiny]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-49-0 CAPLUS

CN 4-Piperidineacetamide, 1-(phenylmethyl)-N-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 265100-50-3 CAPLUS


CN 1H-2-Benzazepine-8-carboxamide, 2,3,4,5-tetrahydro-2-(phenylmethyl)-N-[[1-(phenylmethyl)-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)



RN 265100-51-4 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-.alpha.-methyl-3-


(phenylmethyl)-.alpha.-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-52-5 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-.alpha.-methyl-3-(phenylmethyl)-.alpha.-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]- (9CI)  
(CA INDEX NAME)




RN 265100-53-6 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, oxime (9CI) (CA INDEX NAME)



RN 265100-54-7 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrazone (9CI) (CA INDEX NAME)




RN 265100-55-8 CAPLUS




09/807,599

CN Propanedinitrile, [3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propylidene]- (9CI) (CA INDEX NAME)



RN 265100-56-9 CAPLUS


CN Propanedinitrile, [3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propylidene]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265100-57-0 CAPLUS


CN Benzonitrile, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265100-58-1 CAPLUS

CN Benzenecarboximidamide, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NHMe

RN 265100-59-2 CAPLUS

CN Benzenecarboximidamide, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

—NHMe


RN 265100-60-5 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[3-[1-[[3-(1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 265100-61-6 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-8-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethoxy]-2-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 265100-62-7 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-8-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethoxy]-2-[[2-(trifluoromethyl)phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 265100-63-8 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[2-(trifluoromethyl)phenyl]methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 265100-64-9 CAPLUS  
CN 1H-2-Benzazepine, 8-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[2-(trifluoromethyl)phenyl]methyl- (9CI) (CA INDEX NAME)



RN 265100-65-0 CAPLUS  
CN Propanedinitrile, [1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]propylidene]- (9CI) (CA INDEX NAME)




RN 265100-66-1 CAPLUS  
CN Propanedinitrile, [1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]propylidene]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265100-67-2 CAPLUS


CN 1H-2-Benzazepine-8-methanol, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-  
 .alpha.-methyl-.alpha.-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethyl]-  
 , dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-68-3 CAPLUS

CN 1H-2-Benzazepine-8-methanol, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-  
 .alpha.-methyl-.alpha.-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethyl]-  
 (9CI) (CA INDEX NAME)



RN 265100-69-4 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(  
 phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrazone, trihydrochloride (9CI)  
 (CA INDEX NAME)



● 3 HCl

RN 265100-70-7 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-71-8 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 265100-72-9 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265100-73-0 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-74-1 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 265100-75-2 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265100-77-4 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)-,

09/807,599


dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265100-79-6 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265100-81-0 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 265100-82-1 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)






RN 265100-84-3 CAPLUS  
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265100-86-5 CAPLUS  
 CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265100-87-6 CAPLUS  
 CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 265100-88-7 CAPLUS


CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-7-[2-[1-(phenylmethyl)-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265100-89-8 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-7-[2-[1-(phenylmethyl)-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 265100-90-1 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-(phenylmethyl)-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 265100-91-2 CAPLUS


CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-(phenylmethyl)-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265100-92-3 CAPLUS


CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl

RN 265100-93-4 CAPLUS


CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 265100-94-5 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

09/807,599




RN 265100-95-6 CAPLUS  
CN 1H-2-Benzazepine, 8-[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265100-96-7 CAPLUS  
CN Piperidine, 1-acetyl-4-[2-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 265100-97-8 CAPLUS  
CN Piperidine, 1-acetyl-4-[2-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 265100-98-9 CAPLUS


CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 265100-99-0 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 265101-00-6 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 265101-01-7 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2-  
[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, dihydrochloride (9CI) (CA  
INDEX NAME)


● 2 HCl

RN 265101-02-8 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-  
[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-,  
dihydrochloride (9CI) (CA INDEX NAME)

● 2 HCl

RN 265101-03-9 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-  
[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]- (9CI) (CA  
INDEX NAME)


RN 265101-04-0 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-

09/807,599

[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-CF<sub>3</sub>

RN 265101-05-1 CAPLUS

CN 1H-2-Benzazepine, 2-[[4-(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-[1-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

-CF<sub>3</sub>


RN 265101-06-2 CAPLUS

CN Acetic acid, [2-[[4-[2-[[2-[[4-(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 265101-07-3 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 265101-08-4 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265101-09-5 CAPLUS

CN 1H-2-Benzazepine, 8-[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl

RN 265101-10-8 CAPLUS


CN 1H-2-Benzazepine, 8-[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 265101-11-9 CAPLUS

CN Benzeneacetic acid, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 265101-12-0 CAPLUS

CN Benzeneacetic acid, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

09/807,599


.alpha.,.alpha.-dimethyl-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl


PAGE 1-B



RN 265101-13-1 CAPLUS


CN Benzeneacetic acid, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl


PAGE 1-B



RN 265101-14-2 CAPLUS

CN Benzeneacetic acid, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CO<sub>2</sub>H


RN 265101-15-3 CAPLUS

CN Benzonitrile, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265101-16-4 CAPLUS

CN Benzonitrile, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265101-17-5 CAPLUS

CN Benzenecarboximidic acid, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OEt

RN 265101-18-6 CAPLUS

CN Benzenecarboximidamide, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH<sub>2</sub>


RN 265101-19-7 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]- (9CI)  
(CA INDEX NAME)




RN 265101-20-0 CAPLUS

CN Benzenemethanamine, N,N-diethyl-4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265101-21-1 CAPLUS


CN Benzenemethanamine, N,N-diethyl-4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 265101-22-2 CAPLUS


CN Benzonitrile, 3-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 265101-23-3 CAPLUS

CN Benzonitrile, 3-[[4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 265101-24-4 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]- (9CI)  
(CA INDEX NAME)



RN 265101-25-5 CAPLUS


CN 1H-2-Benzazepine, 8-[2-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 265101-26-6 CAPLUS

CN Piperidine, 1-(4-cyanobenzoyl)-4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 265101-27-7 CAPLUS


CN Piperidine, 1-(4-cyanobenzoyl)-4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 265101-28-8 CAPLUS

CN Benzonitrile, 4-[[4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-7-yl]oxy]methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265101-29-9 CAPLUS

CN Benzonitrile, 4-[[4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-7-yl]oxy]methyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265101-30-2 CAPLUS


CN 1H-2-Benzazepine, 7-[[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)






RN 265101-31-3 CAPLUS

CN Benzonitrile, 4-[[4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265101-32-4 CAPLUS


CN Benzonitrile, 4-[[4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]methyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265101-33-5 CAPLUS

CN 1H-2-Benzazepine, 8-[[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265101-34-6 CAPLUS

CN Benzonitrile, 4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 265101-35-7 CAPLUS

CN 1H-2-Benzazepine, 8-[2-[1-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265101-36-8 CAPLUS

CN Benzenamine, N,N-dimethyl-4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 265101-37-9 CAPLUS


CN Benzenamine, N,N-dimethyl-4-[[4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 265101-38-0 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-[1-(phenylmethyl)-4-piperidinyl]propyl]sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265101-39-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-[1-(phenylmethyl)-4-piperidinyl]propyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265101-40-4 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 265101-41-5 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265101-42-6 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265101-43-7 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265101-44-8 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI)  
(CA INDEX NAME)



RN 265101-45-9 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265101-46-0 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[[3-[1-(phenylmethyl)-4-piperidinyl]propyl]sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265101-47-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[[3-[1-(phenylmethyl)-4-piperidinyl]propyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265101-48-2 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 265101-49-3 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 265101-50-6 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 265101-51-7 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 265101-52-8 CAPLUS

CN Piperidine, 1-benzoyl-4-[2-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 265101-53-9 CAPLUS


CN Piperidine, 1-benzoyl-4-[2-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 265101-54-0 CAPLUS

CN 1H-2-Benzazepine-8-sulfonamide, 2,3,4,5-tetrahydro-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]-2-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 265101-55-1 CAPLUS

CN 1H-2-Benzazepine-8-sulfonamide, 2,3,4,5-tetrahydro-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 265101-56-2 CAPLUS




09/807,599

CN 1H-2-Benzazepine-8-sulfonamide, 2,3,4,5-tetrahydro-2-(phenylmethyl)-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 265101-57-3 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[2-[1-(phenylmethyl)-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 265101-58-4 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]thio]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265101-59-5 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)




RN 265101-60-8 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 265101-61-9 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265101-62-0 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, oxime (9CI) (CA INDEX NAME)




RN 265101-63-1 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, oxime, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 265101-64-2 CAPLUS  
 CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, hydrazone (9CI) (CA INDEX NAME)



RN 265101-65-3 CAPLUS  
 CN Propanedinitrile, [3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]propylidene]- (9CI) (CA INDEX NAME)




RN 265101-66-4 CAPLUS  
 CN Propanedinitrile, [3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]propylidene]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265101-67-5 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 265101-68-6 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-(phenylmethyl)-N-[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 265101-69-7 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[imino[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



09/807,599


RN 265101-70-0 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[imino[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 265101-71-1 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[imino[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 265101-72-2 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[imino[[1-(phenylmethyl)-4-piperidinyl]amino]methyl]-3-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



IT 142853-03-0 215039-82-0 215039-92-2

215040-17-8 215040-21-4 215040-56-5

215040-67-8 215041-68-2 215047-91-9

265102-81-6 265102-82-7 265102-83-8


265102-84-9 265102-85-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of heterocyclic compds. as thermogenesis accelerators)


RN 142853-03-0 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215039-82-0 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215039-92-2 CAPLUS


CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215040-17-8 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe

09/807,599


RN 215040-21-4 CAPLUS

CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215040-56-5 CAPLUS

CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215040-67-8 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(2-phenylethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215041-68-2 CAPLUS

CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215047-91-9 CAPLUS

CN. 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 265102-81-6 CAPLUS

CN 1-Propanone, 3-(1-ethyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 265102-82-7 CAPLUS

CN 1-Propanone, 3-(1-propyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 265102-83-8 CAPLUS


CN 1-Propanone, 3-[1-(1-methylethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 265102-84-9 CAPLUS


CN 1-Propanone, 3-(1-butyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)





RN 265102-85-0 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidiny]- (9CI) (CA INDEX NAME)




IT 265101-80-2P 265101-81-3P 265101-83-5P  
 265101-86-8P 265101-88-0P 265101-90-4P  
 265101-93-7P 265101-95-9P 265101-97-1P  
 265102-00-9P 265102-03-2P 265102-10-1P  
 265102-13-4P 265102-16-7P 265102-19-0P  
 265102-21-4P 265102-22-5P 265102-23-6P  
 265102-24-7P 265102-25-8P 265102-26-9P  
 265102-27-0P 265102-28-1P 265102-29-2P  
 265102-37-2P 265102-38-3P 265102-39-4P  
 265102-40-7P 265102-41-8P 265102-42-9P  
 265102-43-0P 265102-44-1P 265102-45-2P  
 265102-46-3P 265102-48-5P 265102-51-0P  
 265102-53-2P 265102-55-4P 265102-56-5P  
 265102-57-6P 265102-58-7P 265102-59-8P  
 265102-60-1P 265102-61-2P 265102-62-3P  
 265102-64-5P 265102-65-6P 265102-66-7P  
 265102-67-8P 265102-68-9P 265102-69-0P  
 265102-70-3P 265102-71-4P 265102-72-5P  
 265102-73-6P 265102-74-7P 265102-75-8P  
 265102-76-9P 265102-77-0P 265102-78-1P  
 265102-98-5P 265102-99-6P 265103-01-3P  
 265103-03-5P 265103-05-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of heterocyclic compds. as thermogenesis accelerators)


RN 265101-80-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265101-81-3 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-7-[2-(4-piperidinylethoxy)]- (9CI) (CA INDEX NAME)




RN 265101-83-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[2-(4-piperidinylethoxy)]- (9CI) (CA INDEX NAME)




RN 265101-86-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265101-88-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-(4-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 265101-90-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265101-93-7 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-8-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 265101-95-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265101-97-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[3-(4-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 265102-00-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-03-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[2-(4-piperidinylethoxy)]- (9CI) (CA INDEX NAME)




RN 265102-10-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-13-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-16-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-19-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]thio]- (9CI) (CA INDEX NAME)



RN 265102-21-4 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]thio]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265102-22-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-23-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-24-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl)sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-25-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 265102-26-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]sulfinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265102-27-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-28-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



09/807,599


RN 265102-29-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-37-2 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 265102-38-3 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-8-[2-(4-piperidinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265102-39-4 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-7-[2-(4-piperidinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl


RN 265102-40-7 CAPLUS

CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-7-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 265102-41-8 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-7-[2-(4-piperidinyl)ethoxy]-2-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 265102-42-9 CAPLUS


CN 1H-2-Benzazepine, 2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-7-[3-(4-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 265102-43-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

09/807,599




RN 265102-44-1 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 265102-45-2 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-7-(4-piperidinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265102-46-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-48-5 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 265102-51-0 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-(4-piperidinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265102-53-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]thio]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-55-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-56-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)sulfonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-57-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-58-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-59-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-(4-piperidinyl)propyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265102-60-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[[3-(4-piperidinyl)propyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265102-61-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-62-3 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 265102-64-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(trifluoroacetyl)-1H-2-benzazepin-8-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-65-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-66-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-67-8 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-(4-piperidinyl)ethyl]thio]- (9CI) (CA INDEX NAME)




RN 265102-68-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(trifluoroacetyl)-1H-2-benzazepin-8-yl]sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-69-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-70-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]sulfinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265102-71-4 CAPLUS


CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-(4-piperidinyl)ethyl]sulfinyl]- (9CI) (CA INDEX NAME)






RN 265102-72-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(trifluoroacetyl)-1H-2-benzazepin-8-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-73-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-74-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 265102-75-8 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(phenylmethyl)-8-[[2-(4-piperidinyl)ethyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265102-76-9 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-8-[2-(4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 265102-77-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-(4-piperidinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265102-78-1 CAPLUS

CN Benzenecarboximidic acid, 3-[[4-[3-[[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepine-8-yl]ethoxy]propyl]phenyl]methyl]-2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepine-8-yl]ethoxy]- (9CI)

09/807,599

tetrahydro-1H-2-benzazepin-8-yl]oxy]propyl]-1-piperidinyl]methyl]-, ethyl  
ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—OEt


RN 265102-98-5 CAPLUS  
CN 1H-3-Benzazepin-7-ol, 8-[4-(1-acetyl-4-piperidinyl)-1-oxobutyl]-2,3,4,5-  
tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 265102-99-6 CAPLUS  
CN 1H-2-Benzazepin-7-ol, 8-[4-(1-acetyl-4-piperidinyl)-1-oxobutyl]-2,3,4,5-  
tetrahydro-2-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 265103-01-3 CAPLUS  
CN 1H-1-Benzazepin-7-ol, 8-[4-(1-acetyl-4-piperidinyl)-1-(hydroxyimino)butyl]-  
2,3,4,5-tetrahydro-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 265103-03-5 CAPLUS

CN 1H-3-Benzazepin-7-ol, 8-[4-(1-acetyl-4-piperidiny)-1-(hydroxyimino)butyl]-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 265103-05-7 CAPLUS

CN 1H-3-Benzazepin-7-ol, 8-[4-(1-acetyl-4-piperidiny)-1-(hydroxyimino)butyl]-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-, 7-acetate (9CI) (CA INDEX NAME)



RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/807,599

~~LX0~~ ANSWER 8 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 2000:260270 CAPLUS

DN 132:293680

TI Preparation of tetrahydrobenzazepine derivatives as modulators of dopamine D3 receptors (antipsychotic agents)

IN Hadley, Michael Stewart; Johnson, Christopher Norbert; MacDonald, Gregor James; Stemp, Geoffrey; Vong, Antonio Kuok Keong

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 102 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021951	A1	20000420	WO 1999-EP7763	19991006
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1119563	A1	20010801	EP 1999-953833	19991006
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9914370	A	20011127	BR 1999-14370	19991006
	JP 2002527433	T2	20020827	JP 2000-575857	19991006
	NO 2001001745	A	20010606	NO 2001-1745	20010406
PRAI	GB 1998-21976	A	19981008		
	GB 1998-24340	A	19981106		
	GB 1999-10711	A	19990507		
	GB 1999-18032	A	19990730		
	WO 1999-EP7763	W	19991006		
OS	MARPAT 132:293680				
GI					



AB The title compds. I [R1 represents a hydrogen or halogen atom, hydroxy,, etc.; R2 represents a hydrogen atom or a C1-4alkyl group; m is 1 or 2; A represents Ar, etc.; (Ar represents an optionally substituted Ph ring or an optionally substituted 5- or 6-membered arom. heterocyclic ring; or an

optionally substituted bicyclic ring system)] are prepd. In binding expts. on cloned dopamine receptors, compds. of this invention had pK<sub>i</sub> values in the range 7 - 9. Formulations are given.


IT 264262-48-8P 264262-55-7P 264262-57-9P  
264263-25-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of tetrahydrobenzazepine derivs. as modulators of dopamine D3 receptors (antipsychotic agents))

RN 264262-48-8 CAPLUS

CN 4-Quinolinecarboxamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264262-55-7 CAPLUS

CN 4-Quinolineacetamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264262-57-9 CAPLUS

CN 4-Quinolinecarboxamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264263-25-4 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(4-quinolinyl)-, (2E)- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/807,599

120 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 2000:227495 CAPLUS

DN 132:260683

TI Acetylcholinesterase-inhibiting amines for improving bladder vesical excretory strength

IN Ishihara, Yuji; Doi, Takayuki; Nagabukuro, Hiroshi; Ishichi, Yuji

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018391	A1	20000406	WO 1999-JP5367	19990930
	W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	JP 2000169373	A2	20000620	JP 1999-275614	19990929
	AU 9959995	A1	20000417	AU 1999-59995	19990930
	EP 1118322	A1	20010725	EP 1999-969675	19990930
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9914163	A	20010814	BR 1999-14163	19990930
	NO 2001001602	A	20010522	NO 2001-1602	20010329
PRAI	JP 1998-276677	A	19980930		
	WO 1999-JP5367	W	19990930		

OS MARPAT 132:260683


AB Drugs for improving bladder vesical excretory strength which contain a non-carbamate amine compd. (Markush's structures given) having an acetylcholinesterase inhibitory effect.

IT **142852-50-4P 263248-20-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(acetylcholinesterase-inhibiting amines for improving bladder vesical excretory strength)

RN 142852-50-4 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 263248-20-0 CAPLUS

CN 1H-2-Benzazepine, 2-acetyl-2,3,4,5-tetrahydro-8-[1-oxo-3-[1-(phenylmethyl)-4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)






IT 263248-40-4 263248-42-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(acetylcholinesterase-inhibiting amines for improving bladder vesical excretory strength)

RN 263248-40-4 CAPLUS

CN 1H-2-Benzazepine, 2-acetyl-2,3,4,5-tetrahydro-8-[1-oxo-3-[1-(phenylmethyl)-4-piperidinyl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 263248-42-6 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 142852-50-4

CMF C25 H32 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

09/807,599

Double bond geometry as shown.



RE.CNT 40      THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/807,599

LX0 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1999:690943 CAPLUS

DN 131:314195

TI Pharmaceutical composition for neurotropic action

IN Miyamoto, Masaomi; Kato, Koki; Ishihara, Yuji

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9953909	A2	19991028	WO 1999-JP2144	19990422
	WO 9953909	A3	19991209		
	W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2329624	AA	19991028	CA 1999-2329624	19990422
	JP 2000007568	A2	20000111	JP 1999-114513	19990422
	EP 1079816	A2	20010307	EP 1999-917103	19990422
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
PRAI	JP 1998-113662	A	19980423		
	WO 1999-JP2144	W	19990422		
OS	MARPAT 131:314195				
AB	The present invention provides a compn. for neurotropic action which comprises ArCO(CHR)nY, where Ar is an optionally condensed Ph group which may be substituted; n is 1-10; R is H or a hydrocarbon group which may be substituted; and Y is an amino group which may be substituted or a nitrogen-contg. satd. heterocyclic group which may be substituted; or a salt thereof, which compds. are useful for preventing and/or treating (1) neurodegenerative diseases (e.g. senile dementia, Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, diabetic neuropathy, etc.), (2) neuropathy in cerebrovascular diseases (e.g. impairment of cerebral blood flow based on cerebral infarction, cerebral hemorrhage, cerebral sclerosis, etc.), (3) brain trauma, spiral cord injury, cerebritis sequela and cerebral palsy, (4) mental diseases (e.g. depression, panic disorder, schizophrenia, etc.), etc. Tablets were prepd. contg. 3-[1-(phenylmethyl)-4-piperidyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate.				
IT	142852-51-5				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(pharmaceutical compn. contg. piperidylbenzazepinylpropanone deriv. for neurotropic action)				
RN	142852-51-5	CAPLUS			
CN	1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)				
CM	1				

09/807,599


CRN 142852-50-4  
CMF C25 H32 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



09/807,599

L20 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2002 ACS  
AN 1999:672796 CAPLUS  
DN 131:299286  
TI Preparation of amidine compounds as Xa inhibitors  
IN Katoh, Susumu; Yokota, Katsuyuki; Hayashi, Mikio  
PA Japan Tobacco Inc., Japan  
SO PCT Int. Appl., 280 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952895	A1	19991021	WO 1999-JP1900	19990409
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2327488	AA	19991021	CA 1999-2327488	19990409
	AU 9931677	A1	19991101	AU 1999-31677	19990409
	EP 1070714	A1	20010124	EP 1999-913608	19990409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
	BR 9910122	A	20011016	BR 1999-10122	19990409
	JP 2000136190	A2	20000516	JP 1999-103432	19990412
	JP 3283485	B2	20020520		
	NO 2000005083	A	20001208	NO 2000-5083	20001009
PRAI	JP 1998-116233	A	19980410		
	JP 1998-237869	A	19980825		
	WO 1999-JP1900	W	19990409		
OS	MARPAT 131:299286				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. R1R2NCR:NR3 [wherein R1, R2 and R3 are the same or different and each represents hydrogen, hydroxy, lower alkyl or aryl; and R represents formulas Q, Q1, and Q2; A = OCH2, OCH2CH2, SO2NH, ; R4 = H, Cl; R5 = H, CO2H, COOEt, COOMe; B = C6H5CH2SO2, CH2CH2OH, 4-pyridyl, 4-quinolinyl, 4-(2,6-dimethylpyridyl), 4-(2-methylpyridyl), 4-imidazolyl; G = 4-CH2N(4-COC6H4COOH)C6H4O, CH2O, CH2N(COCOOEt); F = (un)substituted aryl; n = 1, 2; D = arylcarbonyl, OMe, H, C6H5CH2; etc.], stereoisomers, and salts thereof or prodrugs of the same are prepd. and tested as factor Xa inhibitors and anticoagulants and usable in preventing and/or treating diseases caused by blood coagulation or thrombi. Thus, the title compd. I was prepd.


IT 247131-53-9P 247131-54-0P 247134-39-0P  
247134-40-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of amidine compds. as Xa inhibitors)

RN 247131-53-9 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-[[[2-(aminoiminomethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]methyl]-1-(4-pyridinyl)-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 247131-54-0 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-[[[2-(aminoiminomethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]methyl]-1-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 247134-39-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[[[2-(aminoiminomethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]methyl]-1-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 247134-40-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[[[2-(aminoiminomethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]methyl]-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)




IT **247133-26-2P 247133-27-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of amidine compds. as Xa inhibitors)

RN 247133-26-2 CAPLUS


CN 2H-2-Benzazepine-2-carboxylic acid, 8-[[[4-(ethoxycarbonyl)-1-(4-pyridinyl)-4-piperidinyl]methoxy]-1,3,4,5-tetrahydro-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



RN 247133-27-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-(4-pyridinyl)-4-[[[2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

09/807,599



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



09/807,599

L20 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1999:638338 CAPLUS

DN 131:252581

TI Use of idebenone in combination with acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

IN Miyamoto, Masaomi; Ohta, Hiroyuki; Goto, Giichi

PA Takeda Chemical Industries, Ltd., Japan

SO U.S., 14 pp., Cont.-in-part of Appl. No. PCT/JP98/00109.

CODEN: USXXAM

DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5962535	A	19991005	US 1998-42625	19980317
	WO 9831356	A1	19980723	WO 1998-JP109	19980114
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
PRAI	JP 1997-6147	A	19970117		
	US 1997-65597P	P	19971118		
	WO 1998-JP109	A2	19980114		
OS	MARPAT 131:252581				
AB	A pharmaceutical compn. comprising idebenone in combination with a compd. having acetylcholinesterase inhibitory activity is useful for treating or preventing Alzheimer's disease. Ameliorative effects of the combined use of idebenone and 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate on learning deficits was investigated in aged rats.				
IT	<b>142852-51-5</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (idebenone in combination with acetylcholinesterase inhibitor for treatment of Alzheimer's disease)				
RN	142852-51-5 CAPLUS				
CN	1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)				

CM 1

CRN 142852-50-4

CMF C25 H32 N2 O




09/807,599

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 9      THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/807,599

~~L20~~ ANSWER 13 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1999:629286 CAPLUS

DN 132:132190

TI Preferential inhibition of acetylcholinesterase molecular forms in normal human brain

AU Rakonczay, Z.; Torok, L.; Kasa, P.

CS Alzheimer's Disease Research Center, Albert Szent-Gyorgyi Medical University, Szeged, Hung.

SO Neurobiology (Budapest) (1999), 7(1), 75-77  
CODEN: NROBEZ; ISSN: 1216-8068

PB Akademiai Kiado

DT Journal

LA English

AB The inhibition of human brain acetylcholinesterase (AChE) by a new generation of cholinesterase inhibitors were measured and compared with those obtained for a homologous enzyme, butyrylcholinesterase (BuChE). In vitro, several inhibitors were more potent at inhibiting human plasma BuChE than human brain AChE. Among the inhibitors tested (tacrine, bis-tacrine, heptyl-physostigmine, and TAK-147), only heptyl-physostigmine displayed preferential inhibition of the G1 form of AChE. All others inhibited both the G1 and G4 forms equally well. Selective loss of the membrane-assocd. G4 form has been reported in the brain in Alzheimer's disease, while the G1 form is relatively unchanged. These results may therefore suggest the suitability of heptyl-physostigmine, a possible mol. for selective inhibitor, for therapeutic application.

IT 142852-51-5, TAK-147

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preferential inhibition of acetylcholinesterase mol. forms in normal human brain)


RN 142852-51-5 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-50-4

CMF C25 H32 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

09/807,599



RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/807,599

L20 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1999:613655 CAPLUS

DN 131:248236

TI Combination of a GABAA.alpha.5 inverse agonist and an acetylcholinesterase inhibitor for treatment of neurodegenerative diseases

IN Dawson, Gerard Raphael

PA Merck Sharp & Dohme Limited, UK

SO PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9947131	A2	19990923	WO 1999-GB778	19990316
	WO 9947131	A3	19991104		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2323618	AA	19990923	CA 1999-2323618	19990316
	AU 9928464	A1	19991011	AU 1999-28464	19990316
	EP 1061952	A2	20001227	EP 1999-909095	19990316
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	JP 2002506815	T2	20020305	JP 2000-536371	19990316
PRAI	GB 1998-5561	A	19980316		
	WO 1999-GB778	W	19990316		
AB	The present invention relates to a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA.alpha.5 receptor subtype, and the use of the combination in treating neurodegenerative conditions such as Alzheimer's Disease.				
IT	<b>142852-51-5</b> , Tak-147 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (acetylcholinesterase inhibitor; combination of a GABAA.alpha.5 inverse agonist and an acetylcholinesterase inhibitor for treatment of neurodegenerative diseases)				
RN	142852-51-5 CAPLUS				
CN	1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)				

CM 1

CRN 142852-50-4

CMF C25 H32 N2 O

09/807,599




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



09/807,599

L20 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1999:487286 CAPLUS

DN 131:116236

TI Preparation of heterocyclylbenzamide derivatives as vasopressin antagonists

IN Setoi, Hiroyuki; Ohkawa, Takehiko; Sawada, Yuki; Osoda, Kazuhiko; Oku, Teruo

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 102 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----		-----	-----	-----
PI	WO 9937637	A1	19990729	WO 1999-JP72	19990111
	W: AU, BR, CA, CN, HU, IN, JP, KR, MX, RU, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9917856	A1	19990809	AU 1999-17856	19990111
	EP 1051415	A1	20001115	EP 1999-900176	19990111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002513425	T2	20020508	JP 1999-538151	19990111
PRAI	AU 1998-1500	A	19980127		
	WO 1999-JP72	W	19990111		
OS	MARPAT 131:116236				
GI					



AB The title compds. I [A is an optionally substituted heterocyclic group; R is a lower alkoxy; Z is CO or CH<sub>2</sub>; and B is a satd. or unsatd. condensed ring group selected from the group consisting of benzazepinyl, benzodiazepinyl, pyridoazepinyl, pyridodiazepinyl, thienoazepinyl, benzoxazepinyl, benzothiazepinyl, imidazobenzazepinyl, pyridobenzoxazepinyl and indolinyl, each member being optionally substituted] are prepd. In an in vitro test for human vasopressin 1 receptor antagonism, 2-methoxy-N-(2-methyl-1H-benzimidazol-4-yl)-4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonylbenzamide showed IC<sub>50</sub> of 0.41 nM.


IT **233263-50-8P 233263-51-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of heterocyclylbenzamide derivs. as vasopressin antagonists)

RN 233263-50-8 CAPLUS


CN Benzamide, N-[2-[4-(dimethylamino)-1-piperidinyl]-1H-benzimidazol-4-yl]-2-methoxy-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]- (9CI) (CA INDEX NAME)

09/807,599



RN 233263-51-9 CAPLUS

CN Benzamide, N-[2-[4-(dimethylamino)-1-piperidinyl]-1H-benzimidazol-4-yl]-2-methoxy-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



09/807,599

120 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1999:193900 CAPLUS

DN 130:227742

TI Stabilized pharmaceutical compositions coated with metal oxides and free radical scavengers

IN Fukuta, Makoto; Itoh, Hiroki

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 18 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 901787	A1	19990317	EP 1998-307200	19980907
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2247011	AA	19990310	CA 1998-2247011	19980909
	US 6187340	B1	20010213	US 1998-149122	19980909
	JP 11147819	A2	19990602	JP 1998-256164	19980910
PRAI	JP 1997-245778	A	19970910		
AB	Disclosed is a stabilized pharmaceutical prepn. which is coated with a coating agent comprising (1) an agent for the protection from light, producing free radicals when exposed to UV rays, i.e. a metal oxide and (2) a free radical scavenger, e.g. a sulfite or a vitamin. The coated pharmaceutical prepn. is stable to light, esp. UV light, or heat and has excellent storage stability. A coating agent contg. hydroxypropyl Me cellulose 121.6, PEG 6000 30, water 2300, TiO <sub>2</sub> 20, Fe <sub>2</sub> O <sub>3</sub> 0.4, NaHSO <sub>3</sub> 14, and NaHCO <sub>3</sub> 14 g was formulated and sprayed onto plain tablets of TAK-147.				
IT	<b>142852-51-5</b> RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tablet coating agents contg. metal oxides and radial scavengers to protect from UV rays and heat)				
RN	142852-51-5 CAPLUS.				
CN	1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)				

CM 1

CRN 142852-50-4

CMF C25 H32 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

09/807,599



RE.CNT 5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/807,599

~~L20~~ ANSWER 17 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1999:17300 CAPLUS

DN 130:276572

TI TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons

AU Kato, Koki; Hayako, Hitomi; Ishihara, Yuji; Marui, Shogo; Iwane, Makoto; Miyamoto, Masaomi

CS Pharmaceutical Research Division, Pharmaceutical Research Laboratories V, Takeda Chemical Industries Ltd., Yodogawa-ku, Osaka, 532-8686, Japan

SO Neuroscience Letters (1999), 260(1), 5-8

CODEN: NELED5; ISSN: 0304-3940

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

AB TAK-147, a potent acetylcholinesterase (AChE) inhibitor, potentiated choline acetyltransferase (ChAT) activity in cultured rat septal cholinergic neurons in a concn.-dependent manner with an EC50 value of 4.47 nM. Donepezil, another potent AChE inhibitor, also increased ChAT activity although its potency was less than that of TAK-147. Other AChE inhibitors (rivastigmine, tacrine, physostigmine and neostigmine) showed no effect. The effects of TAK-147 were greater in the presence of NGF, suggesting a synergistic action of TAK-147 and NGF. TAK-147 and donepezil showed high affinity for .sigma. receptors, whereas tacrine and physostigmine did not. Haloperidol and ifenprodil, high-affinity .sigma. ligands, potentially enhanced ChAT activity in the septal neurons. These results suggest that TAK-147 may have neurotrophic activity on central cholinergic neurons, not via AChE inhibition but possibly via an effect on .sigma. receptors.

IT 142852-51-5, TAK-147

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons)


RN 142852-51-5 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-50-4

CMF C25 H32 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.


09/807,599



RE.CNT 19      THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

120 ANSWER 18 OF 49 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:708810 CAPLUS  
 DN 129:330744  
 TI Preparation of benzazepine thermogenics  
 IN Ishihara, Yuji; Fujisawa, Yukio; Furuyama, Naoki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 399 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846590	A1	19981022	WO 1998-JP1753	19980416
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9868528	A1	19981111	AU 1998-68528	19980416
	EP 975624	A1	20000202	EP 1998-914055	19980416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11310532	A2	19991109	JP 1998-107257	19980417
PRAI	JP 1997-100675		19970417		
	JP 1998-41495		19980224		
	JP 1998-14149		19980224		
	WO 1998-JP1753		19980416		
OS	MARPAT 129:330744				
GI					



II

AB The title compds. ArC(O)(CHR)<sub>n</sub>Y [I; Ar = Ph which may be substituted and/or condensed; n = 1-10; R = H, hydrocarbon group which may be substituted, which may not be the same in n occurrences; R may be bound to either Ar or a substituent on Ar; Y = (un)substituted NH<sub>2</sub>, (un)substituted nitrogen-contg. satd. heterocyclic group] and their salts, useful as thermogenic, antiobesity, and lipolytic agents, or as prophylactic and/or treating drugs for obesity-assocd. diseases or diabetes with a reduced risk for central side effects and high universality in usage, were prepd. and formulated. Thus, reaction of 3-(1-acetyl-4-piperidinyl)propionyl chloride with 3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepine in the presence of AlCl<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> followed by treatment of the resulting 3-(1-acetyl-4-piperidinyl)-1-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-propanone in MeOH with conc. HCl, and reaction of 3-(1-acetyl-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-propanone with benzyl bromide afforded the title compd. II.HCl which


showed cAMP concn. of 1369.1 pmol/mL at 10<sup>-5</sup> M in murine preadipocyte line (3T3-L1).

IT 142853-04-1P 160300-43-6P 215039-79-5P  
 215039-82-0P 215039-84-2P 215039-86-4P  
 215039-88-6P 215040-13-4P 215040-17-8P  
 215040-48-5P 215041-21-7P 215041-22-8P  
 215041-24-0P 215041-59-1P 215041-62-6P  
 215041-92-2P 215041-94-4P 215042-26-5P  
 215042-28-7P 215042-46-9P 215042-48-1P  
 215042-54-9P 215042-60-7P 215042-74-3P  
 215042-78-7P 215042-80-1P 215042-82-3P  
 215042-96-9P 215042-98-1P 215043-02-0P  
 215043-08-6P 215043-10-0P 215043-19-9P  
 215043-46-2P 215043-47-3P 215043-51-9P  
 215043-53-1P 215043-75-7P 215043-77-9P  
 215043-83-7P 215044-05-6P 215044-10-3P  
 215044-15-8P 215044-18-1P 215044-27-2P  
 215044-36-3P 215044-73-8P 215044-79-4P  
 215044-91-0P 215044-93-2P 215045-08-2P  
 215045-24-2P 215045-28-6P 215045-34-4P  
 215045-47-9P 215045-52-6P 215045-56-0P  
 215045-65-1P 215045-69-5P 215045-96-8P  
 215046-25-6P 215046-35-8P 215046-39-2P  
 215046-97-2P 215047-01-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of benzazepine thermogenics)


RN 142853-04-1 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 160300-43-6 CAPLUS

CN 1H-2-Benzazepine, 2-acetyl-2,3,4,5-tetrahydro-8-[1-oxo-3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 215039-79-5 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 215039-82-0 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215039-84-2 CAPLUS

CN Piperidine, 1-acetyl-4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]- (9CI) (CA INDEX NAME)




RN 215039-86-4 CAPLUS

CN 1-Butanone, 4-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215039-88-6 CAPLUS

CN Piperidine, 1-acetyl-4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215040-13-4 CAPLUS


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 215040-17-8 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe


RN 215040-48-5 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]propyl]- (9CI) (CA INDEX NAME)






RN	215041-21-7	CAPLUS	
CN	Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)		



RN	215041-22-8	CAPLUS
CN	1-Propanone, 3-(4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)	




RN	215041-24-0	CAPLUS
CN	1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)	

COc1ccc(cc1)CN2Cc3cc(ccc3N2)C(=O)OCCN4CCCCC4CN(C4)Cc5ccc(cc5)C6=CC=CC=C6

— F


RN	215041-59-1	CAPLUS
CN	Piperidine, 1-acetyl-4-[2-oxo-2-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)	



● HCl


RN 215041-62-6 CAPLUS

CN Ethanone, 2-(4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215041-92-2 CAPLUS

CN Piperidine, 1-acetyl-4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]- (9CI) (CA INDEX NAME)




RN 215041-94-4 CAPLUS

CN 1-Butanone, 4-(4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-26-5 CAPLUS


CN Piperidine, 1-acetyl-4-[4-oxo-4-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215042-28-7 CAPLUS

CN 1-Butanone, 4-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215042-46-9 CAPLUS

CN Benzoic acid, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 215042-48-1 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215042-54-9 CAPLUS

CN 1-Butanone, 4-[1-[(3-methoxyphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-60-7 CAPLUS


CN 1-Butanone, 4-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215042-74-3 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



—OEt


RN 215042-78-7 CAPLUS

CN 1H-3-Benzazepine, 3-acetyl-7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 215042-80-1 CAPLUS

CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 215042-82-3 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

— OEt


RN 215042-96-9 CAPLUS

CN Acetamide, N-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 215042-98-1 CAPLUS

CN 1-Butanone, 4-[1-[(3-aminophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215043-02-0 CAPLUS


CN Benzoic acid, 4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 215043-08-6 CAPLUS

CN Benzeneacetic acid, 4-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 215043-10-0 CAPLUS

CN Benzeneacetic acid, 3-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 215043-19-9 CAPLUS

CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 215043-46-2 CAPLUS

CN 1H-3-Benzazepine, 3-acetyl-7-[5-(1-acetyl-4-piperidinyl)-1-oxopentyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 215043-47-3 CAPLUS

CN 1-Pentanone, 5-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 215043-51-9 CAPLUS


CN Piperidine, 1-acetyl-4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215043-53-1 CAPLUS


CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-(4-piperidinyl)- (9CI) (CA INDEX NAME)





RN 215043-75-7 CAPLUS  
 CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(3-nitrophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NO<sub>2</sub>

RN 215043-77-9 CAPLUS  
 CN 1-Propanone, 3-[1-[(3-aminophenyl)methyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



—NH<sub>2</sub>


RN 215043-83-7 CAPLUS

CN Benzonitrile, 3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 215044-05-6 CAPLUS

CN 1H-3-Benzazepine, 3-acetyl-2,3,4,5-tetrahydro-7-[1-oxo-4-(4-piperidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 215044-10-3 CAPLUS

CN 1H-3-Benzazepine, 3-acetyl-2,3,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)




RN 215044-15-8 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 215044-18-1 CAPLUS

CN Piperidine, 1-acetyl-4-[4-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-oxobutyl]- (9CI) (CA INDEX NAME)




RN 215044-27-2 CAPLUS

CN Benzoic acid, 2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 215044-36-3 CAPLUS


CN Acetic acid, [2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215044-73-8 CAPLUS


CN Acetamide, N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-

methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 215044-79-4 CAPLUS

CN 1-Butanone, 4-[1-[(2-aminophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215044-91-0 CAPLUS

CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 215044-93-2 CAPLUS

CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 215045-08-2 CAPLUS

CN Benzonitrile, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-  
(9CI) (CA INDEX NAME)




RN 215045-24-2 CAPLUS

CN 1H-3-Benzazepine, 3-acetyl-7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 215045-28-6 CAPLUS

CN Benzonitrile, 2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 215045-34-4 CAPLUS

CN Benzonitrile, 3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 215045-47-9 CAPLUS  
CN Benzonitrile, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 215045-52-6 CAPLUS  
CN Benzeneacetic acid, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 215045-56-0 CAPLUS  
CN Acetic acid, [2-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215045-65-1 CAPLUS

CN 1H-2-Benzazepine, 2-acetyl-2,3,4,5-tetrahydro-8-[3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215045-69-5 CAPLUS


CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 215045-96-8 CAPLUS

CN Benzeneacetic acid, 3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A






RN 215046-25-6 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(oxiranylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215046-35-8 CAPLUS

CN Acetamide, N-[3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 215046-39-2 CAPLUS

CN 1-Butanone, 1-[3-[(3-aminophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215046-97-2 CAPLUS

CN Acetamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-




oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]- (9CI)  
(CA INDEX NAME)



RN 215047-01-1 CAPLUS

CN 1-Butanone, 1-[3-[(2-aminophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




IT 142852-50-4P 142852-52-6P 142852-54-8P  
142852-56-0P 142852-89-9P 142853-03-0P  
215039-77-3P 215039-81-9P 215039-83-1P  
215039-85-3P 215039-87-5P 215039-89-7P  
215039-90-0P 215039-91-1P 215039-92-2P  
215039-93-3P 215039-94-4P 215039-95-5P  
215039-96-6P 215039-97-7P 215039-98-8P  
215039-99-9P 215040-00-9P 215040-01-0P  
215040-02-1P 215040-03-2P 215040-04-3P  
215040-06-5P 215040-07-6P 215040-08-7P  
215040-09-8P 215040-10-1P 215040-11-2P  
215040-15-6P 215040-19-0P 215040-21-4P  
215040-23-6P 215040-25-8P 215040-26-9P  
215040-28-1P 215040-30-5P 215040-32-7P  
215040-34-9P 215040-36-1P 215040-37-2P  
215040-38-3P 215040-39-4P 215040-40-7P  
215040-41-8P 215040-42-9P 215040-43-0P  
215040-44-1P 215040-45-2P 215040-46-3P  
215040-47-4P 215040-49-6P 215040-50-9P  
215040-51-0P 215040-52-1P 215040-53-2P  
215040-54-3P 215040-55-4P 215040-56-5P  
215040-57-6P 215040-58-7P 215040-59-8P  
215040-60-1P 215040-61-2P 215040-62-3P  
215040-64-5P 215040-65-6P 215040-66-7P  
215040-67-8P 215041-20-6P 215041-23-9P  
215041-25-1P 215041-26-2P 215041-27-3P  
215041-28-4P 215041-29-5P 215041-30-8P  
215041-31-9P 215041-32-0P 215041-33-1P

215041-34-2P 215041-35-3P 215041-37-5P  
 215041-38-6P 215041-39-7P 215041-60-4P  
 215041-61-5P 215041-63-7P 215041-64-8P  
 215041-65-9P 215041-66-0P 215041-67-1P  
 215041-68-2P 215041-69-3P 215041-70-6P  
 215041-71-7P 215041-72-8P 215041-73-9P  
 215041-74-0P 215041-75-1P 215041-76-2P  
 215041-77-3P 215041-78-4P 215041-79-5P  
 215041-80-8P 215041-81-9P 215041-82-0P  
 215041-83-1P 215041-85-3P 215041-86-4P  
 215041-87-5P 215041-88-6P 215041-89-7P  
 215041-90-0P 215041-91-1P 215041-95-5P  
 215041-96-6P 215041-97-7P 215041-98-8P  
 215041-99-9P 215042-00-5P 215042-01-6P  
 215042-02-7P 215042-03-8P 215042-04-9P  
 215042-05-0P 215042-06-1P 215042-07-2P  
 215042-08-3P 215042-09-4P 215042-10-7P  
 215042-11-8P 215042-12-9P 215042-13-0P  
 215042-14-1P 215042-15-2P 215042-16-3P  
 215042-17-4P 215042-18-5P 215042-19-6P  
 215042-20-9P 215042-21-0P 215042-22-1P  
 215042-23-2P 215042-25-4P 215042-27-6P  
 215042-29-8P 215042-30-1P 215042-31-2P  
 215042-32-3P 215042-33-4P 215042-34-5P  
 215042-35-6P 215042-36-7P 215042-37-8P  
 215042-38-9P 215042-39-0P 215042-40-3P  
 215042-41-4P 215042-42-5P 215042-43-6P  
 215042-44-7P 215042-45-8P 215042-47-0P  
 215042-49-2P 215042-50-5P 215042-51-6P  
 215042-52-7P 215042-53-8P 215042-55-0P  
 215042-57-2P 215042-58-3P 215042-59-4P  
 215042-61-8P 215042-62-9P 215042-63-0P  
 215042-64-1P 215042-65-2P 215042-66-3P  
 215042-67-4P 215042-68-5P 215042-69-6P  
 215042-70-9P 215042-71-0P 215042-72-1P  
 215042-73-2P 215042-75-4P 215042-76-5P  
 215042-77-6P 215042-79-8P 215042-81-2P  
 215042-83-4P 215042-84-5P 215042-85-6P  
 215042-86-7P 215042-87-8P 215042-89-0P  
 215042-90-3P 215042-91-4P 215042-92-5P  
 215042-93-6P 215042-94-7P 215042-95-8P  
 215042-97-0P 215042-99-2P 215043-00-8P  
 215043-01-9P 215043-03-1P 215043-04-2P  
 215043-05-3P 215043-06-4P 215043-07-5P  
 215043-09-7P 215043-11-1P 215043-12-2P  
 215043-13-3P 215043-14-4P 215043-15-5P  
 215043-16-6P 215043-17-7P 215043-18-8P  
 215043-20-2P 215043-21-3P 215043-22-4P  
 215043-23-5P 215043-24-6P 215043-25-7P  
 215043-26-8P 215043-27-9P 215043-28-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of benzazepine thermogenics)


RN 142852-50-4 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 142852-52-6 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1-methyl-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 142852-54-8 CAPLUS

CN 1-Propanone, 1-(1-ethyl-2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-3-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 142852-56-0 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1-propyl-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 142852-89-9 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 142853-03-0 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215039-77-3 CAPLUS


CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 215039-81-9 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




2 HCl

09/807,599

RN 215039-83-1 CAPLUS


CN Piperidine, 1-acetyl-4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 215039-85-3 CAPLUS


CN 1-Butanone, 4-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 215039-87-5 CAPLUS


CN Piperidine, 1-acetyl-4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215039-89-7 CAPLUS

CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215039-90-0 CAPLUS  
CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215039-91-1 CAPLUS  
CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215039-92-2 CAPLUS  
CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



09/807,599

RN 215039-93-3 CAPLUS


CN 1-Propanone, 3-[1-(2-phenylethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215039-94-4 CAPLUS

CN 1-Propanone, 3-[1-(2-phenylethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215039-95-5 CAPLUS


CN 1-Propanone, 3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215039-96-6 CAPLUS

CN 1-Propanone, 3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215039-97-7 CAPLUS


CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl

RN 215039-98-8 CAPLUS


CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215039-99-9 CAPLUS


CN Piperidine, 1-benzoyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 215040-00-9 CAPLUS  
CN Piperidine, 1-benzoyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 215040-01-0 CAPLUS  
CN 1-Propanone, 3-(1-methyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215040-02-1 CAPLUS  
CN 1-Propanone, 3-(1-methyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215040-03-2 CAPLUS


CN 1-Piperidineacetic acid, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 215040-04-3 CAPLUS

CN 1-Piperidineacetic acid, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215040-06-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215040-07-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215040-08-7 CAPLUS

CN Piperidine, 1-(methylsulfonyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)



RN 215040-09-8 CAPLUS


CN 1-Piperidinecarboxamide, N-methyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215040-10-1 CAPLUS

CN 1-Piperidinecarboxamide, N-methyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)



RN 215040-11-2 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-(4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215040-15-6 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B


— OMe

RN 215040-19-0 CAPLUS  
 CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215040-21-4 CAPLUS  
 CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215040-23-6 CAPLUS

09/807,599


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-(1-methyl-4-piperidiny)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215040-25-8 CAPLUS


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-(1-methyl-4-piperidiny)- (9CI) (CA INDEX NAME)



RN 215040-26-9 CAPLUS


CN Benzeneacetic acid, 4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidiny]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B




RN 215040-28-1 CAPLUS

CN Benzeneacetic acid, 4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215040-30-5 CAPLUS

CN 1-Propanone, 3-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

— OMe

RN 215040-32-7 CAPLUS

CN 1-Propanone, 3-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


— OMe

RN 215040-34-9 CAPLUS

CN Acetic acid, [4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




PAGE 1-A




● 2 HCl

PAGE 1-B




RN 215040-36-1 CAPLUS  
 CN Acetic acid, [4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester  
 (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 215040-37-2 CAPLUS  
 CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-(phenylmethyl)-4-piperidinyl]-, dihydrochloride  
 (9CI) (CA INDEX NAME)



● 2 HCl

RN 215040-38-3 CAPLUS


CN 1-Propanone, 1-[3-[[4-(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215040-39-4 CAPLUS

CN 1-Propanone, 3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-piperidinyl]-1-[3-[[4-(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

— Bu-t

RN 215040-40-7 CAPLUS

CN 1-Propanone, 3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-piperidinyl]-1-[3-[[4-(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Bu-t

RN 215040-41-8 CAPLUS


CN Benzoic acid, 4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B




RN 215040-42-9 CAPLUS

CN Benzoic acid, 4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215040-43-0 CAPLUS


CN 1-Propanone, 3-[1-([1,1'-biphenyl]-4-ylmethyl)-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215040-44-1 CAPLUS


CN 1-Propanone, 3-[1-([1,1'-biphenyl]-4-ylmethyl)-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215040-45-2 CAPLUS

09/807,599


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215040-46-3 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215040-47-4 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215040-49-6 CAPLUS


CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-2-[(4-methoxyphenyl)methyl]-1H-2-benzazepin-8-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

09/807,599




● HCl

RN 215040-50-9 CAPLUS  
CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-2-[(4-methoxyphenyl)methyl]-1H-2-benzazepin-8-yl]propyl]- (9CI) (CA INDEX NAME)




RN 215040-51-0 CAPLUS  
CN 1-Propanone, 3-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215040-52-1 CAPLUS  
CN 1-Propanone, 3-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



09/807,599

RN 215040-53-2 CAPLUS


CN 1-Propanone, 3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



●2 HCl


RN 215040-54-3 CAPLUS

CN 1-Propanone, 3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215040-55-4 CAPLUS


CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



●2 HCl


RN 215040-56-5 CAPLUS

CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215040-57-6 CAPLUS


CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl

RN 215040-58-7 CAPLUS


CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215040-59-8 CAPLUS


CN 1-Propanone, 3-[1-[(2,6-dichlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)






● 2 HCl

RN 215040-60-1 CAPLUS  
CN 1-Propanone, 3-[1-[(2,6-dichlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215040-61-2 CAPLUS  
CN 1-Propanone, 3-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215040-62-3 CAPLUS  
CN 1-Propanone, 3-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)

09/807,599



RN 215040-64-5 CAPLUS


CN 1-Propanone, 3-[1-(9H-fluoren-9-yl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215040-65-6 CAPLUS

CN 1-Propanone, 3-[1-(9H-fluoren-9-yl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215040-66-7 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(2-phenylethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215040-67-8 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(2-phenylethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215041-20-6 CAPLUS


CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 215041-23-9 CAPLUS  
 CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

— F


RN 215041-25-1 CAPLUS  
 CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215041-26-2 CAPLUS


CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215041-27-3 CAPLUS

CN 1-Propanone, 3-[1-[(4-(1,1-dimethylethyl)phenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl

PAGE 1-B


— Bu-t

RN 215041-28-4 CAPLUS

09/807,599

CN 1-Propanone, 3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Bu-t


RN 215041-29-5 CAPLUS  
CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-4-[[4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-1-piperidinyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B




RN 215041-30-8 CAPLUS  
CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-4-[[4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-1-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215041-31-9 CAPLUS


CN Piperidine, 1-(4-chlorobenzoyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl

RN 215041-32-0 CAPLUS

CN Piperidine, 1-(4-chlorobenzoyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




09/807,599

RN 215041-33-1 CAPLUS

CN 1-Propanone, 3-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

— Cl

RN 215041-34-2 CAPLUS

CN 1-Propanone, 3-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Cl


RN 215041-35-3 CAPLUS



09/807,599

CN 1-Propanone, 3-[1-([1,1'-biphenyl]-4-ylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

— Ph

RN 215041-37-5 CAPLUS

CN 1-Propanone, 3-[1-([1,1'-biphenyl]-4-ylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Ph

RN 215041-38-6 CAPLUS


CN Piperidine, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215041-39-7 CAPLUS

CN Piperidine, 1-([1,1'-biphenyl]-4-ylcarbonyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]- (9CI)  
(CA INDEX NAME)




RN 215041-60-4 CAPLUS

CN Piperidine, 1-acetyl-4-[2-oxo-2-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 215041-61-5 CAPLUS

CN Ethanone, 2-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215041-63-7 CAPLUS  
 CN Ethanone, 2-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215041-64-8 CAPLUS  
 CN Ethanone, 2-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215041-65-9 CAPLUS  
 CN Ethanone, 2-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215041-66-0 CAPLUS  
 CN Ethanone, 2-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215041-67-1 CAPLUS  
 CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 215041-68-2 CAPLUS  
 CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN	215041-69-3	CAPLUS
CN	1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)	




RN	215041-70-6	CAPLUS
CN	1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)	



RN	215041-71-7	CAPLUS
CN	Ethanone, 2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)	




RN	215041-72-8	CAPLUS
CN	Ethanone, 2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)	



RN 215041-73-9 CAPLUS


CN Ethanone, 2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 215041-74-0 CAPLUS

CN Ethanone, 2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215041-75-1 CAPLUS


CN Ethanone, 2-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



2 HCl


RN 215041-76-2 CAPLUS

CN Ethanone, 2-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215041-77-3 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215041-78-4 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215041-79-5 CAPLUS

CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215041-80-8 CAPLUS  
CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215041-81-9 CAPLUS  
CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215041-82-0 CAPLUS  
CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)





RN 215041-83-1 CAPLUS


CN Benzeneacetic acid, 4-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215041-85-3 CAPLUS

CN Benzeneacetic acid, 4-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215041-86-4 CAPLUS


CN Benzeneacetic acid, 3-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215041-87-5 CAPLUS

CN Benzeneacetic acid, 3-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215041-88-6 CAPLUS


CN Acetic acid, [4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215041-89-7 CAPLUS

CN Acetic acid, [4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215041-90-0 CAPLUS


CN Piperidine, 1-acetyl-4-[3-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215041-91-1 CAPLUS

CN Piperidine, 1-acetyl-4-[3-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215041-95-5 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 215041-96-6 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215041-97-7 CAPLUS


CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215041-98-8 CAPLUS

CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215041-99-9 CAPLUS


CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-00-5 CAPLUS

CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-01-6 CAPLUS


CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-02-7 CAPLUS

CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-03-8 CAPLUS


RX CN	<p>Piperidine, 1-acetyl-4-[3-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)</p>
----------	---



● HCl


RN 215042-04-9 CAPLUS

Piperidine, 1-acetyl-4-[3-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215042-05-0 CAPLUS


CN Piperidine, 1-acetyl-4-[3-(3-butyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


RN 215042-06-1 CAPLUS

CN Piperidine, 1-acetyl-4-[3-(3-butyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215042-07-2 CAPLUS


CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215042-08-3 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 215042-09-4 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215042-10-7 CAPLUS  
CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 215042-11-8 CAPLUS  
CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215042-12-9 CAPLUS  
CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)






RN 215042-13-0 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(2-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215042-14-1 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(2-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 215042-15-2 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(3-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215042-16-3 CAPLUS  
CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-[(3-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 215042-17-4 CAPLUS  
CN Piperidine, 1-acetyl-4-[3-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215042-18-5 CAPLUS  
CN Piperidine, 1-acetyl-4-[3-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 215042-19-6 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215042-20-9 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 215042-21-0 CAPLUS  
 CN Acetic acid, [3-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215042-22-1 CAPLUS

CN Acetic acid, [3-[[7-[3-(1-acetyl-4-piperidiny)]-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215042-23-2 CAPLUS


CN Acetic acid, [2-[[7-[3-(1-acetyl-4-piperidiny)]-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215042-25-4 CAPLUS

CN Acetic acid, [2-[[7-[3-(1-acetyl-4-piperidiny)]-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 215042-27-6 CAPLUS

CN Piperidine, 1-acetyl-4-[4-oxo-4-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]butyl]- (9CI) (CA INDEX NAME)



RN 215042-29-8 CAPLUS


CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-30-1 CAPLUS

CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215042-31-2 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-32-3 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-33-4 CAPLUS


CN 1-Butanone, 1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-4-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-34-5 CAPLUS

CN 1-Butanone, 1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-4-[1-[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215042-35-6 CAPLUS


CN 1-Butanone, 1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-4-[1-[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-36-7 CAPLUS

CN 1-Butanone, 1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-4-[1-[3,5-bis(trifluoromethyl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215042-37-8 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



●2 HCl

RN 215042-38-9 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215042-39-0 CAPLUS


CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)






● 2 HCl

RN 215042-40-3 CAPLUS  
CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215042-41-4 CAPLUS  
CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215042-42-5 CAPLUS  
CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215042-43-6 CAPLUS  
 CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
 (CA INDEX NAME)




● 2 HCl

RN 215042-44-7 CAPLUS  
 CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215042-45-8 CAPLUS  
 CN Benzoic acid, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215042-47-0 CAPLUS


CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215042-49-2 CAPLUS

CN 1-Butanone, 4-[1-[(3-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215042-50-5 CAPLUS


CN 1-Butanone, 4-[1-[(3-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)

09/807,599



RN 215042-51-6 CAPLUS


CN 1-Butanone, 4-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 215042-52-7 CAPLUS

CN 1-Butanone, 4-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-53-8 CAPLUS

CN 1-Butanone, 4-[1-[(3-methoxyphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)




● 2 HCl

RN 215042-55-0 CAPLUS

09/807,599

CN 1-Butanone, 4-[1-[(3-hydroxyphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 215042-57-2 CAPLUS

CN Benzoic acid, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, compd. with  
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 215042-56-1


CMF C34 H40 N2 O3



CM 2


CRN 121-44-8

CMF C6 H15 N



RN 215042-58-3 CAPLUS


CN 1-Butanone, 4-[1-[(4-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 215042-59-4 CAPLUS

CN 1-Butanone, 4-[1-[(4-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-61-8 CAPLUS


CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215042-62-9 CAPLUS


CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



09/807,599

RN 215042-63-0 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-64-1 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215042-65-2 CAPLUS

CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215042-66-3 CAPLUS

CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)


09/807,599

INDEX NAME)



RN 215042-67-4 CAPLUS


CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 215042-68-5 CAPLUS


CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215042-69-6 CAPLUS

CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)






●2 HCl


RN 215042-70-9 CAPLUS

CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215042-71-0 CAPLUS


CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 215042-72-1 CAPLUS


CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215042-73-2 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

-OEt

RN 215042-75-4 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]butyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 215042-76-5 CAPLUS

09/807,599

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl)methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

— OEt

RN 215042-77-6 CAPLUS  
CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

— OEt


RN 215042-79-8 CAPLUS  
CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215042-81-2 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]butyl]-1-piperidinyl)methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A


● 2 HCl

PAGE 1-B

— OEt


RN 215042-83-4 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]butyl]-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 215042-84-5 CAPLUS


CN 1-Butanone, 4-[1-[(2-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 215042-85-6 CAPLUS

CN 1-Butanone, 4-[1-[(2-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-86-7 CAPLUS


CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-87-8 CAPLUS

CN Benzoic acid, 2-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 215042-89-0 CAPLUS


CN Acetic acid, [2-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215042-90-3 CAPLUS

CN Acetic acid, [2-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215042-91-4 CAPLUS


CN 1-Butanone, 4-[1-[(2-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 215042-92-5 CAPLUS

CN 1-Butanone, 4-[1-[(2-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-93-6 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 215042-94-7 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215042-95-8 CAPLUS

CN Acetamide, N-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215042-97-0 CAPLUS

CN 1-Butanone, 4-[1-[(3-aminophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, trihydrochloride (9CI) (CA INDEX NAME)






● 3 HCl

RN 215042-99-2 CAPLUS


CN Urea, N-methyl-N'-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-00-8 CAPLUS

CN Urea, N-methyl-N'-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 215043-01-9 CAPLUS


CN Benzoic acid, 4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-03-1 CAPLUS

CN Benzoic acid, 4-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]carboxylic acid (9CI) (CA INDEX NAME)




RN 215043-04-2 CAPLUS

CN Benzeneacetic acid, .alpha.,.alpha.-dimethyl-3-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]carboxylic acid (9CI) (CA INDEX NAME)



RN 215043-05-3 CAPLUS


CN Methanesulfonamide, N-[3-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]carboxylic acid (9CI) (CA INDEX NAME)



● 2 HCl

RN 215043-06-4 CAPLUS


CN Methanesulfonamide, N-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 215043-07-5 CAPLUS


CN Benzeneacetic acid, 4-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 215043-09-7 CAPLUS


CN Benzeneacetic acid, 3-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B




RN 215043-11-1 CAPLUS

CN Benzeneacetic acid, 4-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



PAGE 1-A






RN 215043-12-2 CAPLUS

CN Benzeneacetic acid, 3-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 215043-13-3 CAPLUS

CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215043-14-4 CAPLUS


CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA

## INDEX NAME)



RN 215043-15-5 CAPLUS


CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-16-6 CAPLUS

CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215043-17-7 CAPLUS

CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215043-18-8 CAPLUS  
 CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215043-20-2 CAPLUS  
 CN Piperidine, 1-(1-oxopropyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215043-21-3 CAPLUS  
 CN Piperidine, 1-(1-oxopropyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)



RN 215043-22-4 CAPLUS


CN Piperidine, 1-(2-methyl-1-oxopropyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 215043-23-5 CAPLUS


CN Piperidine, 1-(2-methyl-1-oxopropyl)-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)



RN 215043-24-6 CAPLUS

CN 1-Piperidinebutanoic acid, .gamma.-oxo-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)






● HCl


RN 215043-25-7 CAPLUS

CN 1-Piperidinebutanoic acid, .gamma.-oxo-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215043-26-8 CAPLUS


CN 1-Piperidinepentanoic acid, .delta.-oxo-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215043-27-9 CAPLUS

CN 1-Piperidinepentanoic acid, .delta.-oxo-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215043-28-0 CAPLUS

CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


IT 215043-29-1P 215043-30-4P 215043-31-5P  
 215043-32-6P 215043-33-7P 215043-34-8P  
 215043-35-9P 215043-36-0P 215043-37-1P  
 215043-38-2P 215043-39-3P 215043-40-6P  
 215043-41-7P 215043-42-8P 215043-43-9P  
 215043-44-0P 215043-45-1P 215043-48-4P  
 215043-49-5P 215043-50-8P 215043-52-0P  
 215043-54-2P 215043-55-3P 215043-56-4P  
 215043-57-5P 215043-58-6P 215043-59-7P  
 215043-60-0P 215043-61-1P 215043-62-2P  
 215043-63-3P 215043-64-4P 215043-65-5P  
 215043-66-6P 215043-67-7P 215043-68-8P  
 215043-69-9P 215043-70-2P 215043-71-3P  
 215043-72-4P 215043-73-5P 215043-74-6P  
 215043-76-8P 215043-78-0P 215043-79-1P  
 215043-80-4P 215043-81-5P 215043-82-6P  
 215043-84-8P 215043-85-9P 215043-86-0P  
 215043-87-1P 215043-88-2P 215043-89-3P  
 215043-90-6P 215043-91-7P 215043-92-8P  
 215043-93-9P 215043-95-1P 215043-97-3P  
 215043-99-5P 215044-01-2P 215044-03-4P  
 215044-07-8P 215044-12-5P 215044-21-6P  
 215044-24-9P 215044-30-7P 215044-33-0P  
 215044-39-6P 215044-42-1P 215044-45-4P  
 215044-48-7P 215044-51-2P 215044-54-5P  
 215044-56-7P 215044-59-0P 215044-62-5P  
 215044-65-8P 215044-67-0P 215044-70-5P

215044-76-1P 215044-81-8P 215044-83-0P  
 215044-85-2P 215044-87-4P 215044-89-6P  
 215044-95-4P 215044-97-6P 215044-99-8P  
 215045-02-6P 215045-04-8P 215045-06-0P  
 215045-10-6P 215045-12-8P 215045-14-0P  
 215045-16-2P 215045-18-4P 215045-20-8P  
 215045-22-0P 215045-26-4P 215045-30-0P  
 215045-32-2P 215045-36-6P 215045-38-8P  
 215045-40-2P 215045-42-4P 215045-43-5P  
 215045-45-7P 215045-48-0P 215045-50-4P  
 215045-53-7P 215045-54-8P 215045-58-2P  
 215045-60-6P 215045-63-9P 215045-67-3P  
 215045-71-9P 215045-72-0P 215045-74-2P  
 215045-76-4P 215045-78-6P 215045-80-0P  
 215045-82-2P 215045-84-4P 215045-86-6P  
 215045-88-8P 215045-90-2P 215045-92-4P  
 215045-94-6P 215045-98-0P 215046-00-7P  
 215046-03-0P 215046-05-2P 215046-07-4P  
 215046-09-6P 215046-11-0P 215046-13-2P  
 215046-15-4P 215046-17-6P 215046-19-8P  
 215046-21-2P 215046-23-4P 215046-27-8P  
 215046-29-0P 215046-31-4P 215046-33-6P  
 215046-37-0P 215046-41-6P 215046-43-8P  
 215046-45-0P 215046-47-2P 215046-49-4P  
 215046-51-8P 215046-53-0P 215046-55-2P  
 215046-57-4P 215046-59-6P 215046-61-0P  
 215046-63-2P 215046-65-4P 215046-67-6P  
 215046-69-8P 215046-71-2P 215046-73-4P  
 215046-75-6P 215046-77-8P 215046-79-0P  
 215046-81-4P 215046-83-6P 215046-85-8P  
 215046-87-0P 215046-89-2P 215046-91-6P  
 215046-93-8P 215046-95-0P 215046-99-4P  
 215047-03-3P 215047-05-5P 215047-07-7P  
 215047-08-8P 215047-09-9P 215047-11-3P  
 215047-13-5P 215047-15-7P 215047-17-9P  
 215047-19-1P 215047-21-5P 215047-23-7P  
 215047-25-9P 215047-27-1P 215047-29-3P  
 215047-31-7P 215047-33-9P 215047-35-1P  
 215047-37-3P 215047-39-5P 215047-41-9P  
 215047-43-1P 215047-45-3P 215047-47-5P  
 215047-49-7P 215047-51-1P 215047-53-3P  
 215047-55-5P 215047-57-7P 215047-59-9P  
 215047-61-3P 215047-63-5P 215047-64-6P  
 215047-65-7P 215047-66-8P 215047-84-0P  
 215047-87-3P 215047-88-4P 215047-90-8P  
 215047-91-9P 215047-98-6P 215048-05-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of benzazepine thermogenics)

RN 215043-29-1 CAPLUS

CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215043-30-4 CAPLUS  
 CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215043-31-5 CAPLUS  
 CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215043-32-6 CAPLUS  
 CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-33-7 CAPLUS

CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215043-34-8 CAPLUS


CN 1-Butanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-35-9 CAPLUS

CN 1-Butanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215043-36-0 CAPLUS


CN 1-Butanone, 1-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-37-1 CAPLUS

CN 1-Butanone, 1-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215043-38-2 CAPLUS


CN 1-Butanone, 1-[3-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-39-3 CAPLUS

CN 1-Butanone, 1-[3-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215043-40-6 CAPLUS


CN Benzonitrile, 2-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-41-7 CAPLUS

CN Benzonitrile, 2-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 215043-42-8 CAPLUS


CN Benzonitrile, 3-[[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215043-43-9 CAPLUS


CN Benzonitrile, 3-[[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 215043-44-0 CAPLUS

CN Benzonitrile, 4-[[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl


RN 215043-45-1 CAPLUS

CN Benzonitrile, 4-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 215043-48-4 CAPLUS


CN 1-Pentanone, 5-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-49-5 CAPLUS

CN 1-Pentanone, 5-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215043-50-8 CAPLUS


CN Piperidine, 1-acetyl-4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 215043-52-0 CAPLUS


CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-(4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 215043-54-2 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(phenylmethyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215043-55-3 CAPLUS  
CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215043-56-4 CAPLUS  
CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215043-57-5 CAPLUS  
CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215043-58-6 CAPLUS


CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-59-7 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(3-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215043-60-0 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215043-61-1 CAPLUS  
CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(4-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215043-62-2 CAPLUS  
CN 1-Propanone, 3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215043-63-3 CAPLUS  
CN 1-Propanone, 3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215043-64-4 CAPLUS  
 CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215043-65-5 CAPLUS  
 CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215043-66-6 CAPLUS  
 CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-67-7 CAPLUS

CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215043-68-8 CAPLUS


CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215043-69-9 CAPLUS


CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215043-70-2 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

—CF<sub>3</sub>

RN 215043-71-3 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 1-B

—CF<sub>3</sub>

RN 215043-72-4 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[[4-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

—CF<sub>3</sub>

RN 215043-73-5 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[[4-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


—CF<sub>3</sub>

09/807,599

RN 215043-74-6 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(3-nitrophenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl


PAGE 1-B

—NO<sub>2</sub>

RN 215043-76-8 CAPLUS

CN 1-Propanone, 3-[1-[(3-aminophenyl)methyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




●3 HCl

PAGE 1-B




RN 215043-78-0 CAPLUS  
 CN Urea, [3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl


PAGE 1-B



RN 215043-79-1 CAPLUS  
 CN Urea, [3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 215043-80-4 CAPLUS


CN Benzonitrile, 2-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]-, dihydrochloride  
(9CI) (CA INDEX NAME)



● 2 HCl


RN 215043-81-5 CAPLUS

CN Benzonitrile, 2-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 215043-82-6 CAPLUS


CN Benzonitrile, 3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]-, dihydrochloride  
(9CI) (CA INDEX NAME)



● 2 HCl

RN 215043-84-8 CAPLUS


CN Benzonitrile, 4-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]-, dihydrochloride  
(9CI) (CA INDEX NAME)



● 2 HCl

RN 215043-85-9 CAPLUS


CN Benzonitrile, 4-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 215043-86-0 CAPLUS


CN Benzamide, 3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]-, dihydrochloride  
(9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B




RN 215043-87-1 CAPLUS

CN    Benzamide, 3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215043-88-2 CAPLUS


CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(2-pyridinylmethyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

09/807,599




● 3 HCl

RN 215043-89-3 CAPLUS  
CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(2-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215043-90-6 CAPLUS  
CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(3-pyridinylmethyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 215043-91-7 CAPLUS  
CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(3-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



09/807,599

RN 215043-92-8 CAPLUS


CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(4-pyridinylmethyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 215043-93-9 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(4-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215043-95-1 CAPLUS

CN Formamide, N-[3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A

● 2 HCl




—NH—CHO

RN 215043-97-3 CAPLUS

CN Formamide, N-[3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH—CHO

RN 215043-99-5 CAPLUS


CN Urea, N-[3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenyl]-N'-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B




RN 215044-01-2 CAPLUS

CN Urea, N-[3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenyl]-N'-methyl-  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215044-03-4 CAPLUS


CN 1H-3-Benzazepine, 3-acetyl-2,3,4,5-tetrahydro-7-[1-oxo-4-(4-piperidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215044-07-8 CAPLUS

CN 1H-3-Benzazepine, 3-acetyl-2,3,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 215044-12-5 CAPLUS  
CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215044-21-6 CAPLUS  
CN 1-Butanone, 1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 215044-24-9 CAPLUS  
CN Benzoic acid, 2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl)methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215044-30-7 CAPLUS

CN Benzoic acid, 2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 215044-33-0 CAPLUS


CN Acetic acid, [2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215044-39-6 CAPLUS

CN Acetic acid, [2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 215044-42-1 CAPLUS


CN Piperazine, 1-methyl-4-[2-[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidiny]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]benzoyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 215044-45-4 CAPLUS

CN Piperazine, 1-methyl-4-[2-[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidiny]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 215044-48-7 CAPLUS

CN 1-Butanone, 1-[3-[2-(diethylamino)ethyl]-2,3,4,5-tetrahydro-1H-3-

09/807,599


benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 215044-51-2 CAPLUS

CN 1-Butanone, 1-[3-[2-(diethylamino)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215044-54-5 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215044-56-7 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215044-59-0 CAPLUS  
 CN 1-Butanone, 1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215044-62-5 CAPLUS  
 CN 1-Butanone, 1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215044-65-8 CAPLUS  
 CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(3-pyridinylmethyl)-1H-3-benzazepin-7-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 215044-67-0 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(3-pyridinylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215044-70-5 CAPLUS

CN Acetamide, N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 215044-76-1 CAPLUS

CN 1-Butanone, 4-[1-[(2-aminophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, trihydrochloride (9CI) (CA INDEX NAME)






●3 HCl

RN 215044-81-8 CAPLUS


CN Methanesulfonamide, N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 215044-83-0 CAPLUS


CN Methanesulfonamide, N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 215044-85-2 CAPLUS

CN Urea, N-methyl-N'-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-


methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl)methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215044-87-4 CAPLUS

CN Urea, N-methyl-N'-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 215044-89-6 CAPLUS

CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl)methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215044-95-4 CAPLUS  
 CN Benzamide, 2-[[4-[4-oxo-4-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215044-97-6 CAPLUS  
 CN Benzamide, 2-[[4-[4-oxo-4-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 215044-99-8 CAPLUS  
 CN 1-Butanone, 4-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA

INDEX NAME)




● 2 HCl

RN 215045-02-6 CAPLUS  
 CN Benzamide, 4-[[4-[[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215045-04-8 CAPLUS  
 CN Benzamide, 4-[[4-[[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, (9CI) (CA INDEX NAME)




RN 215045-06-0 CAPLUS  
 CN Benzonitrile, 3-[[4-[[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215045-10-6 CAPLUS


CN Benzamide, 3-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-4-cyanophenyl]benzamide, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 215045-12-8 CAPLUS

CN Benzamide, 3-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-4-carbamoylphenyl]benzamide, dihydrochloride (9CI)  
(CA INDEX NAME)




RN 215045-14-0 CAPLUS

CN Benzenecarboximidamide, 3-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-4-carbamoylphenyl]benzimidamide, dihydrochloride (9CI)  
(CA INDEX NAME)



RN 215045-16-2 CAPLUS


CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-2-thiazolyl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215045-18-4 CAPLUS

CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-2-thiazolyl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215045-20-8 CAPLUS


CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 215045-22-0 CAPLUS

CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215045-26-4 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 215045-30-0 CAPLUS


CN Benzamide, 2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215045-32-2 CAPLUS

CN Benzamide, 2-[[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 215045-36-6 CAPLUS

CN Benzamide, 3-[[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215045-38-8 CAPLUS


CN Benzamide, 3-[[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)





RN 215045-40-2 CAPLUS


CN Benzenecarboximidamide, 3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 215045-42-4 CAPLUS

CN Benzenecarboximidamide, 3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



RN 215045-43-5 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 215045-45-7 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215045-48-0 CAPLUS

CN Benzamide, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 215045-50-4 CAPLUS

CN Benzeneacetic acid, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A

Cl




● 2 HCl

PAGE 1-B



RN 215045-53-7 CAPLUS


CN Benzeneacetic acid, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-.alpha.,.alpha.-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215045-54-8 CAPLUS


CN Acetic acid, [2-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215045-58-2 CAPLUS

CN Acetic acid, [2-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 215045-60-6 CAPLUS


CN 1H-2-Benzazepine, 2-acetyl-2,3,4,5-tetrahydro-8-[1-oxo-3-(4-piperidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215045-63-9 CAPLUS

CN 1H-2-Benzazepine, 2-acetyl-2,3,4,5-tetrahydro-8-[3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 215045-67-3 CAPLUS  
 CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215045-71-9 CAPLUS  
 CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215045-72-0 CAPLUS  
 CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215045-74-2 CAPLUS


CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215045-76-4 CAPLUS

CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(3-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215045-78-6 CAPLUS

CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(4-methylphenyl)methyl]-1H-2-benzazepin-8-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 215045-80-0 CAPLUS  
CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(4-methylphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215045-82-2 CAPLUS  
CN 1-Propanone, 1-[2-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 215045-84-4 CAPLUS  
CN 1-Propanone, 1-[2-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215045-86-6 CAPLUS


CN 1-Propanone, 1-[2-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215045-88-8 CAPLUS


CN 1-Propanone, 1-[2-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215045-90-2 CAPLUS


CN 1-Propanone, 1-[2-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl

RN 215045-92-4 CAPLUS  
CN 1-Propanone, 1-[2-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215045-94-6 CAPLUS  
CN Benzeneacetic acid, 3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl




RN 215045-98-0 CAPLUS

CN Benzeneacetic acid, 3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl



RN 215046-00-7 CAPLUS


CN Benzeneacetic acid, 3-[[4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-1-piperidinyl]methyl]-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)





RN 215046-03-0 CAPLUS


CN 1-Piperidineacetic acid, 4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-05-2 CAPLUS

CN 1-Piperidineacetic acid, 4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215046-07-4 CAPLUS


CN 1-Piperidinebutanoic acid, 4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-09-6 CAPLUS

CN 1-Piperidinebutanoic acid, 4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215046-11-0 CAPLUS


CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(2-hydroxyethyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-13-2 CAPLUS

CN 1-Propanone, 1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-[1-(2-hydroxyethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215046-15-4 CAPLUS


CN 1-Propanone, 3-[1-[2-(diethylamino)ethyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 215046-17-6 CAPLUS

CN 1-Propanone, 3-[1-[2-(diethylamino)ethyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 215046-19-8 CAPLUS


CN Piperidine, 1-(chloroacetyl)-4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215046-21-2 CAPLUS

09/807,599


CN Piperidine, 1-[(dimethylamino)acetyl]-4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-23-4 CAPLUS

CN Piperidine, 1-[(dimethylamino)acetyl]-4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215046-27-8 CAPLUS

CN 1-Propanone, 3-[1-[3-(dimethylamino)-2-hydroxypropyl]-4-piperidinyl]-1-[2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A

3 HCl


PAGE 1-B

—NMe<sub>2</sub>

RN 215046-29-0 CAPLUS

CN 1-Propanone, 3-[1-[3-(dimethylamino)-2-hydroxypropyl]-4-piperidinyl]-1-[2-  
[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl]- (9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NMe<sub>2</sub>


RN 215046-31-4 CAPLUS

CN 1-Piperidineacetonitrile, 4-[3-[2-[(4-fluorophenyl)methyl]-2,3,4,5-  
tetrahydro-1H-2-benzazepin-8-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 215046-33-6 CAPLUS

CN Acetamide, N-[3-[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-  
oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215046-37-0 CAPLUS  
 CN 1-Butanone, 1-[3-[(3-aminophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 215046-41-6 CAPLUS  
 CN Urea, [3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A

Cl



● 2 HCl







RN 215046-43-8 CAPLUS  
 CN Urea, [3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A


Cl



PAGE 1-B




RN 215046-45-0 CAPLUS  
 CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 215046-47-2 CAPLUS  
 CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215046-49-4 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-51-8 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215046-53-0 CAPLUS


CN 1-Butanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 215046-55-2 CAPLUS


CN 1-Butanone, 1-[3-[(2,6-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 215046-57-4 CAPLUS

CN 1-Butanone, 1-[3-[(2,6-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215046-59-6 CAPLUS

CN 1-Butanone, 1-[3-[(2,3-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215046-61-0 CAPLUS  
 CN 1-Butanone, 1-[3-[(2,3-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215046-63-2 CAPLUS  
 CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[2-(trifluoromethyl)phenyl]methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215046-65-4 CAPLUS  
 CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[2-(trifluoromethyl)phenyl]methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215046-67-6 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[3-(trifluoromethyl)phenyl]methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-69-8 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[3-(trifluoromethyl)phenyl]methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215046-71-2 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[3-(trifluoromethoxy)phenyl]methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215046-73-4 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-75-6 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215046-77-8 CAPLUS

CN 1-Butanone, 1-[3-[(2-bromophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215046-79-0 CAPLUS

CN 1-Butanone, 1-[3-[(2,6-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215046-81-4 CAPLUS

CN 1-Butanone, 1-[3-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215046-83-6 CAPLUS


CN 1-Butanone, 1-[3-(1,3-benzodioxol-5-ylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-85-8 CAPLUS

CN 1-Butanone, 1-[3-(1,3-benzodioxol-5-ylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 215046-87-0 CAPLUS

CN Piperazine, 1-methyl-4-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]benzoyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 215046-89-2 CAPLUS


CN Piperazine, 1-methyl-4-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]benzoyl]- (9CI) (CA INDEX NAME)





RN 215046-91-6 CAPLUS


CN Morpholine, 4-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215046-93-8 CAPLUS

CN Morpholine, 4-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 215046-95-0 CAPLUS


CN Acetamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 215046-99-4 CAPLUS

CN 1-Butanone, 1-[3-[(2-aminophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 215047-03-3 CAPLUS

CN Urea, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-


1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-N'-methyl-,  
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215047-05-5 CAPLUS

CN Urea, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-N'-methyl- (9CI)  
(CA INDEX NAME)



RN 215047-07-7 CAPLUS


CN Benzenesulfonamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215047-08-8 CAPLUS

CN Benzenesulfonamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 215047-09-9 CAPLUS


CN Methanesulfonamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215047-11-3 CAPLUS

CN Methanesulfonamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 215047-13-5 CAPLUS


CN Benzenesulfonamide, 4-methyl-N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215047-15-7 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 215047-17-9 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(2-naphthalenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 215047-19-1 CAPLUS  
 CN Piperidine, 1-acetyl-4-[3-oxo-3-(2-naphthalenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)



RN 215047-21-5 CAPLUS  
 CN 1H-3-Benzazepine, 7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-3-benzoyl-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 215047-23-7 CAPLUS  
 CN 1H-3-Benzazepine, 7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-2,3,4,5-tetrahydro-3-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)



RN 215047-25-9 CAPLUS


09/807,599

CN 1H-3-Benzazepine, 7-[3-(1-acetyl-4-piperidiny1)-1-oxopropyl]-3-(2-furany1carbonyl)-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 215047-27-1 CAPLUS


CN 1H-3-Benzazepine, 7-[3-(1-acetyl-4-piperidiny1)-1-oxopropyl]-2,3,4,5-tetrahydro-3-(3-pyridiny1carbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215047-29-3 CAPLUS

CN 1H-3-Benzazepine, 7-[3-(1-acetyl-4-piperidiny1)-1-oxopropyl]-2,3,4,5-tetrahydro-3-(3-pyridiny1carbonyl)- (9CI) (CA INDEX NAME)




RN 215047-31-7 CAPLUS

CN 1-Propanone, 3-[1-(1-naphthalenylmethyl)-4-piperidiny1]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 215047-33-9 CAPLUS  
 CN 1-Propanone, 3-[1-(1-naphthalenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215047-35-1 CAPLUS  
 CN 1-Propanone, 3-[1-(2-naphthalenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




2 HCl



09/807,599


RN 215047-37-3 CAPLUS

CN 1-Propanone, 3-[1-(2-naphthalenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 215047-39-5 CAPLUS


CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(2-pyridinylmethyl)-1H-3-benzazepin-7-yl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215047-41-9 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(2-pyridinylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)



RN 215047-43-1 CAPLUS


CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(3-pyridinylmethyl)-1H-3-benzazepin-7-yl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 215047-45-3 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(3-pyridinylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 215047-47-5 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(4-pyridinylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)



RN 215047-49-7 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(2-thienylmethyl)-1H-3-benzazepin-7-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

09/807,599


RN 215047-51-1 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(2-thienylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)



RN 215047-53-3 CAPLUS


CN Piperidine, 1-acetyl-4-[3-[3-(2-furanylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215047-55-5 CAPLUS

CN Piperidine, 1-acetyl-4-[3-[3-(2-furanylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215047-57-7 CAPLUS


CN Benzoic acid, 2-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215047-59-9 CAPLUS

CN Benzoic acid, 2-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 215047-61-3 CAPLUS


CN Benzoic acid, 3-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215047-63-5 CAPLUS

CN Benzoic acid, 3-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 215047-64-6 CAPLUS


CN Benzoic acid, 4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 215047-65-7 CAPLUS


CN Benzoic acid, 4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 215047-66-8 CAPLUS

CN Carbamic acid, [[[3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 215047-84-0 CAPLUS

CN 1-Butanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215047-87-3 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-[(4-methoxyphenyl)methyl]-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 215047-88-4 CAPLUS

CN 1-Propanone, 1-(2-ethyl-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-3-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 215047-90-8 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-(4-methoxybenzoyl)-8-[1-oxo-3-[1-(phenylmethyl)-4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




RN 215047-91-9 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 215047-98-6 CAPLUS

CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-8-[1-oxo-3-[1-(phenylmethyl)-4-piperidinyl]propyl]-2-(phenylacetyl)- (9CI) (CA INDEX NAME)



RN 215048-05-8 CAPLUS

CN 1-Propanone, 3-[1-[[4-[(methylamino)carbonyl]oxy]phenyl]methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



IT 215047-69-1P 215047-70-4P 215047-71-5P

215047-72-6P 215047-73-7P 215047-74-8P

215047-76-0P 215047-77-1P 215047-79-3P


215047-80-6P 215047-81-7P 215047-82-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of benzazepine thermogenics)


RN 215047-69-1 CAPLUS

CN Piperidine, 1-acetyl-4-[3-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 215047-70-4 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215047-71-5 CAPLUS


CN 1H-3-Benzazepine, 7-[4-(1-acetyl-4-piperidinyl)-1-oxobutyl]-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 215047-72-6 CAPLUS


CN Piperidine, 1-acetyl-4-[4-oxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butyl]- (9CI) (CA INDEX NAME)






RN 215047-73-7 CAPLUS

CN Piperidine, 1-acetyl-4-[3-(2-formyl-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 215047-74-8 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 215047-76-0 CAPLUS

CN Piperidine, 1-acetyl-4-[2-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 215047-77-1 CAPLUS

CN Ethanone, 2-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




RN 215047-79-3 CAPLUS

CN Piperidine, 1-acetyl-4-[4-(2-formyl-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-4-oxobutyl]- (9CI) (CA INDEX NAME)




RN 215047-80-6 CAPLUS

CN	Piperidine, 1-acetyl-4-[4-oxo-4-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)butyl]- (9CI) (CA INDEX NAME)
----	--




RN 215047-81-7 CAPLUS

CN Piperidine, 1-acetyl-4-[4-oxo-4-[2,3,4,5-tetrahydro-2-[(2-methylphenyl)methyl]-1H-2-benzazepin-8-yl]butyl]- (9CI) (CA INDEX NAME)



RN 215047-82-8 CAPLU'S

CN 1-Piperidinecarboxylic acid, 4-[4-(3-acetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-oxobutyl]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



~~12~~ ANSWER 19 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1998:509093 CAPLUS

DN 129:144870

TI Idebenone containing combination agent for treating Alzheimer's disease

IN Miyamoto, Masaomi; Ohta, Hiroyuki; Goto, Giichi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9831356	A1	19980723	WO 1998-JP109	19980114
	W:				
	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW,				
	HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN,				
	MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US,				
	UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,				
	FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,				
	GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9854953	A1	19980807	AU 1998-54953	19980114
	EP 952826	A1	19991103	EP 1998-900361	19980114
	EP 952826	B1	20011114		
	R: DE				
	JP 10259126	A2	19980929	JP 1998-6261	19980116
	US 5962535	A	19991005	US 1998-42625	19980317
PRAI	JP 1997-6147	A	19970117		
	US 1997-65597P	P	19971118		
	WO 1998-JP109	W	19980114		
OS	MARPAT 129:144870				
AB	A pharmaceutical compn. comprising idebenone in combination with a compd. having acetylcholinesterase inhibitory activity is useful for treating or preventing Alzheimer's disease. Ameliorative effect of the combined use of idebenone and donepezil on learning deficits was investigated in aged rats; tests for passive avoidance learning and water maze learning, showed that the drug combination significantly improved the learning deficits in aged rats.				
IT	142852-51-5				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(idebenone and acetylcholinesterase inhibitor combination for treatment of Alzheimer's disease)				
RN	142852-51-5	CAPLUS			
CN	1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)				
CM	1				
CRN	142852-50-4				
CMF	C25 H32 N2 O				

09/807,599




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



09/807,599

~~120~~ ANSWER 20 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1998:504876 CAPLUS

DN 129:193712

TI Sustained-release microcapsules of acetylcholinesterase inhibitors for Alzheimer's disease

IN Motodani, Toshio; Ikari, Yasutaka; Miyamoto, Masaomi

PA Takeda Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10203966	A2	19980804	JP 1997-320223	19971121
PRAI	JP 1996-311078		19961121		


AB Sustained-release microcapsules contg. acetylcholinesterase inhibitors [i.e. 8-(1-oxo-3-(1-(phenylmethyl)piperidin-4-yl)propyl)-2,2,4,5-tetrahydro-1H-1-benzazepine and 1-benzyl-4-((5,6-dimethoxy-1-oxoindan-2-yl)methyl)piperidine] and biodegradable glycolic acid-lactic acid copolymer for treatment of Alzheimer's disease are claimed. The preps. showed high bioavailability.

IT **142852-50-4**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release microcapsules of acetylcholinesterase inhibitors for Alzheimer's disease)


RN 142852-50-4 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



~~120~~ ANSWER 21 OF 49 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:485052 CAPLUS  
 DN 129:122575  
 TI Preparation of N-(pyridinylamino)isoindolines and related compounds for treatment of memory dysfunction and depression.  
 IN Kurys, Barbara E.; Fink, David M.; Freed, Brian S.; Merriman, Gregory H.  
 PA Hoechst Marion Roussel, Inc., USA  
 SO PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829407	A2	19980709	WO 1997-US20591	19971113
	WO 9829407	A3	19981022		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6004977	A	19991221	US 1997-959789	19971029
	AU 9854349	A1	19980731	AU 1998-54349	19971113
	AU 720466	B2	20000601		
	EP 950056	A2	19991020	EP 1997-948250	19971113
	EP 950056	B1	20020918		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	CN 1242012	A	20000119	CN 1997-181021	19971113
	BR 9714189	A	20000229	BR 1997-14189	19971113
	JP 2001511119	T2	20010807	JP 1998-529990	19971113
	ZA 9711520	A	19980629	ZA 1997-11520	19971222
	NO 9903180	A	19990826	NO 1999-3180	19990625
PRAI	US 1996-774308	A	19961227		
	US 1997-959789	A	19971029		
	WO 1997-US20591	W	19971113		
OS	MARPAT 129:122575				
GI					




AB Title compds. [I; Q = (CH<sub>2</sub>)<sub>n</sub>; R = H, R<sub>2</sub>O, (R<sub>3</sub>)<sub>3</sub>Si, R<sub>4</sub>R<sub>5</sub>NCO; R<sub>2</sub> = H, alkyl, PhCH<sub>2</sub>; R<sub>3</sub> = alkyl; R<sub>4</sub>, R<sub>5</sub> = H, alkyl, PhCH<sub>2</sub>; R<sub>4</sub>R<sub>5</sub> = tetrahydroisoquinolinyl, pyridinylpiperazinyl; R<sub>1</sub> = H, alkyl; X, Y = H, alkyl, halo, OH, alkoxy, CF<sub>3</sub>; m, p = 1, 2; n = 1-3], were prep'd. Thus,

2,3-dihydro-2-(4-pyridinylamino)-1H-isoindol-4-yl dimethylcarbamate  
(prepn. given) inhibited acetylcholinesterase with IC50 = 0.029 mM.

IT **210172-24-0P 210172-53-5P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of N-(pyridinylamino)isoindolines and related compds. for treatment of memory dysfunction and depression)


RN 210172-24-0 CAPLUS

CN 2H-2-Benzazepin-2-amine, 8-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,3,4,5-tetrahydro-7-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 210172-53-5 CAPLUS

CN 1H-2-Benzazepin-8-ol, 2,3,4,5-tetrahydro-7-methoxy-2-(4-pyridinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT **210172-26-2P 210172-30-8P 210172-57-9P**  
**210172-66-0P 210172-80-8P 210173-11-8P**  
**210173-30-1P 210173-97-0P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of N-(pyridinylamino)isoindolines and related compds. for treatment of memory dysfunction and depression)

RN 210172-26-2 CAPLUS

CN 2H-2-Benzazepin-2-amine, 1,3,4,5-tetrahydro-7-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 210172-30-8 CAPLUS




09/807,599

CN 2H-2-Benzazepin-2-amine, 1,3,4,5-tetrahydro-7-methoxy-N-methyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 210172-57-9 CAPLUS


CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-2-(4-pyridinylamino)-1H-2-benzazepin-7-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 210172-66-0 CAPLUS


CN Carbamic acid, dimethyl-, 2,3,4,5-tetrahydro-7-methoxy-2-(4-pyridinylamino)-1H-2-benzazepin-8-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 210172-80-8 CAPLUS

CN 1H-2-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-2-(4-pyridinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 210173-11-8 CAPLUS  
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 2,3,4,5-tetrahydro-7-methoxy-2-(4-pyridinylamino)-1H-2-benzazepin-8-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 210173-30-1 CAPLUS  
 CN 1H-2-Benzazepin-8-ol, 2,3,4,5-tetrahydro-7-methoxy-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 210173-97-0 CAPLUS  
 CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 2,3,4,5-tetrahydro-7-methoxy-2-(4-pyridinylamino)-1H-2-benzazepin-8-yl ester (9CI) (CA INDEX NAME)




IT **210173-78-7**  
 RL: RCT (Reactant); RACT (Reactant or reagent)

09/807,599

(prepn. of N-(pyridinylamino)isoindolines and related compds. for treatment of memory dysfunction and depression)

RN 210173-78-7 CAPLUS

CN 1H-2-Benzazepin-7-ol, 2,3,4,5-tetrahydro-2-(4-pyridinylamino)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


IT 210173-61-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-(pyridinylamino)isoindolines and related compds. for treatment of memory dysfunction and depression)

RN 210173-61-8 CAPLUS

CN 1H-2-Benzazepin-7-ol, 2,3,4,5-tetrahydro-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




09/807,599

~~L20~~ ANSWER 22 OF 49 CAPLUS COPYRIGHT 2002 ACS  
~~AN~~ 1998:423115 CAPLUS  
DN 129:197402  
TI Preclinical pharmacology of TAK-147, a novel acetylcholinesterase inhibitor, as a potential therapeutic drug for Alzheimer's disease  
AU Miyamoto, Masaomi; Goto, Giichi  
CS Pharmaceutical Research Division, Pharmaceutical Research Laboratories V, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan  
SO CNS Drug Reviews (1997), 3(4), 301-324  
CODEN: CDREFB; ISSN: 1080-563X  
PB Neva Press  
DT Journal; General Review  
LA English  
AB A review with 83 refs.  
IT **142852-51-5**, TAK-147  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(preclin. pharmacol. of TAK-147, a novel acetylcholinesterase inhibitor, as a potential therapeutic drug for Alzheimer's disease)  
RN 142852-51-5 CAPLUS  
CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-50-4  
CMF C25 H32 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.




09/807,599

~~L20~~ ANSWER 23 OF 49 CAPLUS COPYRIGHT 2002 ACS  
AN 1998:146757 CAPLUS  
DN 128:235140  
TI Solid formulations of cholinesterase inhibitors  
IN Ito, Hiroki; Fukuda, Masato  
PA Takeda Chemical Industries, Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 10 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10053529	A2	19980224	JP 1997-149558	19970606
PRAI	JP 1996-145260		19960607		
OS	MARPAT 128:235140				
AB	Solid formulations of cholinesterase inhibitors, benzazepine derivs., or their salts as active ingredients and mannitol to impart stability. Tablets contg. 8-[1-oxo-3-[1-(phenylmethyl)piperidin-4-yl]propyl]-2,3,4,5-tetrahydro-1H-1-benzazepine fumarate (I) and mannitol with addn. of other excipients are formulated. Prepn. of I is given.				
IT	<b>142852-50-4P 142853-11-0P 204701-73-5P</b> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (solid formulations of cholinesterase inhibitors)				
RN	142852-50-4	CAPLUS			
CN	1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)				




RN 142853-11-0 CAPLUS  
CN 1H-1-Benzazepine, 1-acetyl-8-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 204701-73-5 CAPLUS  
CN 1-Propanone, 3-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

09/807,599



●2 HCl

IT 142852-51-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solid formulations of cholinesterase inhibitors)


RN 142852-51-5 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-50-4

CMF C25 H32 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



09/807,599

~~120~~ ANSWER 24 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1997:675536 CAPLUS

DN 127:318964

TI Tricyclic azepine derivatives as platelet aggregation inhibitors

IN Himmelsbach, Frank; Pieper, Helmut; Austel, Volkhard; Linz, Guenter; Guth, Brian; Weisenberger, Johannes

PA Dr. Karl Thomae GmbH, Germany

SO Ger. Offen., 32 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 19612376	A1	19971002	DE 1996-19612376	19960328
OS	MARPAT 127:318964				
GI					




AB Title compds. were prepd. Thus, imidazobenzazepine I.3HCl [R = H, R1 = CH2CO2H] was obtained by treating I [R = CF3CO, R1 = H] with BrCH2CO2CMe3 and deblocking. I.3HCl [R = H, R1 = CH2CO2H] had an EC50 for platelet aggregation inhibition of 93 nM.

IT **197585-09-4P 197585-11-8P 197585-13-0P**  
**197585-15-2P 197585-31-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of tricyclic azepine derivs. as platelet aggregation inhibitors)

RN 197585-09-4 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 197585-11-8 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[2,3,4,5-tetrahydro-8-nitro-3-

(trifluoroacetyl)-1H-3-benzazepin-7-yl]amino]carbonyl]-, methyl ester  
(9CI) (CA INDEX NAME)




RN 197585-13-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]amino]-3-oxopropyl]-, methyl ester  
(9CI) (CA INDEX NAME)



RN 197585-15-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[8-amino-2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]amino]carbonyl]-, methyl ester  
(9CI) (CA INDEX NAME)



RN 197585-31-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-oxo-3-[[2,3,4,5-tetrahydro-8-(methylamino)-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)






IT **197585-33-4P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of tricyclic azepine derivs. as platelet aggregation inhibitors)

RN 197585-33-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-oxo-3-[[2,3,4,5-tetrahydro-8-nitro-3-(trifluoroacetyl)-1H-3-benzazepin-7-yl]amino]propyl]-, methyl ester (9CI)  
(CA INDEX NAME)



09/807,599

~~120~~ ANSWER 25 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1997:594560 CAPLUS

~~DN~~ 127:248027

~~TI~~ Preparation and formulation of benzazepine derivatives and analogs as pharmaceuticals with affinity for vasopressin receptors

~~IN~~ Ogawa, Hidenori; Kondo, Kazumi; Yamashita, Hiroshi; Suga, Keizo; Matsuzaki, Noriyuki; Shinohara, Tomokazu; Tanada, Yoshihisa; Kurimura, Muneaki; Tominaga, Michiaki; Yabuuchi, Yoichi

~~PA~~ Otsuka Pharmaceutical Co., Ltd., Japan

~~SO~~ Jpn. Kokai Tokkyo Koho, 646 pp.



CODEN: JKXXAF

~~DT~~ Patent

~~LA~~ Japanese

~~FAN~~.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09221476	A2	19970826	JP 1996-354761	19961216
PRAI	JP 1995-348123		19951215		
OS	MARPAT 127:248027				
GI					



AB The title compds. I [G = CR<sub>2</sub>R<sub>3</sub>X, etc.; X = CH<sub>2</sub>, etc.; R<sub>1</sub> = H, halo, etc.; R<sub>2</sub> = H, etc.; R<sub>3</sub> = H, CH<sub>2</sub>CO<sub>2</sub>R<sub>15</sub>, etc.; R<sub>15</sub> = H, alkyl, etc.; R = adamantylcarbonyl, etc.], useful as pharmaceuticals with affinity for the vasopressin receptors and as oxytocin antagonists, are prepd. The title compd. II showed oral ED<sub>50</sub> of 1 mg/kg against vasopressin-induced increase in blood pressure in rats.

IT 175149-13-OP 175149-15-2P 175149-24-3P

175149-31-2P 175149-33-4P 175149-36-7P

175151-20-9P 175151-44-7P 175151-45-8P

175151-51-6P 175151-52-7P 175151-53-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzazepine derivs. and analogs as pharmaceuticals with affinity for vasopressin receptors)


RN 175149-13-0 CAPLUS

CN Carbamic acid, [3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, (1-acetyl-4-piperidinyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175149-15-2 CAPLUS

CN Carbamic acid, [3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, (1-ethyl-4-piperidinyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175149-24-3 CAPLUS

CN Carbamic acid, [3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175149-31-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]amino]carbonyl]oxy)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175149-33-4 CAPLUS  
 CN Carbamic acid, [3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, 4-piperidinylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 175149-32-3  
 CMF C24 H28 Cl N3 O3

PAGE 1-A




PAGE 2-A



CM 2



CRN 76-05-1

CMF C2 H F3 O2



RN 175149-36-7 CAPLUS


CN 1H-1-Benzazepine, 1-[4-[[[ethyl(4-pyridinylmethyl)amino]carbonyl]amino]benzoyl]-2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 175151-20-9 CAPLUS  
 CN 1H-1-Benzazepine, 1-[2-chloro-4-(4-oxo-1-piperidiny)benzoyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)






RN 175151-44-7 CAPLUS  
 CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]-, 4-piperidinylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175151-45-8 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[[[[4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]amino]carbonyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 175151-51-6 CAPLUS


09/807,599

CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]-, 2-(4-pyridinyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175151-52-7 CAPLUS

CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-3-methoxyphenyl]-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175151-53-8 CAPLUS  
CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]-, (1-methyl-4-piperidinyl)methyl ester (9CI)  
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



09/807,599

120 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1997:543479 CAPLUS

DN 127:161698

TI Heterocyclic diphenylmethane derivatives as MIP-1.alpha./RANTES receptor antagonists

IN Kato, Kaneyoshi; Yamamoto, Mitsuo; Honda, Susumu; Fujisawa, Tomoyuki

PA Takeda Chemical Industries, Ltd., Japan; Kato, Kaneyoshi; Yamamoto, Mitsuo; Honda, Susumu; Fujisawa, Tomoyuki

SO PCT Int. Appl., 250 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724325	A1	19970710	WO 1996-JP3820	19961226
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9712083	A1	19970728	AU 1997-12083	19961226
	JP 10081665	A2	19980331	JP 1996-349136	19961227
PRAI	JP 1995-343905		19951228		
	JP 1996-187375		19960717		
	WO 1996-JP3820		19961226		
OS	MARPAT 127:161698				
GI					



II

AB Compds. which are MIP-1.alpha./RANTES-receptor antagonists are disclosed, specifically I [Ar1, Ar2 = (un)substituted arom. group; Q1, Q2 = (un)substituted divalent C1-6 aliph. hydrocarbon group which may have either O or S within the C chain; R1 = H, (un)substituted alkyl or (un)substituted alkylcarbonyl; R2 = (un)substituted hydrocarbon group or (un)substituted acyl; or NR1R2 = (un)substituted N-contg. heterocyclic; NZ = (un)substituted N-contg. mono- or fused heterocyclic group], and salts thereof. The compds. are useful for therapy or prophylaxis of inflammatory, allergic, and other diseases. Over 120 title compds., and a variety of intermediates, were prepd. For instance, N-alkylation of 4-(4-chlorophenyl)-4-hydroxypiperidine by 5-(formylamino)-1-iodo-4,4-diphenylpentane in MeCN in the presence of K2CO3 at 60.degree. gave title compd. II, isolated as the monohydrochloride (III). III displaced 125I-RANTES from human RANTES receptors in vitro with an IC50 of 0.04 .mu.M, vs. 3 .mu.M for ioperamide.


IT 193541-99-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of heterocyclic diphenylmethane derivs. as MIP-1.alpha./RANTES  
 receptor antagonists)

RN 193541-99-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-  
 piperidiny]]-2,2-diphenylpentyl]-1,2,4,5-tetrahydro- (9CI) (CA INDEX  
 NAME)



120 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2002 ACS  
 AN 1997:199565 CAPLUS  
 DN 126:287925  
 TI Neurochemical effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats  
 AU Hirai, Keisuke; Kato, Koki; Nakayama, Takahiro; Hayako, Hitomi; Ishihara, Yuji; Goto, Giichi; Miyamoto, Masaomi  
 CS Pharmaceutical Research Division, Pharmaceutical Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 532, Japan  
 SO Journal of Pharmacology and Experimental Therapeutics (1997), 280(3), 1261-1269  
 CODEN: JPETAB; ISSN: 0022-3565  
 PB Williams & Wilkins  
 DT Journal  
 LA English  
 AB The authors examd. the neurochem. effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase (AChE) inhibitor in vitro and in vivo. TAK-147 showed a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC<sub>50</sub> = 51.2 nM), and was 3.0- and 2.4-fold more potent than tacrine and physostigmine, resp. By contrast, TAK-147 was the least potent inhibitor of butyrylcholinesterase activity in rat plasma (IC<sub>50</sub> = 23,500 nM). Tacrine and physostigmine inhibited butyrylcholinesterase activity potently and nonselectively. TAK-147 showed a moderate inhibition of muscarinic M1 and M2 receptor binding with K<sub>i</sub> values of 234 and 340 nM, resp. TAK-147 showed very weak or no inhibition of high-affinity choline uptake, nicotinic receptor binding and choline acetyltransferase activity. In ex vivo expts., oral administration of TAK-147 at doses ranging from 1 to 10 mg/kg induced a statistically significant and dose-dependent decrease in AChE activity in the cerebral cortex. Of the monoaminergic systems, TAK-147 moderately inhibited uptake of noradrenaline and serotonin with IC<sub>50</sub> values of 4020 and 1350 nM, resp. TAK-147 also inhibited ligand binding at alpha-1, alpha-2 and serotonin 2 receptors with K<sub>i</sub> values of 324, 2330 and 3510 nM, resp., whereas it showed only weak activities on D1, D2 and serotonin 1A receptor bindings. Oral administration of TAK-147 (3 mg/kg) significantly accelerated the turnover rates of dopamine, noradrenaline and serotonin in the rat brain. These results suggest that TAK-147 activates the central cholinergic system by specific inhibition of AChE activity without affecting peripheral butyrylcholinesterase activity, and that TAK-147 also moderately activates the monoaminergic systems.  
 IT 142852-51-5, TAK-147  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (neurochem. effects of novel acetylcholinesterase inhibitor in rats)  
 RN 142852-51-5 CAPLUS  
 CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 142852-50-4  
 CMF C25 H32 N2 O



09/807,599




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



~~LN~~ ANSWER 28 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1996:375647 CAPLUS

DN 125:104862

TI Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models

AU Miyamoto, Masaomi; Takahashi, Hideki; Kato, Koki; Hirai, Keisuke; Ishihara, Yuji; Goto, Giichi

CS Pharmaceutical Research Laboratories I, Takeda Chemical Industries Ltd., Osaka, Japan

SO Journal of Pharmacology and Experimental Therapeutics (1996), 277(3), 1292-1304

CODEN: JPETAB; ISSN: 0022-3565

PB Williams & Wilkins

DT Journal

LA English

AB We examd. the effects of p.o. administered 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel AChE inhibitor, on impaired learning and memory in animal models. At 1 to 3 mg/kg, TAK-147 ameliorate the passive avoidance deficit induced by diazepam. TAK-147 did not affect delayed-matching-to-position (DMTP) performance of normal rats at doses of 1 to 30 mg/kg assessed by using a three-lever operant chamber, but 9-amino-tetrahydroacridine disrupted the DMTP response at 5 to 20 mg/kg. Scopolamine (0.02-0.1 mg/kg s.c.) impaired DMTP performance, whereas methylscopolamine did not affect the DMTP task. TAK-147 ameliorated the impairment of DMTP performance induced by scopolamine without affecting the general behavior of the rats; however, 9-amino-tetrahydroacridine produced no significant amelioration of the impairment. The intraventricular injection of AF64A disrupted differential-reinforcement-of-low-rate 10-s performance in rats, as demonstrated by marked decreases in reinforcement rate and response efficiency. TAK-147 slightly increased the reinforcement rate in AF64A-treated rats at a low dose of 1 mg/kg, but the effect was not significant statistically. TAK-147 had no significant effect on the duration of immobility in rats in a forced swimming test at doses of 2 to 10 mg/kg. 9-Aminotetrahydroacridine prolonged the duration of immobility at 5 to 20 mg/kg. Furthermore, TAK-147 reversed reserpine-induced hypothermia and ptosis in mice at doses of 3 to 10 mg/kg, a result that implies an antidepressant-like action. These results indicate that TAK-147 ameliorates learning and memory impairment in animal models without affecting the general behavior or causing behavioral depression and suggest that TAK-147 may be useful for the treatment of Alzheimer's disease.

IT 142852-51-5, TAK 147

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models)


RN 142852-51-5 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

09/807,599


CRN 142852-50-4  
CMF C25 H32 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



~~L20~~ ANSWER 29 OF 49 CAPLUS COPYRIGHT 2002 ACS

AM 1996:294876 CAPLUS

DN 124:343273

TI Preparation of urea moiety-containing benzazepine blood platelet aggregation inhibitors

IN Himmelsbach, Frank; Austel, Volkhard; Pieper, Helmut; Weisenberger, Johannes; Guth, Brian

PA Dr. Karl Thomae GmbH, Germany

SO Ger. Offen., 41 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4429079	A1	19960222	DE 1994-4429079	19940817
	WO 9605194	A1	19960222	WO 1995-EP3233	19950816
	W:	AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SK, TJ, TM, TT, UA, UG, UZ, VN			
	RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2197789	AA	19960222	CA 1995-2197789	19950816
	AU 9533459	A1	19960307	AU 1995-33459	19950816
	EP 777667	A1	19970611	EP 1995-929874	19950816
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
	JP 10504298	T2	19980428	JP 1995-507030	19950816
PRAI	DE 1994-4429079		19940817		
	WO 1995-EP3233		19950816		
OS	MARPAT 124:343273				
GI					



I

AB The title compds. [I; (un)substituted (un)branched alkylene, alkenylene, 1,2-arylene, etc.; (un)substituted alkylene, arylene, cycloalkylene, etc.; E = (un)substituted alkylene, etc.; F = alkoxycarbonyl, hydroxycarbonyl, etc.; Ra, Rb = H, F, Cl, Br, I, alkyl, CF<sub>3</sub>, CN, alkoxy, etc.; R1, R3 = H, alkyl, aryl, HO, alkoxy, CN, (un)substituted CO<sub>2</sub>H, etc.; R2, R4, R6, R8 = H, alkyl; R5, R7 = H, alkyl, aryl, CO<sub>2</sub>H, alkoxycarbonyl, (un)substituted CONH<sub>2</sub>, etc.; R9 = H, (un)substituted alkyl, cycloalkyl, etc.], useful as blood platelet aggregation inhibitors, are prepd. and I-contg. formulations presented. Thus, N-(2,2-diethoxyethyl)-N-(1,4-dioxaspiro[4.5]decan-8-yl)-N'-(3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)urea was prepd. and demonstrated EC<sub>50</sub> for blood platelet aggregation of 150 nM.

IT **176492-62-9**


RL: RCT (Reactant); RACT (Reactant or reagent)

09/807,599

(prepn. of urea moiety-contg. benzazepine blood platelet aggregation inhibitors)

RN 176492-62-9 CAPLUS

CN 1H-3-Benzazepin-7-amine, N-[[ (2,2-dimethoxyethyl) [1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]-2,3,4,5-tetrahydro-3-(trifluoroacetyl)- (9CI)  
(CA INDEX NAME)



09/807,599

~~120~~ ANSWER 30 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1996:211765 CAPLUS

~~DN~~ 124:260869

TI Preparation of benzazepine and benzodiazepine derivatives as vasopressin antagonists and agonists or oxytocin antagonists

IN Ogawa, Hidenori; Kondo, Kazumi; Yamashita, Hiroshi; Kan, Keizo; Matsuzaki, Takayuki; Shinohara, Tomoichi; Tanada, Yoshihisa; Kurimura, Muneaki; Tominaga, Michiaki; Yabuuchi, Yoichi

PA Otsuka Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 678 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9534540	A1	19951221	WO 1995-JP1124	19950607
	W: AU, CA, CN, KR, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2192928	AA	19951221	CA 1995-2192928	19950607
	AU 9526293	A1	19960105	AU 1995-26293	19950607
	AU 690283	B2	19980423		
	EP 765314	A1	19970402	EP 1995-921112	19950607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1150799	A	19970528	CN 1995-193642	19950607
	EP 1221440	A1	20020710	EP 2002-7987	19950607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	TW 467899	B	20011211	TW 1995-84105805	19950608
	JP 08301848	A2	19961119	JP 1995-177127	19950615
	JP 3215910	B2	20011009		
	JP 11349570	A2	19991221	JP 1999-111038	19950615
	JP 2000351768	A2	20001219	JP 2000-155830	19950615
	US 6096735	A	20000801	US 1996-737432	19961113
	US 6335327	B1	20020101	US 1999-431635	19991101
	CN 1313280	A	20010919	CN 2000-131787	20001018
	US 2002049194	A1	20020425	US 2001-874452	20010606
PRAI	JP 1994-132355	A	19940615		
	JP 1995-70727	A	19950303		
	EP 1995-921112	A3	19950607		
	WO 1995-JP1124	W	19950607		
	JP 1995-177127	A3	19950615		
	US 1996-737432	A3	19961113		
	US 1999-431635	A3	19991101		

OS MARPAT 124:260869

GI



I



II

AB Title compds. I and II [R1 = H, halo, alkyl, etc.; R2 = H, OH,

(substituted) amino, etc.; R3 = H, hydroxy-substituted alkyl; R2R3 = O, (substituted) alkylidene; R4 = H, alkoxy, (substituted) benzoyl, etc.; X = CH2, a single bond, (substituted) imino, etc.; Y = (substituted) imino], useful as antihypertensives, diuretics and antidiuretics, were prepd. and formulated. Treatment of 4-ethoxy-2-methoxybenzoic acid with SOCl2 followed by addn. of I [R1 = 7-Cl; R2 = Et2NCH2CH2N(Me)COCH2; R3 = R4 = H; X = CH2] in the presence of Et3N in CH2Cl2 and treatment of the base with conc. HCl afforded I.HCl [R1 = 7-Cl; R2 = Et2NCH2CH2N(Me)COCH2; R3 = H; R4 = 4,2-(EtO)(MeO)C6H3CO; X = CH2] which showed IC50 of 0.021 .mu.M in a vasopressin V1 receptor binding assay and IC50 of 0.15 .mu.M in a vasopressin V2 receptor binding assay.

IT 175149-13-0P 175149-15-2P 175149-24-3P  
 175149-31-2P 175149-33-4P 175149-36-7P  
 175151-20-9P 175151-34-5P 175151-44-7P  
 175151-45-8P 175151-51-6P 175151-52-7P  
 175151-53-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzazepine and benzodiazepine derivs. as vasopressin antagonists and agonists or oxytocin antagonists)


RN 175149-13-0 CAPLUS

CN Carbamic acid, [3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, (1-acetyl-4-piperidinyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175149-15-2 CAPLUS

CN Carbamic acid, [3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, (1-ethyl-4-piperidinyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 175149-24-3 CAPLUS

CN Carbamic acid, [3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-




yl)carbonyl]phenyl]-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175149-31-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]amino]carbonyloxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 175149-33-4 CAPLUS  
 CN Carbamic acid, [3-chloro-4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, 4-piperidinylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 175149-32-3  
 CMF C24 H28 Cl N3 O3

PAGE 1-A




PAGE 2-A



CM 2



CRN 76-05-1

CMF C2 H F3 O2




RN 175149-36-7 CAPLUS

CN 1H-1-Benzazepine, 1-[4-[[[ethyl(4-pyridinylmethyl)amino]carbonyl]amino]benzoyl]-2,3,4,5-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 175151-20-9 CAPLUS  
 CN 1H-1-Benzazepine, 1-[2-chloro-4-(4-oxo-1-piperidiny)benzoyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 175151-34-5 CAPLUS

CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175151-44-7 CAPLUS  
 CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]-, 4-piperidinylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175151-45-8 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[[4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]amino]carbonyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175151-51-6 CAPLUS  
 CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]-, 2-(4-pyridinyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 175151-52-7 CAPLUS  
CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-3-methoxyphenyl]-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)






RN 175151-53-8 CAPLUS  
CN Carbamic acid, [4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]-, (1-methyl-4-piperidinyl)methyl ester (9CI)  
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



09/807,599

L20 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1995:695864 CAPLUS

DN 123:83222

TI preparation and formulation of benzazepine derivatives as vasopressin antagonists and oxytocin antagonists

IN Ogawa, Hidenori; Kondo, Kazumi; Yamashita, Hiroshi; Nakaya, Kenji; Komatsu, Hajime; Tanaka, Michinori

PA Otsuka Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9408582	A1	19940428	WO 1993-JP1483	19931015
	W: AU, CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2124696	AA	19940428	CA 1993-2124696	19931015
	AU 9351614	A1	19940509	AU 1993-51614	19931015
	AU 663628	B2	19951012		
	EP 620003	A1	19941019	EP 1993-922637	19931015
	R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, LU, NL, SE				
	CN 1098716	A	19950215	CN 1993-119219	19931016
	CN 1039999	B	19980930		
	JP 06211800	A2	19940802	JP 1993-284485	19931018
	JP 2913082	B2	19990628		
	US 5622947	A	19970422	US 1994-244424	19940525
	US 5753644	A	19980519	US 1996-732595	19961015
	CN 1183277	A	19980603	CN 1997-123155	19971120
PRAI	JP 1992-277589		19921016		
	WO 1993-JP1483		19931015		
	US 1994-244424		19940525		
OS	MARPAT 123:83222				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Benzazepine derivs. [I, II; R1 = H, halo, OH, acyloxy, etc.; R2 = H, alkyl, OH, halo, alkoxy; R3 = (un)substituted benzamido, phenylacetamido, etc.; R4 = H, (un)substituted amino, etc.; R5 = H, OH, R4R5 = O; dotted bond = satd. or unsatd.], useful as antihypertensives and diuretics, are prepd. and formulated. Amidation of 50 g benzazepine deriv. III with 66.5 g chloride IV in aq. Me2CO gave 99.3 g amide I [R1 = R2 = R5 = H; R3 = 4-(2-ClC6H4CH2CONH), R4 = Me2N], which showed IC50 of 0.56 .mu.M in V2 receptor binding assay. Tablet and injection formulations were given. Also prepd. were 495 addnl. I and II.

IT 165312-31-2P 165314-07-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. and formulation of benzazepine derivs. as vasopressin antagonists and oxytocin antagonists)

RN 165312-31-2 CAPLUS

CN Benzamide, 2-[3-[4-(acetylamino)-1-piperidinyl]propoxy]-N-[4-[(7-chloro-


09/807,599

2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-2-methoxyphenyl]- (9CI)  
(CA INDEX NAME)



RN 165314-07-8 CAPLUS

CN Benzamide, 5-[4-[4-(acetylamino)-1-piperidinyl]butoxy]-2-chloro-N-[4-[(7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI)  
(CA INDEX NAME)



09/807,599

~~120~~ ANSWER 32 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1995:550906 CAPLUS

DN 122:314547

TI Preparation of urea residue-substituted heterocyclic compounds with antithrombotic, antineoplastic and blood platelet-aggregation inhibition activities

IN Himmelsbach, Frank; Pieper, Helmut; Austel, Volkhard; Linz, Guenter; Guth, Brian; Mueller, Thomas; Weisenberger, Johannes

PA Dr. Karl Thomae GmbH, Germany

SO Eur. Pat. Appl., 81 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 612741	A1	19940831	EP 1994-102557	19940221
	EP 612741	B1	19980610		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE 4305388	A1	19940825	DE 1993-4305388	19930222
	DE 4332168	A1	19950323	DE 1993-4332168	19930922
PRAI	DE 1993-4305388	A	19930222		
	DE 1993-4332168	A	19930922		

OS MARPAT 122:314547

AB The title compds., which contain urea-like moieties, often in the form of divalent imidazolidinone groups, which demonstrate a combination of antithrombotic, antineoplastic (no data), and blood platelet-aggregation inhibition activities, are prepd. and pharmaceutical dosage forms contg. them presented. Thus, 1-[4-(2-carboxyethyl)phenyl]-3-(1,2,3,4-tetrahydroisoquinolin-6-yl)imidazolidin-2-one was prepd. and demonstrated ED50 for blood platelet aggregation inhibition of 40 nM.


IT **163066-45-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea residue-substituted heterocyclic compds. with antithrombotic, antineoplastic and blood platelet aggregation inhibition activities)

RN 163066-45-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[2-oxo-3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-imidazolidinyl]acetyl]- (9CI) (CA INDEX NAME)



~~120~~ ANSWER 33 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1995:452025 CAPLUS

DN 122:213956

TI Preparation of N-(3-benzazepinopropyl)benzamides and analogs as antiarrhythmics

IN Nadler, Guy Marguerite Marie Gerard; Martin, Michel Jean Roger

PA Smithkline Beecham Laboratoires Pharmaceutiques, Fr.

SO PCT Int. Appl., 38 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9427971	A1	19941208	WO 1994-EP1705	19940524
	W:	AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, US, UZ, VN			
	RW:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	FR 2705675	A1	19941202	FR 1993-6346	19930527
	FR 2705675	B1	19960503		
	AU 9469718	A1	19941220	AU 1994-69718	19940524
	EP 700389	A1	19960313	EP 1994-918377	19940524
	R:	AT, CH, DE, FR, GB, IT, LI, NL			
	JP 09501405	T2	19970210	JP 1994-500225	19940524
	ZA 9403641	A	19950412	ZA 1994-3641	19940525
PRAI	FR 1993-6346		19930527		
	FR 1993-9327		19930729		
	WO 1994-EP1705		19940524		
OS	MARPAT 122:213956				
GI					



AB Title compds. [I; A = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH:CH, CO, COCH<sub>2</sub>; B = CH<sub>2</sub>, CO; R = EN(ZR<sub>3</sub>)DQ; D = CO, SO<sub>2</sub>, NHCO, CH:CH, P(O)OR<sub>6</sub>; E = (alkyl-substituted) alkylene; Q = aryl[alk(en)yl], heteroaryl, etc.; R<sub>1</sub>, R<sub>2</sub> = H, OH, alkyl, alkoxy, etc.; R<sub>3</sub> = (un)substituted Ph; R<sub>6</sub> = alkyl; Z = bond, CH<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>,


etc.] were prepd. Thus, 2,3,4,5-tetrahydro-7,8-dimethoxy-1H-3-benzazepine was N-alkylated by 3,4-(MeO)C<sub>6</sub>H<sub>3</sub>NHCOCH<sub>2</sub>CH<sub>2</sub>Cl and the reduced product N-acylated by 4-(O<sub>2</sub>N)C<sub>6</sub>H<sub>4</sub>COCl to give title compd. II. Data for effect of II on action potential duration of isolated guinea pig papillary muscle were given in graphic form.

IT **161885-14-9P 161885-34-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of N-(3-benzazepinopropyl)benzamides and analogs as antiarrhythmics)

RN 161885-14-9 CAPLUS


CN 4-Pyridinecarboxamide, N-(3,4-dimethoxyphenyl)-N-[3-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 161885-34-3 CAPLUS

CN 4-Pyridinecarboxamide, N-(3,4-dimethoxyphenyl)-N-[3-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)propyl]- (9CI) (CA INDEX NAME)



09/807,599

~~L20~~ ANSWER 34 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1995:195657 CAPLUS

DN 122:81100

TI Central cholinergic agents. 7. Regioselective Friedel-Crafts acylation of 2,3,4,5-tetrahydro-1H-2-benzazepine and related nitrogen heterocycles

AU Ishihara, Yuji; Tanaka, Toshimasa; Miwatashi, Seiji; Fujishima, Akira; Goto, Giichi

CS Pharmaceutical Research Laboratories I, Takeda Chemical Industries, Ltd., Osaka, 532, Japan

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1994), (20), 2993-9  
CODEN: JCPRB4; ISSN: 0300-922X

PB Royal Society of Chemistry

DT Journal

LA English

AB It is revealed that NH-protected 2,3,4,5-tetrahydro-1H-2-benzazepine is acylated on C-8 with greater than 95% regioselectivity. This regioselectivity has been applied to the synthesis of 3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)propan-1-one, an inhibitor of acetylcholinesterase (AChE). The regioselectivities of the acylation of the following nitrogen heterocycles have also been studied: 4-formyl-2,3,4,5-tetrahydro-1,4-benzoxazepine, 2,3,4,5-tetrahydro-1H-2-benzazepin-3-one, 2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, 7,11b,12,13-tetrahydro-5H-isoindolo[2,1-b][2]benzazepin-7-one, and 6,7,9,13b-tetrahydro-5H-isoindolo[1,2-a][2]benzazepin-9-one. An MO calcn. on the Lewis acid coordinated substrates has been used for predicting regioselectivity.


IT 160300-42-5P 160300-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of (benzylpiperidinyl)(tetrahydrobenzazepinyl)propanone)


RN 160300-42-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(2-acetyl-2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-3-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 160300-43-6 CAPLUS

CN 1H-2-Benzazepine, 2-acetyl-2,3,4,5-tetrahydro-8-[1-oxo-3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)






09/807,599

IT **142853-04-1P 160300-33-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of (benzylpiperidiny1)(tetrahydrobenzazepiny1)propanone)


RN 142853-04-1 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny1]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 160300-33-4 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny1]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

09/807,599

~~L20~~ ANSWER 35 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1995:43431 CAPLUS

DN 122:160431

TI Docking Analysis of a Series of Benzylamino Acetylcholinesterase Inhibitors with a Phthalimide, Benzoyl, or Indanone Moiety

AU Yamamoto, Yoshio; Ishihara, Yuji; Kuntz, Irwin D.

CS Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Osaka, 532, Japan

SO Journal of Medicinal Chemistry (1994), 37(19), 3141-53

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB The enzyme-binding mode of a series of acetylcholinesterase inhibitors has been analyzed on the basis of the crystal structure of the Torpedo enzyme using docking programs DOCK and directed-DOCK. The inhibitors have a benzyl group connected to tertiary ammonium nitrogen at one end and a phthalimide, benzoyl, or indanone moiety at the other. Our modeling results have indicated that the benzyl group interacts with Trp 84, which is located near the bottom of the binding pocket and is postulated to be the quaternary ammonium binding site for acetylcholine. The other arom. ring has been found to interact with Trp 279 at the peripheral hydrophobic site. In addn., the hydrogen-bonding interaction between a carbonyl group of the inhibitor and Tyr 121 OH seems to play an important role. Our active-orientation model is, at least qual., consistent with structure-activity data for more than 50 compds. and should be useful for the design of more potent inhibitors.

IT 142852-50-4 142852-52-6 142852-54-8


142852-56-0 142852-82-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(docking anal. and structure-activity of, as acetylcholinesterase inhibitor)


RN 142852-50-4 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 142852-52-6 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1-methyl-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 142852-54-8 CAPLUS


09/807,599

CN 1-Propanone, 1-(1-ethyl-2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-3-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 142852-56-0 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1-propyl-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 142852-82-2 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-1-(phenylmethyl)-1H-1-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



09/807,599

120 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1994:680508 CAPLUS

DN 121:280508

TI Central Cholinergic Agents. 6. Synthesis and Evaluation of  
3-[1-(Phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanones and Their Analogs as Central Selective  
Acetylcholinesterase Inhibitors

AU Ishihara, Yuji; Hirai, Keisuke; Miyamoto, Masaomi; Goto, Giichi

CS Pharmaceutical Research Division, Takeda Chemical Industries Ltd.,  
Yodogawaku, 532, Japan


SO Journal of Medicinal Chemistry (1994), 37(15), 2292-9

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

GI



AB In an attempt to find central selective acetylcholinesterase (AChE) inhibitors, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanones, e.g. I, and their analogs were designed on the basis of the authors' working hypothesis of the enzyme's active site. These compds. were prepd. by regioselective Friedel-Crafts acylation of 2,3,4,5-tetrahydro-1H-1-benzazepines and related nitrogen heterocycles as a key step. Most compds. showed potent inhibitory activities with IC50s in the 10-300 nM range. In order to est. their central selectivities, the authors examd. their effects on the apomorphine-induced circling behavior in rats with unilateral striatal lesions. Among compds. with potent AChE inhibition, I (IC50 of AChE inhibition = 97.7 nM) inhibited the circling behavior at 3 mg/kg po, in which it had no significant effect on peripheral cholinergic effects. This demonstrates that I has favorable central selectivity. Furthermore, I significantly ameliorated diazepam-induced passive avoidance deficit at 1 mg/kg po. The benzazepine deriv. I was selected as a candidate for clin. evaluation.

IT 142852-51-5P 142852-53-7P 142852-55-9P

142852-57-1P 142852-59-3P 142852-61-7P

142852-63-9P 142852-65-1P 142852-67-3P

142852-69-5P 142852-71-9P 142852-73-1P

142852-75-3P 142852-77-5P 142852-83-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and acetylcholinesterase inhibition by)


RN 142852-51-5 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

09/807,599


CRN . 142852-50-4  
CMF C25 H32 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-53-7 CAPLUS  
CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1-methyl-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-52-6  
CMF C26 H34 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-55-9 CAPLUS  
CN 1-Propanone, 1-(1-ethyl-2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-3-[1-

09/807,599

(phenylmethyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-54-8  
CMF C27 H36 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-57-1 CAPLUS  
CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1-propyl-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-56-0  
CMF C28 H38 N2 O




CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.

09/807,599




RN 142852-59-3 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-58-2

CMF C25 H32 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-61-7 CAPLUS

CN 1-Propanone, 3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-60-6

CMF C25 H31 F N2 O




CM 2

CRN 110-17-8

09/807,599

CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-63-9 CAPLUS  
CN 1-Propanone, 3-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-62-8  
CMF C26 H34 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-65-1 CAPLUS  
CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-64-0  
CMF C25 H31 Cl N2 O






09/807,599

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-67-3 CAPLUS

CN 1-Propanone, 3-[1-[(2-fluorophenyl)methyl]-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-66-2

CMF C25 H31 F N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 142852-69-5 CAPLUS


CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-68-4

CMF C25 H31 F N2 O

09/807,599




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-71-9 CAPLUS

CN 1-Propanone, 3-[1-[(3-methoxyphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-70-8

CMF C26 H34 N2 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 142852-73-1 CAPLUS


CN 1-Propanone, 3-[1-[(2-methoxyphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-72-0

09/807,599

CMF C26 H34 N2 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-75-3 CAPLUS

CN 1-Propanone, 3-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-74-2

CMF C26 H34 N2 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-77-5 CAPLUS

CN 1-Propanone, 3-[1-[(3-nitrophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

09/807,599


CRN 142852-76-4  
CMF C25 H31 N3 O3



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-83-3 CAPLUS  
CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-1-(phenylmethyl)-1H-1-benzazepin-8-yl]-, (2E)-2-butenedioate (1:1) (9CI)  
(CA INDEX NAME)

CM 1


CRN 142852-82-2  
CMF C32 H38 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



IT 142852-16-2P 142853-11-0P 142853-13-2P


**142853-20-1P 142853-21-2P 144161-00-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(prepn. and reaction of, in prepn. of cholinergic  
piperidinyl(benzazepinyl)propanones)


RN 142852-16-2 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-  
(9CI) (CA INDEX NAME)




RN 142853-11-0 CAPLUS

CN 1H-1-Benzazepine, 1-acetyl-8-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-  
2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 142853-13-2 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 142853-20-1 CAPLUS

CN Piperidine, 1-acetyl-4-[3-(1-ethyl-2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 142853-21-2 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-(2,3,4,5-tetrahydro-1-propyl-1H-1-


09/807,599

benzazepin-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 144161-00-2 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-  
(9CI) (CA INDEX NAME)



09/807,599

~~D20~~ ANSWER 37 OF 49 CAPLUS COPYRIGHT 2002 ACS

AN 1994:290828 CAPLUS

DN 120:290828

TI Carbostyryl derivatives and benzoheterocyclic compounds as oxytocin antagonists for treating oxytocin-related diseases

IN Ogawa, Hidenori; Miyamoto, Hisashi; Kondo, Kazumi; Yamashita, Hiroshi; Nakaya, Kenji; Tanaka, Michinori; Kitano, Kazuyoshi

PA Otsuka Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 207 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9401113	A1	19940120	WO 1993-JP835	19930622
	W: AU, CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9343569	A1	19940131	AU 1993-43569	19930622
	AU 657424	B2	19950309		
	EP 602209	A1	19940622	EP 1993-913553	19930622
	R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, LU, NL, SE				
	JP 06087747	A2	19940329	JP 1993-161715	19930630
	JP 2969206	B2	19991102		
	JP 06092854	A2	19940405	JP 1993-161716	19930630
	JP 2969207	B2	19991102		
	CN 1091288	A	19940831	CN 1993-109876	19930702
PRAI	JP 1992-175563		19920702		
	JP 1992-175566		19920702		
	WO 1993-JP835		19930622		
OS	MARPAT 120:290828				
GI					



AB Oxytocin antagonists comprise, as active ingredients, carbostyryl derivs. I [R1 = H, NO2, lower alkyl, lower alkoxy, lower alkoxy-carbonyl, halo, etc.; q = 1-3; R = substituted Ph, (substituted) 5-6-membered ring contg. NR2; R2 = H, lower alkoxy-carbonyl, (substituted) phenoxy-carbonyl, naphthyl-carbonyl, etc.] or benzoheterocyclic compds. II [R16 = H, halo, lower alkyl, (lower alkyl substituted) amino, lower alkoxy; R17 = H, halo, lower alkoxy, phenyl(lower)alkoxy, HO, lower alkyl, etc.; R18 = NR19R20, CONR26R27; R19 = H, lower alkyl, (halo substituted) benzoyl; R20 = (substituted) COC6H4, lower alkanoyl, phenyl-lower alkoxy-carbonyl, cycloalkyl-carbonyl, etc.; R26 = H, lower alkyl; R27 = cycloalkyl, (substituted) Ph; W = (CH2)t, CH=CH(CH2)v, etc.; t = 3-5; v = 1-3] or their pharmaceutically acceptable salts,. These compds. show excellent

oxytocin antagonist activity and hence are useful in the protection or treatment of oxytocin-related diseases, esp. for treatment of premature delivery, dysmenorrhea, endometritis, or for stopping labor preparatory to cesarean delivery. IC50 values were detd. for I and II compds. in a rat oxytocin receptor binding assay. Coated tablet and injection formulations are given.


IT **154890-34-3**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(oxytocin antagonist)


RN 154890-34-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(diethylamino)acetyl]-N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





09/807,599

~~120~~ ANSWER 38 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1994:270451 CAPLUS

~~DN~~ 120:270451

~~TI~~ Condensed heterocyclic ketone cholinesterase inhibitors, their production and use

~~IN~~ Goto, Giichi; Miyamoto, Masaomi; Ishihara, Yuji

~~PA~~ Takeda Chemical Industries, Ltd., Japan

~~SO~~ Eur. Pat. Appl., 95 pp.


CODEN: EPXXDW

~~DT~~ Patent

~~LA~~ English

~~FAN.CNT~~ 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 560235	A1	19930915	EP 1993-103614	19930306
	EP 560235	B1	19970604		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9333803	A1	19930916	AU 1993-33803	19930225
	AU 658481	B2	19950413		
	NO 9300783	A	19930910	NO 1993-783	19930303
	ZA 9301510	A	19940903	ZA 1993-1510	19930303
	US 5462934	A	19951031	US 1993-26041	19930304
	AT 154020	E	19970615	AT 1993-103614	19930306
	CA 2091216	AA	19930910	CA 1993-2091216	19930308
	JP 06166676	A2	19940614	JP 1993-46747	19930308
	CN 1078969	A	19931201	CN 1993-102438	19930309
	CN 1039119	B	19980715		
	HU 67283	A2	19950328	HU 1993-659	19930309
PRAI	JP 1992-50960		19920309		
	JP 1992-97948		19920417		
	JP 1992-145852		19920605		
	JP 1992-210225		19920806		
	JP 1992-259606		19920929		
OS	MARPAT 120:270451				
GI					



AB The title compds. I [R1 = H, (un)substituted hydrocarbon or acyl group; R2-R4 = H, (un)substituted hydrocarbon group; k = 0-3; m = 1-8; n = 1-10; R3R4N = (un)substituted heterocyclic group; when k = 0 and n = 2 then n = .gtoreq.2], which are effective cholinesterase inhibitors and useful in the treatment of senile dementia (no data) and/or Alzheimer's disease (no data), are prepd. and I-contg. formulations presented. Thus, dihydroindole deriv. II, m.p. 194-196.degree., was prepd. and demonstrated 50% acetylcholinesterase inhibitory activity (rat cerebral cortex as the

cholinesterase source) of 0.0152.mu.M vs. 0.220.mu.M for physostigmine.

IT 153030-38-7P 153030-43-4P 153030-47-8P

153030-51-4P 153030-67-2P 153030-75-2P


153030-82-1P 153031-00-6P 153031-06-2P

153031-10-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and cholinesterase inhibitory activity of)

RN 153030-38-7 CAPLUS


CN 1H-3-Benzazepine, 3-acetyl-2,3,4,5-tetrahydro-7-[1-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153030-43-4 CAPLUS

CN 1H-3-Benzazepine, 3-acetyl-2,3,4,5-tetrahydro-7-[1-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)



RN 153030-47-8 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 153030-51-4 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 153030-67-2 CAPLUS


CN 4-Piperidinone, 1-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 153030-75-2 CAPLUS


CN 1-Propanone, 3-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 153030-82-1 CAPLUS


CN 1-Propanone, 3-[4-(4-pyridinylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl


RN 153031-00-6 CAPLUS

CN 4-Piperidinone, 1-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (9CI) (CA INDEX NAME)




RN 153031-06-2 CAPLUS

CN 1-Propanone, 3-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 153031-10-8 CAPLUS

CN 1-Propanone, 3-[4-(4-pyridinylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (9CI) (CA INDEX NAME)



~~120~~ ANSWER 39 OF 49 CAPLUS COPYRIGHT 2002 ACS  
~~AN~~ 1993:649979 CAPLUS  
~~DN~~ 119:249979  
 TI Preparation of N-benzoyl benzo-fused heterocyclic compounds as vasopressin antagonists  
 IN Ogawa, Hidenori; Miyamoto, Hisashi; Kondo, Kazumi; Yamashita, Hiroshi; Nakaya, Kenji; Komatsu, Hajime; Tanaka, Michinori; Takara, Shinya; Tominaga, Michiaki; Yabuchi, Yoichi  
 PA Otsuka Pharmaceutical Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 318 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04321669	A2	19921111	JP 1991-182066	19910419
	JP 2905909	B2	19990614		
	US 5258510	A	19931102	US 1992-851541	19920313
	US 5559230	A	19960924	US 1993-76804	19930610
	US 5753677	A	19980519	US 1995-474544	19950607
	US 5985869	A	19991116	US 1997-893925	19970715
PRAI	JP 1989-274338		19891020		
	JP 1990-66063		19900315		
	JP 1990-105580		19900420		
	JP 1990-181858		19900709		
	JP 1991-182066		19910419		
	US 1991-762015		19910619		
	US 1992-851541		19920313		
	US 1993-76804		19930610		
	US 1995-474544		19950607		
OS	MARPAT 119:249979				
GI					



AB The title compds. [I; R1 = H, halo, alkyl, (alkyl)amino, alkoxy; R2 = H, halo, alkoxy, phenylalkoxy, HO, alkyl, (alkyl)amino, carbamoylalkyl, (N-alkyl)aminoalkoxy, (halo)benzoyl; R3 = (un)substituted NH2 or CONH2; W = (CH2)p (where p = 3-5) or CH:CH(CH2)q (where q = 1-3) each optionally having the C atom replaced with O, S, SO, SO2, or (un)substituted NH], useful as vasodilators, antihypertensives, blood platelet aggregation inhibitors, diuretics, etc., are prepd. Thus, 38.8 g K2CO3 was added to a soln. of 8.7 g 1,2,3,4-tetrahydroquinoline in aq. acetone followed by dropwise addn. of 56 g 4-benzoylamino benzoyl chloride under ice-cooling and the mixt. was stirred at room temp. overnight to give, after silica

gel chromatog., 57 g 1-[4-(benzoylamino)benzoyl]-1,2,3,4-tetrahydroquinoline. A total of 529 I including N-benzoylquinoline, -quinoxaline, -benzazepine, -benzodiazepine, and -benzoxazepine derivs. were prepd. and showed IC50 of 0.003-9.1 .mu.M for inhibiting the binding of [3H]vasopressin to V2 receptor in a rat kidney sample.


IT 137980-88-2P 137981-19-2P 137981-87-4P

137981-88-5P 137982-48-0P 138470-98-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as vasopressin antagonist)

RN 137980-88-2 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 137981-19-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-oxo-2-[[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 137981-87-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 137981-88-5 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-acetyl-N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)






RN 137982-48-0 CAPLUS

CN 4-Piperidinecarboxamide, N,1-dimethyl-N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 138470-98-1 CAPLUS

CN 4-Piperidinecarboxamide, N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

09/807,599

~~DO~~ ANSWER 40 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1993:495362 CAPLUS

~~DN~~ 119:95362

TI Preparation of (heteroalkoxy)benzazepines

IN Demarinis, Robert Michael; Pfeiffer, Francis Richard

PA SmithKline Beckman Corp., USA

SO PCT Int. Appl., 37 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	-----	-----	-----	-----
PI	WO 9303015	A1	19930218	WO 1992-US6538	19920805
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	AU 9224330	A1	19930302	AU 1992-24330	19920805
	JP 06511239	T2	19941215	JP 1992-503834	19920805
	EP 630372	A1	19941228	EP 1992-917522	19920805
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	US 5639748	A	19970617	US 1994-193075	19940204
PRAI	GB 1991-16824		19910805		
	WO 1992-US6538		19920805		
OS	MARPAT 119:95362				
GI					



AB Title compds. I (X = H, halo, F3C, C1-6 alkyl, NC, O2N, F3CS, R1CO, R1S (wherein R1 = C1-6 alkyl, Ph, (CH2)0-6), R2O2C, (R2)2NCO (wherein R2 = H, C1-6 alkyl, Ph(CH2)0-6), R4R3N, R3O (wherein R3 = H, C1-6 alkyl, CHO, R1CO, R1O2S, R4 = H, C1-6 alkyl); R = H, C1-6 alkyl, C3-5 alkenyl; A = OCO(CH2)1-4 OCH2CH:CH, CO2(CH2)1-4, (CH2)0-6, (CH2)nZ(CH2)m wherein Z = O, S, n = 0-4, m = 1-5, m + n = .ltoreq.5; Het = (substituted) thienyl, furanyl, pyrazolyl, imidazolyl, etc.) or a salt thereof, useful as .alpha.-adrenoceptor antagonists in treatment of congestive heart failure, peripheral vascular disease and benign prostatic cancer (no data), are prepd. Redn. of 9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-benzazepine-6-carbonitrile (prepn. given) with LiAlH4 in THF (reflux 3 h) gave the 6-methanamine deriv. which was treated with 2,5-dimethoxytetrahydrofuran to give I (X = 6-Cl, R = Me, A = 9-CH2, Het = 1H-pyrrol-1-yl) and converted to the HCl salt. Addnl. I were prepd. Pharmaceutical formulations comprising I, are given.

IT **147829-71-8P 147847-33-4P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as .alpha.-adrenergic antagonist)

RN 147829-71-8 CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-

09/807,599


pyridinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 147847-33-4 . CAPLUS

CN 1H-3-Benzazepine, 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




09/807,599


L20 ANSWER 41 OF 49 CAPLUS COPYRIGHT 2002 ACS  
AN 1993:408698 CAPLUS  
DN 119:8698

TI Preparation and formulation of N-[(1-phenylethyl)piperidinylmethyl]benzazepinones and analogs for treating sinus tachycardia  
IN Psiorz, Manfred; Heider, Joachim; Bomhard, Andreas; Reiffen, Manfred; Hael, Norbert; Noll, Klaus; Narr, Berthold; Lillie, Christian; Kobinger, Walter; Dammgen, Jurgen  
PA Boehringer Ingelheim G.m.b.H., Germany  
SO U.S., 76 pp. Cont.-in-part of U.S. Ser. No. 552,352, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5175157	A	19921229	US 1991-725855	19910703
	DE 3541811	A1	19870604	DE 1985-3541811	19851127
	DE 3717561	A1	19881208	DE 1987-3717561	19870525
PRAI	DE 1985-3541811		19851127		
	US 1986-934277		19861124		
	DE 1987-3717561		19870525		
	US 1988-170185		19880318		
	US 1988-197064		19880520		
	US 1988-259228		19881017		
	US 1989-426922		19891024		
	US 1989-438279		19891116		
	US 1990-552352		19900712		
	US 1991-638001		19910104		
OS	CASREACT 119:8698; MARPAT 119:8698				
GI					



I



III

AB Title compds. I (R1 = H, halo, F3C, O2N, C1-3 alkyl, (substituted) amino, HO, alkoxy, phenylalkoxy; R2 = H, halo, HO, alkoxy, phenylalkoxy, C1-3 alkyl; R1R2 = C1-2 alkylenedioxy; E = (substituted) C1-3 alkylene; A = CH2CH2, CH:CH, CH2CO, NHCO, COCO, CH(OH)CO, CH2; B = CH2CH2, CH2, CO, CH2CO; G = (substituted) C1-6 alkylene, etc.; R = (substituted) Ph, (substituted) heterocyclyl; m = 1-5; n = 0-2) or a salt thereof, were prepd. Thus, 3-[(piperidin-3-yl)methyl]-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one, Et3N and 3,4-(MeO)2C6H3CH2CH2Br were refluxed for 2

09/807,599


h to give the title compd. II as the HCl salt (III). III at 5.0 mg/kg lowered blood pressure in ratio after 20 min -208 beats/min. A large no of I were prepd. some of which were tested. Pharmaceutical compns. comprising I are given.

IT 119917-85-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, for treatment of sinus tachycardia)

RN 119917-85-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethyl-3-[2-[1-[3-(4-pyridinyl)propyl]-2-piperidinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

09/807,599

~~D20~~ ANSWER 42 OF 49 CAPLUS COPYRIGHT 2002 ACS  
~~AM~~ 1992:612341 CAPLUS  
~~DN~~ 117:212341  
TI Preparation of cyanoguanidine class II antiarrhythmics  
IN Liang, Chi Dean  
PA Searle, G. D., and Co., USA  
SO U.S., 8 pp. Cont.-in-part of U.S. Ser. No. 545,250.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5132311	A	19920721	US 1991-737963	19910730
PRAI	US 1990-545250		19900627		
OS	MARPAT 117:212341				
GI					




AB Title compds.  $R_2C(:R_1)R_3$  [I;  $R_1 = NC:N$ ;  $R_2 = Q$ , morpholinyl, indolinyl, isoindolinyl, etc.;  $X = H$ , C1-10 alkyl;  $p = 0-10$ ;  $R_3 = Q1$ ;  $Y = C2-6$  alkylene which may be substituted by O;  $R_4 = H$ ,  $NO_2$ , C1-6 alkyl, C1-6 alkoxy, Cl, F, Br] were prepd. as class III antiarrhythmic agents. Thus,  $(PhO)_2C:NCN$  in MeCN was added to 2,3-dihydro-1H-inden-1-amine and the mixt. was stirred 4 h at room temp. Then, 4-amino-1-benzylpiperidine was added and the mixt. was stirred an addnl. 2 h. The mixt. was then subjected to 20000 psi for 17 h to give title compd. II. II at 3 .times.  $10^{-5}$  M increased ventricular refractory period by 70 ms for guinea pig ventricular papillary muscle in vitro, compared with 8 ms for H<sub>2</sub>O and 24 ms for clotilium.

IT **143922-23-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as class III antiarrhythmic)

RN 143922-23-0 CAPLUS

CN 3H-3-Benzazepine-3-carboximidamide, N-cyano-1,2,4,5-tetrahydro-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)





09/807,599

~~L20~~ ANSWER 43 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1992:531091 CAPLUS

~~DN~~ 117:131091

~~TI~~ Preparation of [(piperidinyl)acyl]heterocycles as cholinesterase inhibitors

~~IN~~ Goto, Giichi; Ishihara, Yuji; Miyamoto, Masaomi

~~PA~~ Takeda Chemical Industries, Ltd., Japan

~~SO~~ Eur. Pat. Appl., 88 pp.



CODEN: EPXXDW

~~DT~~ Patent

~~LA~~ English

~~FAN.CNT~~ 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 487071	A1	19920527	EP 1991-119818	19911121
	EP 487071	B1	19950705		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05140149	A2	19930608	JP 1991-305062	19911120
	JP 2650537	B2	19970903		
	CA 2055947	AA	19920523	CA 1991-2055947	19911121
	FI 9105488	A	19920523	FI 1991-5488	19911121
	NO 9104558	A	19920525	NO 1991-4558	19911121
	NO 179868	B	19960923		
	NO 179868	C	19970102		
	AU 9188045	A1	19920528	AU 1991-88045	19911121
	AU 643337	B2	19931111		
	HU 59676	A2	19920629	HU 1991-3643	19911121
	HU 214573	B	20000428		
	ES 2074205	T3	19950901	ES 1991-119818	19911121
	RU 2095361	C1	19971110	RU 1991-5010491	19911121
	CN 1062143	A	19920624	CN 1991-110950	19911122
	ZA 9109252	A	19930524	ZA 1991-9252	19911122
	US 5273974	A	19931228	US 1991-796430	19911122
	FI 9802436	A	19981110	FI 1998-2436	19981110
PRAI	JP 1990-319897	A	19901122		
	JP 1991-70286	A	19910114		
	JP 1991-209358	A	19910821		
	JP 1991-243768	A	19910924		
OS	MARPAT 117:131091				
GI					



AB Title compds. I [X = O, S, NR1; R1 = H, (substituted)hydrocarbyl,


(substituted)acyl; R2 = (substituted)hydrocarbyl, H; k = 0-3; m = 1-8; n = 1-6; benzene ring may be substituted] were prepd. as cholinesterase inhibitors useful for treatment of senile dementia and/or Alzheimer's disease. Thus, 3-(1-acetylpiperidin-4-yl)propionic acid (prepn. given) was converted to the acid chloride, then treated with 1-acetyl-1,2,3,4-tetrahydroquinoline. The product formed was deacetylated and then benzylated by PhCH2Br to give title compd. II.2HCl. The latter had IC50 of 0.014 .mu.M against acetylcholinesterase. Formulations contg. I were prepd.

IT 142852-16-2P 142852-22-0P 142852-23-1P  
 142852-24-2P 142852-50-4P 142852-51-5P  
 142852-53-7P 142852-55-9P 142852-57-1P  
 142852-58-2P 142852-59-3P 142852-61-7P  
 142852-63-9P 142852-65-1P 142852-67-3P  
 142852-69-5P 142852-71-9P 142852-73-1P  
 142852-75-3P 142852-77-5P 142852-83-3P  
 142852-88-8P 142852-89-9P 142852-90-2P  
 142852-91-3P 142852-98-0P 142853-01-8P  
 142853-02-9P 142853-03-0P 142853-04-1P  
 142853-40-5P 144161-00-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as cholinesterase inhibitor)


RN 142852-16-2 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-  
 (9CI) (CA INDEX NAME)




RN 142852-22-0 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1-methyl-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 142852-23-1 CAPLUS

CN 1-Propanone, 1-(1-ethyl-2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-3-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 142852-24-2 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 142852-50-4 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 142852-51-5 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-50-4

CMF C25 H32 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

09/807,599


Double bond geometry as shown.



RN 142852-53-7 CAPLUS  
CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1-methyl-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-52-6  
CMF C26 H34 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-55-9 CAPLUS  
CN 1-Propanone, 1-(1-ethyl-2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-54-8  
CMF C27 H36 N2 O




09/807,599

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-57-1 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1-propyl-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-56-0

CMF C28 H38 N2 O




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 142852-58-2 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 142852-59-3 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-

09/807,599

benzazepin-7-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-58-2  
CMF C25 H32 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-61-7 CAPLUS  
CN 1-Propanone, 3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-60-6  
CMF C25 H31 F N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




09/807,599

RN	142852-63-9	CAPLUS
CN	1-Propanone, 3-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)	

CM 1


CRN 142852-62-8  
CMF C26 H34 N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN	142852-65-1	CAPLUS
CN	1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)	

CM 1

CRN 142852-64-0  
CMF C25 H31 Cl N2 O




CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.


09/807,599



RN 142852-67-3 CAPLUS  
CN 1-Propanone, 3-[1-[(2-fluorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-66-2  
CMF C25 H31 F N2 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-69-5 CAPLUS  
CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-68-4  
CMF C25 H31 F N2 O




CM 2

CRN 110-17-8  
CMF C4 H4 O4



09/807,599

Double bond geometry as shown.




RN 142852-71-9 CAPLUS

CN 1-Propanone, 3-[1-[(3-methoxyphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-70-8

CMF C26 H34 N2 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-73-1 CAPLUS

CN 1-Propanone, 3-[1-[(2-methoxyphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-72-0

CMF C26 H34 N2 O2




CM 2

09/807,599

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-75-3 CAPLUS  
CN 1-Propanone, 3-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-74-2  
CMF C26 H34 N2 O2



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 142852-77-5 CAPLUS  
CN 1-Propanone, 3-[1-[(3-nitrophenyl)methyl]-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-76-4  
CMF C25 H31 N3 O3




09/807,599

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 142852-83-3 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-[2,3,4,5-tetrahydro-1-(phenylmethyl)-1H-1-benzazepin-8-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142852-82-2

CMF C32 H38 N2 O




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 142852-88-8 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 142852-89-9 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 142852-90-2 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 142852-91-3 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



RN 142852-98-0 CAPLUS


CN 1H-1-Benzazepine, 1-acetyl-2,3,4,5-tetrahydro-8-[1-oxo-3-[1-(phenylmethyl)-4-piperidinyl]propyl]-1-oxo-3-[1-(phenylmethyl)-4-piperidinyl]propyl)- (9CI) (CA INDEX NAME)

4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)



RN 142853-01-8 CAPLUS


CN 1-Propanone, 3-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 142853-02-9 CAPLUS


CN 1-Propanone, 3-(4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-7-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 142853-03-0 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-2-(phenylmethyl)-1H-2-benzazepin-8-yl]- (9CI) (CA INDEX NAME)



09/807,599

RN 142853-04-1 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 142853-40-5 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142852-89-9  
CMF C25 H32 N2 O



CM 2


CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



RN 144161-00-2 CAPLUS

CN 1-Propanone, 3-(4-piperidiny)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)- (9CI) (CA INDEX NAME)




IT 142853-11-0P 142853-12-1P 142853-13-2P  
 142853-19-8P 142853-20-1P 142853-21-2P  
 142853-23-4P 142853-34-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as intermediate for cholinesterase inhibitors)


RN 142853-11-0 CAPLUS

CN 1H-1-Benzazepine, 1-acetyl-8-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-  
 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 142853-12-1 CAPLUS

CN 1H-1-Benzazepine, 1-acetyl-7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-  
 2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 142853-13-2 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 142853-19-8 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-(2,3,4,5-tetrahydro-1-methyl-1H-1-benzazepin-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 142853-20-1 CAPLUS

CN Piperidine, 1-acetyl-4-[3-(1-ethyl-2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 142853-21-2 CAPLUS

CN Piperidine, 1-acetyl-4-[3-oxo-3-(2,3,4,5-tetrahydro-1-propyl-1H-1-benzazepin-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 142853-23-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 7-[3-(1-benzoyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)



RN 142853-34-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[2-[2-(1-benzoyl-4-piperidinyl)ethyl]-1,3-dioxolan-2-yl]-1,2,4,5-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)





~~D20~~ ANSWER 44 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1992:128686 CAPLUS

~~DN~~ 116:128686

~~TI~~ Benzoheterocyclic compounds

~~IN~~ Ogawa, Hidenori; Miyamoto, Hisashi; Kondo, Kazumi; Yamashita, Hiroshi; Nakaya, Kenji; Komatsu, Hajime; Tanaka, Michinori

~~PA~~ Otsuka Pharmaceutical Co., Ltd., Japan

~~SO~~ PCT Int. Appl., 909 pp.

CODEN: PIXXD2

~~DT~~ Patent

~~LA~~ English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9105549	A1	19910502	WO 1990-JP1340	19901018
	W: KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	EP 450097	A1	19911009	EP 1990-915185	19901018
	EP 450097	B1	19960424		
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	ES 2089033	T3	19961001	ES 1990-915185	19901018
	CN 1051038	A	19910501	CN 1990-108449	19901019
	CN 1027505	B	19950125		
	JP 04154765	A2	19920527	JP 1990-282568	19901019
	JP 07076214	B4	19950816		
	AU 9172917	A1	19911219	AU 1991-72917	19910314
	AU 630284	B2	19921022		
	CA 2066104	AA	19921020	CA 1992-2066104	19920415
	AU 9214984	A1	19921022	AU 1992-14984	19920416
	AU 646334	B2	19940217		
	EP 514667	A1	19921125	EP 1992-106606	19920416
	EP 514667	B1	19950809		
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	CN 1066653	A	19921202	CN 1992-103409	19920416
	CN 1035670	B	19970820		
	ES 2078576	T3	19951216	ES 1992-106606	19920416
	JP 05132466	A2	19930528	JP 1992-96880	19920417
	JP 2916536	B2	19990705		
	US 5244898	A	19930914	US 1992-870318	19920417
	CN 1107146	A	19950823	CN 1994-101827	19940302
	CN 1048484	B	20000119		
	US 5753677	A	19980519	US 1995-474544	19950607
PRAI	JP 1989-274338		19891020		
	JP 1990-66063		19900315		
	JP 1990-105580		19900420		
	JP 1990-181858		19900709		
	JP 1991-87994		19910419		
	WO 1990-JP1340		19901018		
	US 1991-762015		19910619		
	US 1992-851541		19920313		
	US 1993-76804		19930610		

OS MARPAT 116:128686

GI For diagram(s), see printed CA Issue.

AB Title compds. I [X = atoms required to complete a 6-8-membered ring optionally contg. other heteroatoms; R = substituted Ph; R1 = H, halogen, alkyl, NH2, substituted NH2, aminoalkoxy, (un)substituted BzO] (.apprx.1000 compds.) were prepd. by various methods. Benzazepines II (R2 = NMe2, R3 = 2-MeC6H4; R2 = OH, R3 = 3,5-Cl2C6H3; R2 = H, R3 =


2,3-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>) tripled urine excretion in rats at 0.4-4.2 mg/kg i.v.

IT **137976-51-3**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(methylation of)

RN 137976-51-3 CAPLUS

CN 4-Piperidinecarboxamide, N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



IT **137980-88-2P 137980-96-2P 137981-19-2P**


**137981-87-4P 137981-88-5P 137982-48-0P**

**138470-71-0P 138470-98-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 137980-88-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 137980-96-2 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[1,4-dioxo-4-[[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]amino]butyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 137981-19-2 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[2-oxo-2-[[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 137981-87-4 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 137981-88-5 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-acetyl-N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 137982-48-0 CAPLUS


CN 4-Piperidinecarboxamide, N,1-dimethyl-N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 138470-71-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(diethylamino)acetyl]-N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 138470-98-1 CAPLUS  
 CN 4-Piperidinecarboxamide, N-[4-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)






09/807,599

~~LD~~ ANSWER 45 OF 49 CAPLUS COPYRIGHT 2002 ACS  
AN 1991:6302 CAPLUS  
DN 114:6302  
TI Preparation of piperidine derivatives as cholinergics  
IN Sugimoto, Hachiro; Tsuchiya, Yutaka; Higure, Kunizo; Karibe, Norio;  
Iimura, Yoichi; Sasaki, Atsushi; Yamanishi, Yoshiharu; Ogura, Hiroo;  
Araki, Shin; Et, Al.  
PA Eisai Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 54 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02169569	A2	19900629	JP 1988-324620	19881222
	JP 2777159	B2	19980716		
OS	MARPAT 114:6302				
GI					



AB The title compds. I [J = (substituted) Ph, pyridyl, quinolyl, indenyl, etc.; Z = (R<sub>2</sub>CH)<sub>n</sub>, CO(CHR<sub>2</sub>)<sub>n</sub>, etc.; n = 0-10; R<sub>2</sub> = H, Me; T = N, C; Q = N, C, etc.; K = H, (substituted) Ph, cinnamyl, etc.; q = 1-3; dotted line indicates either single or double bond] were prepd. Hydrogenation of piperidine deriv. II in MeOH contg. 5% Rh-C under hydrogen gave a piperidine deriv. III. III in vitro exhibited an IC<sub>50</sub> of 0.23 .mu.M against acetylcholinesterase.


IT **130927-73-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as cholinergic)

RN 130927-73-0 CAPLUS

CN 1H-1-Benzazepine, 2,3,4,5-tetrahydro-8-methoxy-1-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

09/807,599



● HCl

09/807,599

~~120~~ ANSWER 46 OF 49 CAPLUS COPYRIGHT 2002 ACS  
~~AN~~ 1990:458970 CAPLUS

DN 113:58970

TI Dihydroisoindoles and tetrahydrobenzazepines as antidepressants and drugs with affinity for 5-HT<sub>1A</sub> serotonin receptors and their preparation

IN George, Pascal; Sevrin, Mireille; Mangane, Michel; Merly, Jean Pierre; Bigg, Dennis

PA Synthelabo S. A., Fr.

SO Eur. Pat. Appl., 14 pp.


CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 351283	A1	19900117	EP 1989-401899	19890703
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FR 2634207	A1	19900119	FR 1988-9450	19880712
	FR 2634207	B1	19900907		
	FR 2634208	A1	19900119	FR 1988-9451	19880712
	FR 2634208	B1	19901123		
	DK 8903420	A	19900113	DK 1989-3420	19890711
	FI 8903366	A	19900113	FI 1989-3366	19890711
	NO 8902871	A	19900115	NO 1989-2871	19890711
	AU 8938030	A1	19900118	AU 1989-38030	19890711
	AU 616543	B2	19911031		
	HU 50329	A2	19900129	HU 1989-3489	19890711
	HU 202228	B	19910228		
	JP 02072174	A2	19900312	JP 1989-180141	19890711
	ZA 8905271	A	19900425	ZA 1989-5271	19890711
	US 5081128	A	19920114	US 1989-377929	19890711
	US 5096900	A	19920317	US 1990-503941	19900208
PRAI	FR 1988-9450		19880712		
	FR 1988-9451		19880712		
	US 1989-377929		19890711		
OS	CASREACT 113:58970; MARPAT 113:58970				
GI					



AB The title compds. I [ $m = n = 1$ , or  $m = n = 2$ , or  $m = 3$ ,  $n = 1$ ;  $R = H$ , (un)substituted  $\text{PhCH}_2$  or  $\text{Bz}$ ] were prepd. A mixt. of 1-(phenylmethyl)piperidine-4-carboxamide (prepn. given) and  $\text{LiAlH}_4$  in ether was refluxed for 8 h to give the corresponding amine, which was isolated as the  $\text{HCl}$  salt. A mixt. contg. the  $\text{HCl}$  salt of the above amine,  $\text{K}_2\text{CO}_3$ , and 1,2-di(bromomethyl)benzene in  $\text{DMF}$  was stirred at room temp. for 4 h to give, after workup and treatment with  $\text{HCl}$ ,  $\text{I} \cdot 2\text{HCl}$  ( $m = n = 1$ ,  $R = \text{PhCH}_2$ ).  $\text{I}$  in vitro exhibited  $\text{IC}_{50}$  values of 0.001 to 1  $\mu\text{M}$  in in vitro tests

09/807,599

using rat brain tissue and 3H-8-hydroxy-2-dipropylaminotetralin.

IT 128185-68-2P 128185-70-6P 128185-72-8P  
128185-74-0P 128185-75-1P 128185-76-2P  
128185-78-4P 128185-79-5P 128185-81-9P  
128185-82-0P 128185-84-2P 128185-85-3P  
128185-87-5P 128185-88-6P 128185-89-7P  
128185-92-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as drug with affinity for serotonin receptor)


RN 128185-68-2 CAPLUS

CN Piperidine, 1-benzoyl-4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]-  
, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 128185-67-1

CMF C23 H28 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 128185-70-6 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 128185-69-3

CMF C23 H30 N2




09/807,599

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 128185-72-8 CAPLUS

CN Piperidine, 1-(3-chlorobenzoyl)-4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 128185-71-7

CMF C23 H27 Cl N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 128185-74-0 CAPLUS


CN 1H-3-Benzazepine, 3-[[1-[(3-chlorophenyl)methyl]-4-piperidinyl)methyl]-2,3,4,5-tetrahydro-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 128185-73-9

CMF C23 H29 Cl N2

09/807,599




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 128185-75-1 CAPLUS

CN Piperidine, 1-(3-methylbenzoyl)-4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]- (9CI) (CA INDEX NAME)




RN 128185-76-2 CAPLUS

CN Piperidine, 1-(3-methylbenzoyl)-4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 128185-75-1

CMF C24 H30 N2 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

09/807,599


Double bond geometry as shown.



RN 128185-78-4 CAPLUS  
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[[1-[(3-methylphenyl)methyl]-4-piperidinyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 128185-77-3  
CMF C24 H32 N2




CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



RN 128185-79-5 CAPLUS  
CN Piperidine, 1-benzoyl-4-[(1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 128185-81-9 CAPLUS  
CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1



09/807,599


CRN 128185-80-8  
CMF C23 H30 N2




CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



RN 128185-82-0 CAPLUS  
CN Piperidine, 1-(3-chlorobenzoyl)-4-[(1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 128185-84-2 CAPLUS  
CN 1H-2-Benzazepine, 2-[[1-[(3-chlorophenyl)methyl]-4-piperidinyl)methyl]-2,3,4,5-tetrahydro-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 128185-83-1  
CMF C23 H29 Cl N2




CM 2


09/807,599

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



RN 128185-85-3 CAPLUS  
CN Piperidine, 1-(3-methylbenzoyl)-4-[(1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 128185-87-5 CAPLUS  
CN 1H-2-Benzazepine, 2,3,4,5-tetrahydro-2-[[1-[(3-methylphenyl)methyl]-4-piperidinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 128185-86-4  
CMF C24 H32 N2




CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




RN 128185-88-6 CAPLUS  
CN Piperidine, 1-(3-ethoxybenzoyl)-4-[(1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 128185-89-7 CAPLUS


CN 1H-2-Benzazepine, 2-[[1-[(3-ethoxyphenyl)methyl]-4-piperidinyl]methyl]-2,3,4,5-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 128185-92-2 CAPLUS

CN Piperidine, 1-(3-methylbenzoyl)-4-[(1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl)methyl]- (9CI) (CA INDEX NAME)



09/807,599

~~LEO~~ ANSWER 47 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1989:154172 CAPLUS

~~DN~~ 110:154172

TI Preparation of cyclic amine derivatives as antihypertensives and  
bradycardiac agents

IN Heider, Joachim; Psiorz, Manfred; Bomhard, Andreas; Hael, Norbert; Narr,  
Berthold; Noll, Klaus; Lillie, Christian; Kobinger, Walter; Daemmgen,  
Juergen

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Eur. Pat. Appl., 102 pp.



CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 292840	A2	19881130	EP 1988-107867	19880524
	EP 292840	A3	19900411		
	EP 292840	B1	19950809		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 3717561	A1	19881208	DE 1987-3717561	19870525
	DD 284678	A5	19901121	DD 1988-315962	19880520
	CA 1330993	A1	19940726	CA 1988-567464	19880520
	FI 8802418	A	19881126	FI 1988-2418	19880523
	FI 94343	B	19950515		
	FI 94343	C	19950825		
	DK 8802821	A	19881126	DK 1988-2821	19880524
	NO 8802258	A	19881128	NO 1988-2258	19880524
	NO 171017	B	19921005		
	NO 171017	C	19930113		
	AU 8816562	A1	19881201	AU 1988-16562	19880524
	AU 607765	B2	19910314		
	HU 46906	A2	19881228	HU 1988-2647	19880524
	HU 198201	B	19890828		
	JP 01045381	A2	19890217	JP 1988-126910	19880524
	JP 2634190	B2	19970723		
	ZA 8803680	A	19900131	ZA 1988-3680	19880524
	SU 1561823	A3	19900430	SU 1988-4355736	19880524
	IL 86477	A1	19920715	IL 1988-86477	19880524
	ES 2076147	T3	19951101	ES 1988-107867	19880524
PRAI	DE 1987-3717561		19870525		
OS	MARPAT 110:154172				
GI					




AB The title benzo-fused cyclic amines I [A = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CH:CZ; B = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, CO, CH<sub>2</sub>CO; R = (un)substituted aryl, optionally benzo-fused 5- or 6-membered heteroaryl; R<sub>1</sub> = H, C1-3 alkyl, CF<sub>3</sub>, C1-3 alkoxy, phenyl-C1-3 alkoxy, halo, NO<sub>2</sub>, NH<sub>2</sub>, (di)alkylamino, OH; R<sub>2</sub> = H, C1-3 alkyl, C1-3 alkoxy, phenyl-C1-3 alkoxy, halo, OH, R<sub>1</sub>R<sub>2</sub> = C1-2 alkylenedioxy; Z = (un)substituted C1-6 alkylene; Z<sub>1</sub> = C1-3 alkyl-(un)substituted C1-3 alkylene; m = 1-6; n = 0-3; m + n = 3-6] and their enantiomers, diastereomers, N-oxides, and acid salts were prepd. as antihypertensives and for lowering heart rate. 1,3,4,5-Tetrahydro-7,8-dimethoxy-3-(3-piperidinylmethyl)-2H-3-benzazepin-2-one and 2-(2-bromoethyl)naphthalene were heated 3 h in Me<sub>2</sub>SO contg. K<sub>2</sub>CO<sub>3</sub> to give, after acidification, 35% title cyclic amine II.HCl (III). In rats 5.0 mg III/kg i.v. reduced blood pressure by 46 mmHg and 32 mmHg and reduced heart rate by 218 beats/min and 259 beats/min after 5 min and 20 min, resp.

IT **119917-85-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as antihypertensive and bradycardiac agent)

RN 119917-85-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethyl-3-[2-[1-[3-(4-pyridinyl)propyl]-2-piperidinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

~~DO~~ ANSWER 48 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1987:423256 CAPLUS

DN 107:23256

TI Heteroaromatic amine derivatives and their use

IN Bomhard, Andreas; Psiorz, Manfred; Heider, Joachim; Hauer, Norbert; Noll, Klaus; Narr, Berthold; Kobinger, Walter; Lillie, Christian

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Eur. Pat. Appl., 96 pp.


CODEN: EPXXDW

DT Patent


LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 204349	A2	19861210	EP 1986-107836	19860521
	EP 204349	A3	19900103		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DE 3519735	A1	19861204	DE 1985-3519735	19850601
	DE 3522552	A1	19870102	DE 1985-3522552	19850624
PRAI	DE 1985-3519735		19850601		
	DE 1985-3522552		19850624		
OS	CASREACT 107:23256				
GI					



I



II

AB Heteroarom. amines I [R = (un)substituted heterocyclyl; R1 = H, Cl, F, Br, CF3 NO2, (di)(alkyl)amino, alkyl, alkylthio, OH, (phenyl)alkoxy; R2 = H, Cl, Br, OH, (phenyl)alkoxy, alkyl; R1R2 = alkylenedioxy; R3 = H, alkenyl, (phenyl)alkyl; X = CH2CH2, CH:CH, CH2CO (clockwise insertion), X1 = CH2, CO, CS; X = COCO, CH(OH)CO (clockwise insertion); Z = C2-4 alkylene (un)substituted with alkyl; Z1 = C1-5 alkylene (un)substituted with alkyl], useful in lowering the heart rate, were prepd. by 8 methods. 3,4-(MeO)2C6H3CH2CO2H was converted into 80% its acid chloride which was amidated with H2NCH2CH(OMe)2, and the product cyclized to give 75.4% 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepinone. This was alkylated with Br(CH2)3Cl to give 87.3% 1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-3-chloropropane which alkylated 3-(N-methyl-2-aminoethyl)benzo[b]thiophene [prepd. in 48% yield from benzo[b]thienyl-3-acetic acid via 40% its N-Me amide] to give 87.3%, II (R4R4 = bond), which was converted to 35% II (R4R4 = bond).HCl. At 5 mg/kg in rats, II (R4 = H).HCl gave a heart frequency 66% lower after 5 min and 52% lower after 20 min. Five pharmaceutical compns. are given.


09/807,599

IT **108802-13-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as heart rate lowering drug)

RN 108802-13-7 CAPLUS

CN 3H-3-Benzazepine-3-propanamine, 1,2,4,5-tetrahydro-7,8-dimethoxy-N-methyl-  
N-[2-(4-pyridinyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

09/807,599

~~L20~~ ANSWER 49 OF 49 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 1987:102108 CAPLUS

DN 106:102108

TI Heteroaromatic amines, their preparation, and their use in treating sinus tachycardia and heart ischemia

IN Bomhard, Andreas; Psiorz, Manfred; Heider, Joachim; Hael, Norbert; Noll, Klaus; Narr, Berthold; Kobinger, Walter; Lillie, Christian

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 70 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3519735	A1	19861204	DE 1985-3519735	19850601
	EP 204349	A2	19861210	EP 1986-107836	19860521
	EP 204349	A3	19900103		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	FI 8602270	A	19861202	FI 1986-2270	19860529
	FI 79846	B	19891130		
	FI 79846	C	19900312		
	DD 247898	A5	19870722	DD 1986-290727	19860529
	DK 8602550	A	19861202	DK 1986-2550	19860530
	NO 8602159	A	19861202	NO 1986-2159	19860530
	AU 8658216	A1	19861204	AU 1986-58216	19860530
	AU 585351	B2	19890615		
	ES 555513	A1	19870416	ES 1986-555513	19860530
	HU 43587	A2	19871130	HU 1986-2287	19860530
	ZA 8604043	A	19880224	ZA 1986-4043	19860530
	US 4737495	A	19880412	US 1986-868986	19860530
	IL 78970	A1	19900610	IL 1986-78970	19860530
	JP 61282377	A2	19861212	JP 1986-127834	19860602
	ES 557286	A1	19871016	ES 1987-557286	19870109
PRAI	DE 1985-3519735		19850601		
	DE 1985-3522552		19850624		

GI



AB The title amines [I; A = CH<sub>2</sub>CH<sub>2</sub>, CH:CH, CH<sub>2</sub>CO, COCO, CH(OH)CO; B = CH<sub>2</sub>, CO, CS; E, G = alkylene (un)substituted with C1-3 alkyl; R = (un)substituted heterocyclyl; R1 = H, Cl, Br, CF<sub>3</sub>, NO<sub>2</sub>, (di)(alkyl)amino, alkyl, OH, alkoxy, phenylalkoxy; R2 = H, Cl, Br, OH, alkoxy, phenylalkoxy, alkyl; R1R2 = C1-2 alkylenedioxy; R3 = H, C3-5 alkenyl, (phenyl)alkyl], their N-oxides, and their acid addn. salts, useful in treating sinus tachycardia and heart ischemia (no data), were prepd. by 8 methods. 1-(7,8-Dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl)-3-[methyl[2-(6-methoxybenzo[b]thien-3-yl)ethyl]amino]propane-2HCl was prepd. in 6 steps from 3,4-(MeO)2C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>CO<sub>2</sub>H and SOCl<sub>2</sub>. Tablets were prepd contg.




1-(7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl)-3-[methyl[3-(2-thienyl)propyl]amino]propane-HCl 10.0, cornstarch, 57.0, lactose 43.0, polyvinylpyrrolidone 4.0, and Mg stearate 1.0 mg.

IT **106891-61-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as drug for sinus tachycardia and heart ischemia)

RN 106891-61-6 CAPLUS

CN 3H-3-Benzazepine-3-propanamine, 1,2,4,5-tetrahydro-7,8-dimethoxy-N-methyl-N-[2-(4-pyridinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl